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Introduction  1 
Intent and preview of the investigations 
 
According to the Food and Drug Administration (FDA) pharmaceutical excipients are 
any inactive ingredients that are intentionally added to therapeutic and diagnostic 
products, but that are not intended to exert therapeutic effects at the intended 
dosage. Nevertheless excipients may improve drug delivery, such as enhance 
absorption or control drug release [Food and Drug Administration, 2005]. The term 
“new excipients” refers to ingredients that are not fully qualified by existing safety 
data with respect to the currently proposed level of exposure, duration of exposure, 
or route of administration [Food and Drug Administration, 2005].  
 
The excipient n-octenylsuccinate starch (Fig. 1), further referred to as AS, is an FDA 
approved food and cosmetics additive with amphiphilic characteristics. Starch is 
chemically modified by replacing hydrophilic starch moieties by lipophilic n-
octenylsuccinic acid groups [Caldwell and Wurzburg, 1953; Järnström et al., 1995]. 
AS sodium salts especially perform as stabilizers for emulsions and as encapsulation 
carriers for lipophilic or oxidizable substances.  
starch O
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Fig. 1: Chemical structure of n-octenylsuccinate starch (m = 1 and n = 2 or m = 2 and n = 1)   
 
Though at present not approved for pharmaceutical applications, a few publications 
deal with investigations on AS employed in drug dosage forms, serving as a 
dissolution enhancer in solid dosage forms [Ntawukuliyayo et al., 1993] or carrier in 
hydrophilic sustained release matrices [Ntawukuliyayo et al., 1996]. 
 
The primary aim of this thesis was to assess whether AS is an applicable excipient 
for non-enteral therapeutics with focus on ophthalmic formulations. Sodium 
diclofenac (DfNa), a therapeutic in ocular inflammation treatment and associated with 
2  Introduction 
problems such as instability in aqueous solutions and low corneal permeation rates, 
was chosen as a model drug. Advantages and limitations of AS in drug-loaded and 
unloaded systems were evaluated, regarding pharmaceutical technological and 
biopharmaceutical aspects and toxicology.  
 
 
PART I – Pharmaceutical technological aspects  
 
Since emulsions are suitable carrier systems for DfNa [Bock et al., 1994] the 
capability of AS as an oil-in-water emulsion stabilizer was studied. In chapter 2 two 
AS types with different molecular weights were assessed for their emulsifying 
properties.  
 
Before incorporating the model drug substance sodium diclofenac into AS carrier 
systems drug stability and drug-excipient interaction studies were performed using 
isothermal heat conduction calorimetry, differential scanning calorimetry and HPLC 
(chapter 3). 
 
The AS type, that proved to be more suitable, as drawn from results obtained in 
chapter 2, was further employed (chapter 4) to develop emulsions with appropriate 
composition, particle size distributions and long-term stability. The influence of 
processing parameters of high pressure homogenization and preparation, e. g. spray 
drying, emulsion composition, using different oils and co-emulsifiers, and pH 
variations on emulsion formation and stability during storage and autoclaving were 
studied. Excipient interactions were measured by isothermal heat conduction 
calorimetry.  
 
 
PART II – Cytotoxicity studies and ocular tolerance  
 
Surface active additives in commercial ophthalmic preparations may act as 
solubilizers for poorly soluble drugs, emulsion/suspension stabilizers or penetration 
enhancers. However, these substances have to be chosen and dosed carefully since 
Introduction  3 
they are often irritating causing a rapid removal of the therapeutic from the site of 
absorption.  
 
Chapter 6 deals with the evaluation of the irritation potential of different AS types and 
formulations. In vitro tissue acceptability studies on human erythrocytes and excised 
porcine cornea and in vivo ocular tolerance tests were carried out in rabbit eyes using 
confocal laser scanning microscopy.  
 
 
PART III – Biopharmaceutical aspects  
 
Numerous protective mechanisms of the eye including reflex blinking, lachrymation 
and a highly selective corneal barrier make the development of ocular dosage forms, 
which enhance corneal permeation and prolong the drug’s precorneal residence 
time, an interesting challenge. Mucoadhesive substances can be added to ocular 
drug delivery systems to improve ocular residence time and bioavailability. While in 
chapter 8 the influence of AS on the in vitro corneal permeation behaviour of sodium 
diclofenac is discussed, in chapter 9 the interaction of AS and mucin was 
investigated rheologically. Finally chapter 10 deals with the in vivo evaluation of the 
pre-ocular residence time of different AS formulations labelled with sodium 
fluorescein and its elimination from the anterior chamber compartment using ocular 
fluorophotometry in human volunteers. 
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Aspects of Formulation  7  
1 n-octenylsuccinate starch and general aspects of emulsion formulation 
  
1.1 n-octenylsuccinate starch    
 
Native starch granules are primarily composed of two polyglucans, amylose and 
amylopectin. Amylose, which is a linear polymer, consists of 1,4-linked α-D-
glucopyranosyl units. Amylopectin is a branched polymer of 1,4-linked α-D-
glucopyranosyl units with branches resulting from 1,6-linkages. Within the granule, 
amylopectin is partially crystalline, while amylose is completely amorphous [Shannon 
and Garwood, 1984]. 
 
Derivatization of starch is conducted to modify typical starch properties like 
gelatinization, cooking characteristics or decrease set-back tendencies of amylose 
containing starch granules. Waxy maize starch has an amylopectin content of almost 
99 %. Since amylopectin requires much longer to set back than amylose, waxy maize 
starch pastes remain fluid on cooling. Therefore waxy maize starch is used for most 
food applications [Moore, 1984; Viswanathan 1999a].   
 
Hence, modification is an important factor providing appropriate starch products with 
defined thickening, swelling, gelling, binding or adhesive qualities to meet the 
formulator’s needs. Starch derivatives include those modifications which change the 
chemical structure of the D-glucopyranosyl molecule, usually involving oxidation, 
esterification, etherification, hydrolysis and dextrinization [Rutenberg and Solarek, 
1984].  
 
Due to its polyhydroxyl groups, starch is hydrophilic and therefore incompatible with 
water-insoluble substances. Modification by adding lipophilic groups leads to 
amphiphilic properties. Hydrophobically modified starches can be obtained by 
reaction of starch with alkylene oxides which are most commonly hydroxyethyl or 
hydroxypropyl chains. While the pulp and paper industry prefers products with a low 
degree of substitution (ds) highly substituted products may serve as hydrophobic 
coatings or adhesives [Rutenberg and Solarek, 1984; Wesslén and Wesslén, 2002]. 
Medical applications of hydroxyethylstarch cover its use as a blood volume extender 
or as a cryoprotective agent for erythrocytes [Rutenberg and Solarek, 1984]. 
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Amphiphilic starch of the n-octenylsuccinate starch type (AS), with a molecular 
weight over 5000 D, is a chemically modified waxy maize starch gained by 
substituting hydrophilic starch moieties by lipophilic n-octenylsuccinic acid groups 
(Fig. 1-1) [Caldwell and Wurzburg, 1953; Järnström et al., 1995; Gers-Barlag and 
Müller, 2002]. Consequently, the starch acquires emulsifying properties due to 
feasible formation of hydrophobic-hydrophobic interactions.  
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Fig. 1-1: Esterification of starch with cyclic octenylsuccinic anhydride (m = 1 and n = 2 or m = 
2 and n = 1)   
 
AS is an FDA-approved food additive with the stipulation that the octenylsuccinate 
content does not exceed 3 % [Food and drug administration, 1989; Park and Goins, 
1995]. Due to emulsifying properties and high retention of volatiles, the main 
application field of AS is the food and cosmetic industry. AS is an economical 
alternative to traditional stabilizers such as spray dried gum acacia, vegetal proteins, 
lecithin or gelatin which are associated with problems of uncertain supply and 
fluctuating price [Järnström et al., 1995; McGlinchey, 1997]. AS sodium salts 
especially perform as stabilizers for beverage emulsions or dressings and as 
encapsulation carriers for oxidizable substances useful in nutritional supplementation 
[King and Perry, 1976; Buttolph and Newberne, 1979; Järnström et al., 1995]. AS 
aluminium salts on the other hand are highly hydrophobic [Nair and Yamarik, 2002] 
and can be used as a talc replacement in body powders to adsorb moisture or 
excess oil from the skin.  
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Since a high swelling capacity and high viscosity are not in accordance with the 
formulators’ requirements, additional treatment of fluidification is necessary. By 
dextrinization, acid or enzymatic hydrolysis or extrusion, a range of octenylsuccinated 
starches with different levels of viscosity is available. AS is highly dispersible in cold 
water and produces low viscosities at high solid contents [Heinze, 2000], which is a 
major point in encapsulation technology.  
 
Despite the modification, biodegradability of the starch is maintained [Järnström et 
al., 1995]. AS has proven to be useful in the development of degradable plastics 
composed of AS and hydrophobic plastics [Evangelista et al., 1991; Jane et al., 
1991]. However, substituted starch shows higher resistance to enzymatic 
degradation [Viswanathan, 1999b]. Test persons have shown a reduced glycemic 
response after AS intake with food as compared to an equivalent glucose challenge. 
Thus, food containing AS has a decreased caloric density and may perform well as a 
carbohydrate source with higher glycemic control [Wolf et al., 2001]. Furthermore, it 
has been found that increasing the ds of AS does not necessarily improve 
emulsification activity [Järnström et al., 1995].  
 
AS may be beneficial for certain aspects of pharmaceutical formulation. As reported 
in the literature, low substituted AS increases dissolution rates in solid dosage forms 
[Ntawukuliyayo et al., 1993]. Associations of AS with xanthan-gum have revealed 
advantages in the formulation of hydrophilic sustained release matrices 
[Ntawukuliyayo et al., 1996a] and properties of crystal growth inhibition in sucrose 
ester suspensions [Ntawukuliyayo et al., 1996b].  
 
 
1.2 Emulsions as carrier systems for sodium diclofenac 
 
Diclofenac (Fig. 1-2), a non-steroidal anti-inflammatory drug (NSAID), is a widely 
spread active substance in solid dosage forms [Al Gohary, 1998]. In eye drop 
formulations NSAIDs are used as an alternative to topical steroids in the treatment of 
(postoperative) ocular inflammation [Agata et al., 1984; Goodman and Gilman, 1996; 
González-Peñas et al., 1998].  
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Due to its low solubility diclofenac (Df) is commercially available as sodium 
diclofenac (DfNa) [Palomo et al., 1999]. Aqueous DfNa solutions are chemically and 
physically unstable [Backensfeld et al., 1991]. Considering parenteral and 
ophthalmic DfNa preparations this problem is overcome by the addition of 
antioxidants, stabilizing agents, such as polyoxyethylene castor oil as found in the 
commercial eye drop formulation Voltaren ophtha, or cyclodextrins [Backensfeld et 
al., 1991]. As reported, DfNa solubility in aqueous systems can also be increased 
[Baydoun and Müller-Goymann, 2003] with octenylsuccinate starch (AS).  
 
 CH2 - COO – Na+
NH
ClCl
 
 
 
 
  
Fig. 1-2: Chemical structure of sodium diclofenac (DfNa) 
 
At physiological pH values Df is mainly charged, therefore polar with a weaker 
membrane permeability. Decreasing the formulation’s pH to improve membrane 
permeability, in turn affects the drug’s solubility. As reported in the literature 
emulsions are suitable carrier systems for DfNa [Bock et al., 1994]. Emulsions can 
solubilize considerable amounts of amphiphilic or lipophilic drugs, with partition 
coefficients higher than 1, in the surface monolayer or within the lipophilic core. 
Diclofenac is a weak acid (pKa 4.0) with a partition coefficient of 13 in 
octanol/phosphate buffer (pH 7.4) [Khazaeinia and Jamali, 2003]. Therefore, in an 
emulsion system Df is likely to be located in the lipophilic core of the oil droplets 
[Lindenstruth and Müller, 2004] or, due to its amphiphlic character, in the interface 
[Reer, 1994].  
 
Appropriate emulsions for ocular or parenteral application, stabilized, e.g. with 
phospholipids [Reer, 1994] and a non-ionic ABA copolymer surfactant [Jumaa and 
Müller, 1998], can be easiliy autoclaved and they may decrease the irritating 
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potential of irritative substances [Jumaa and Müller, 2000]. Furthermore, as 
compared to eye drop solutions emulsions may show an extended ocular residence 
time due to a higher viscosity.  
 
 
1.3 Isothermal heat conduction calorimetry: a tool to investigate drug 
stability and excipient compatibility 
 
Information about interaction potential are crucial in preformulation studies with new 
excipients since certain drug-excipient interactions can change stability and 
bioavailability of a product [Al Gohary, 1998]. In order to assess information on 
compatibility and stability of drugs in combination with excipients different methods, 
like differential scanning calorimetry (DSC) [Al Gohary, 1998; Palomo et al., 1999] 
and isothermal heat conduction calorimetry (IHCC), using a thermal activity monitor 
(TAM), can be applied [Selzer et al., 1998]. Although thermal analyses do not replace 
chemical methods, such as HPLC, valuable information about degree of interaction 
and change in characteristic features of a drug can be obtained.  
 
The thermal activity monitor (TAM) (Fig. 1-3) is a multichannel microcalorimetric 
system to measure several samples simultaneously, depending on the number of 
channels the apparatus is equipped with. IHCC can be used to investigate stability, 
compatibility, amorphicity, polymorphism, binding and many other characteristics of 
compounds that are important to the pharmaceutical industry. Isothermal 
microcalorimetry is a technique by which the heat flow produced by a chemical, 
physical or biological process is continuously monitored while the sample is kept at 
isothermal conditions. The heat flow is directly related to the rate of heat produced or 
consumed by the sample placed in the calorimeter. In most cases, the sample is 
contained in a removable insertion vessel positioned in an ampoule holder inside the 
microcalorimeter during measurement [Suurkuusk and Wadsö, 1982].  
 
Calorimetric sample vessels can be classified as closed and open ampoules. A 
closed ampoule is totally sealed from the environment and is generally employed 
when studying slow processes such as in stability or compatibility experiments. A 
special case of a closed ampoule is having a solid sample and a saturated salt 
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solution or pure water, physically separated but connected through the vapour phase 
inside the ampoule, to create defined humidities. After a sorption process a physical 
or chemical reaction of the sample takes place, e.g. a slow decomposition reaction, 
solvate formation or recrystallization of amorphous lactose [Suurkuusk and Wadsö, 
1982].  
 
Open ampoules are used when a process is to be initiated in situ after a base line 
has been recorded. An example is alteration of the chemical composition of a 
solution by injecting a catalyst, reactant or a ligand in order to initiate a physical, 
chemical or biological response, which is then continuously measured [Suurkuusk 
and Wadsö, 1982].  
 
 
external 
circulator 
digital 
voltmeter hinged cover 
ampoule lifter 
heat 
exchanger 
measuring 
cylinder 
water 
thermostat 
water pump 
temperature  
regulator unit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-3: Schematic assembly of a thermal activity monitor (TAM 2277, Thermometric, 
Jarfälla, Sweden)  
Stability can refer to both chemical and physical stability of a raw drug or formulation.  
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At present, the standard method to study stability of a chemical substance is HPLC. 
The change in the concentration of the substance itself or its decomposition 
product(s) is measured as a function of storage time. However, the sensitivity of 
HPLC is limited. The application of IHCC in stability studies, which has proven to be 
more sensitive than HPLC [Beezer et al., 1998; Phipps and Mackin, 2000], offers the 
advantages of being non-invasive, the samples do not need further preparation prior 
to analysis, such as proper dissolution, and formulated dosage forms can directly be 
investigated [Beezer et al., 1998; Selzer et al, 1998]. Nevertheless, calorimetry is a 
non-specific technique and signals not always simply correspond to chemical 
decomposition but may be a complex signal of thermal events, such as drying, 
sorption, melting, change in crystallinity, etc. [Lehto and Laine, 1997; Selzer et al., 
1998; Phipps and Mackin, 2000].  
 
Compatibility is an important area in the drug and dosage form development. 
Conventional compatibility studies require both multiple sample preparation and long 
storage periods to obtain meaningful results. Especially larvated incompatibilities, 
which cannot be detected macroscopically directly after formulation, can often only 
be identified during long time storage. Using IHCC an easy method can be applied to 
predict and study compatibility of binary mixtures within a shorter time [Phipps and 
Mackin, 2000].   
 
 
 
 
 
 
 
 
 
 
time
B
A
A+B (measured)
A+B (expected)
h
ea
t f
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w
(µ
W
/ g
)
B A + BA  
Fig. 1-4: Calorimetric responses (exemplified) of two incompatible substances (A and B): the 
measured mixture profile (A + B (measured)) differs from the calculated/expected mixture 
profile (A + B (expected)). 
The method involves, after measuring the two substances separately (Fig. 1-4, A, B) 
in the microcalorimeter under defined conditions (temperature, relative humidity), 
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preparing a corresponding binary mixture (Fig. 1-4, A + B), which is measured under 
the same conditions. As exemplified in Figure 1-4 the mixture presented is clearly 
incompatible as the mixture profile (A + B (measured)) is very different from the 
profile calculated (A + B (expected)) from the individual components’ curves (A, B).  
 
The microcalorimetric method is only designed as a screen and, according to stability 
studies, serves as a complementary method to conventional analysis. It does not give 
quantification of the amount of degraded active or degree of interaction. The amount 
of heat flow released from the mixture sample provides valuable information as to 
which excipients are likely to be compatible and allows cutting down the number of 
conventional compatibility samples to prepare and saving time [Phipps and Mackin, 
2000].  
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2  Comparison of two different n-octenylsuccinate starch types with 
respect to emulsifying properties  
 
2.1 Introduction 
 
Amphiphilic characteristics can be introduced in starch by treating it with cyclic 
dicarboxylic acid anhydride, whereas the specific product octenylsuccinate starch 
(AS) can be synthesized [Caldwell and Wurzburg, 1953; Viswanathan, 1999]. Starch 
modified with 3 % octenylsuccinic anhydride with a degree of substitution (ds) of 
0.015 is a commercially available product. The advantage of octenylsuccinate starch 
at that ds level is that hydrophilicity is retained, while hydrophobicity is obtained 
[Viswanathan, 1999]. Increasing the ds does not necessarily increase emulsifying 
properties, quite the contrary, which was suggested to be caused by octenyl chains 
tending to fold theirself inside toward the center of the granule, thereby decreasing 
the interactions between the oil phase and the hydrophobic chains [Viswanathan, 
1999]. After synthesis an AS dispersion is treated with acids and/or enzymes to 
reduce the molecular weight by controlling the viscosity. Better emulsion formation is 
favoured by higher AS concentrations and/or a decrease in molecular weight during 
modification [Viswanathan 1999]. Depending on synthesis conditions, e.g. extent of 
starch hydrolysis, differently manufactured AS types may vary in viscosity and 
osmotic activity. Both characteristics may provide indications about the polymer’s 
molecular weight and its molecular weight distribution. 
 
The aim of the present preliminary study was to compare two different AS types of 
unknown molecular weights and degree of substitution with respect to their 
emulsifying properties. Molecular weight distributions of the tested AS types were 
compared by means of viscosity and vapour pressure measurements. The influence 
of the polymer's molecular weight distribution, pH adjustment and drug incorporation, 
using sodium diclofenac as a model drug, on emulsion properties, i.e. droplet sizes 
and short term stability, was investigated.  
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2.2 Experimental section 
 
2.2.1 Materials  
 
Sodium diclofenac (DfNa), purchased from Synopharm (Barsbüttel, Germany), 
medium chain triglycerides (MCT 812) from Hüls (Witten/Ruhr, Germany), purified 
castor oil from Henry Lamotte (Bremen, Germany), sorbitol from Caesar & Loretz 
(Hilden, Germany); double-distilled water was used for all preparations; all used 
substances were of pharmacopoeial or reagent grade. AS 100 and AS 300, both 
emulsifying starches, were supplied by National Starch & Chemical (Manchester, 
United Kingdom) and by Roquette frères (Lestrem, France), respectively. 
 
 
2.2.2 Experimental methods 
 
2.2.2.1 Flow measurements 
 
Rheological properties were assessed using a rheometer CVO (Bohlin Instruments, 
Mühlacker, Germany) equipped with a concentric cylinder measuring geometry C25. 
Viscosity data were derived from the linear region of the flow profile (shear rate 50–
300 1/s, n = 50). AS dispersions were prepared (10, 15, 20, 25, 30, 35 and 40 % (w/w)) 
by dissolving AS in double-distilled water. Four o/w-emulsions containing 10 % (w/w) 
MCT-castor oil 1:1 stabilized with AS 10 and 15 % (w/w), respectively, were also 
characterized. Each formulation was measured at 20 °C in triplicate. 
 
2.2.2.2 Osmolality  
 
In order to compare both AS types, the osmotic activities of AS dispersions of different 
concentrations (10, 15, 20, 25 % (w/w)) were measured. Osmotic activities of 
investigated preparations were analysed by vapour pressure measurements at 37 °C 
(vapour pressure osmometer type: No 11.00, Knauer KG, Berlin, Germany; the 
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apparatus was calibrated with sorbitol solutions within the concentration range of 3.0–
8.0 % (w/w); the correlation coefficient obtained was > 0.999).  
 
2.2.2.3 Surface tension 
 
Surface tension measurements were carried out with a thermostatically-controlled 
Processor Tensiometer K100 (Krüss GmbH, Hamburg, Germany) provided with a Du 
Noüy ring (ring radius: 9.545 mm, wire diameter: 0.37 mm) at 20 °C. The apparatus 
was calibrated with double-distilled water achieving a surface tension of 72.14 mN/m. 
The reduction of surface tension caused by AS 100/300 15 % (w/w), both adjusted to 
pH 6.5 with 0.1 N-NaOH, was measured in triplicate.  
 
 
2.2.2.4 Preparation and characterization of AS emulsions 
 
Oil-in-water (o/w) emulsions (10 % oily phase) stabilized with 15 % (w/w) AS 100 or 
300 were investigated. The oily phase consisted of MCT 812 and castor oil (1:1). AS 
was mixed with cold water by stirring gently on a magnetic stirrer until fully dissolved. 
If necessary, the aqueous dispersion was isotonized with sorbitol and added to the 
oily phase. A pre-emulsion was prepared using an Ultra-Turrax (Janke & Kunkel, 
Staufen, Germany) before the emulsion was passed through a high pressure 
homogenizer (Niro Soavi, type: Panda, Parma, Italy) at room temperature at a 
pressure of 300 bar (8 cycles, 20 °C) to obtain a submicron emulsion. The pH of the 
emulsions was adjusted to 6.5 and 7.4 using a 0.1 N sodium hydroxide solution. 
More details and information on the chosen concentrations and homogenization 
conditions are given in chapter 4. 
 
In case of drug loaded emulsions the required DfNa amount was dissolved in water 
and added to a slightly concentrated AS dispersion after pH adjustment. Water was 
then added to set the necessary AS concentration and the pH was controlled prior to 
high pressure homogenization.  
 
Particle size distributions depending on the number of homogenization cycles, pH 
value and DfNa incorporation were determined by laser diffraction (Mastersizer MS 
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20, Malvern, Worcs, United Kingdom) and calculated by Malvern SB 09 software 
using the Mie approximation. 
 
 
2.3 Results and discussion 
 
2.3.1 Rheological properties 
 
Both AS types produce dispersions and emulsions revealing Newtonian flow 
behaviour, which can be drawn from a linear dependence (R=0.999–1.000) between 
applied shear rate and shear stress (Figs. 2-1 and -3).  
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Fig 2-1: Flow profiles of AS 100 and AS 300 dispersions (both 40 and 10 % (w/w)) 
characterized by a linear increase of shear stress with shear rate (R = 0.999 – 1.000),  
profiles of AS 100/300 10 % (w/w) overlap.   
 
Fig. 2-2 displays for both AS types tested an increase in viscosity with higher 
concentrations, whereas AS 100 yields higher viscosities than AS 300, which is an 
indication of the presence of rather long chain starch molecules. According to the 
Stokes law, which suggests that the rate of creaming or sedimentation is inversely 
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proportional to the viscosity, this means that at equal concentrations AS 100 may 
yield more stable emulsions as compared to AS 300.  
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Fig. 2-2: Viscosities of different AS type dispersions depending on concentration (n = 3), 
mean ± SD, symbol includes standard deviation 
 
 
 
Tab. 2-1: Viscosities of different AS type emulsions depending on concentration (n = 3), 
mean (± SD); emulsions consist of AS/MCT-castor oil 1:1 concentration outer 
phase/concentration inner phase in % (w/w)  
 
AS 100 15/10 AS 300 15/10 AS 100 10/10 AS 300 10/10 
7.1 (± 0.2) mPa s 5.9 (± 0.2) mPa s 39.7 (± 2.6) mPa s 21.2 (± 0.2) mPa s 
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Fig. 2-3: Flow profiles of AS 100 and AS 300 emulsions (both 15 and 10 % (w/w)); inner 
phase consists of MCT-castor oil 1:1 10 % (w/w); characterized by a linear increase of shear 
stress with shear rate (R = 0.998 – 1.000). 
 
2.3.2 Osmotic activity 
 
Figure 2-4 shows that, depending on synthesis conditions, e.g. extent of starch 
hydrolysis, AS vary in their osmotic activities. Higher osmotic activities indicate the 
presence of short chain starch molecules, which promote a better emulsion 
formation and finer droplets [Viswanathan, 1999]. AS 100 reveals a stronger osmotic 
activity than AS 300 which, taking viscosity data into account, indicates a broader 
molecular weight distribution.  
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Fig. 2-4: Osmotic activities of different AS type dispersions depending on concentration 
(n = 3), mean ± SD, symbols include standard deviation 
 
 
2.3.3 Surface tension 
 
Table 2-2 shows that at pH 6.5 AS 100 lowers surface tension by a greater value, 
about 34 mN/m than AS 300, which is about 28 mN/m, regardless of the 
measurement temperature (20 °C or 32 °C). At pH 7.4 the difference seems to be 
less pronounced.  
 
 
Tab. 2-2: Decrease of water surface tension (72.14 mN/m) mean (SD) (n=3)  
 
AS 100 (mN/m) AS 300 (mN/m)  
 
20 °C 33.71 (0.62) 28.16 (1.47) 
pH 6.5 
32 °C 34.39 (0.03) 28.46 (1.58) 
20 °C 30.38 (0.91) 25.49 (1.28) 
pH 7.4 
32 °C 30.21 (0.35) 26.16 (3.16) 
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As compared to pH 6.5, both AS types show a slightly diminished decrease of 
surface tension when the pH value is adjusted to 7.4. As further presented in chapter 
4 paragraph 4.3.1.3, the emulsifying character of AS is weakened with pH values 
higher than 7.   
 
 
2.3.4 Particle size measurements and emulsion short term stability 
 
Figure 2-5 displays the decrease of the D90 and D50 particle diameters in 
dependence on the homogenization time. The D90/50 diameter means that 90/50 % 
of the particles are below the given size. AS 100, under chosen conditions (300 bar, 
20 °C), yields emulsions with smaller droplet sizes and decreased particle size 
distributions already within shorter homogenization times (Fig. 2-5). 
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Fig. 2-5: Droplet sizes of o/w emulsions containing AS (15 % (w/w)) and 10 % (w/w) oily 
phase vs. homogenization time (300 bar, 20 °C), mean ± SD (n = 9) 
 
This is in accordance with osmolarity data which suggested that AS 100 enhances 
emulsion formation as a result of the presence of short chain molecules.  
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As AS loses its emulsifying character when the pH is adjusted to 7 or higher (see 
also chapter 4, paragraph 4.3.1.3) the emulsions presented in the tables 2-3 and -4 
were adjusted to pH 6.5.  
 
Tab. 2-3: Droplet sizes of emulsions (300 bar, 8 cycles) after pH adjustment to pH 6.5 
shortly after homogenization and after 24 h; mean (SD) (n = 9) 
 
 
 
 
 
after 
homogenization 
 
after 24 h 
 before pH 
adjustment 
after pH 
adjustment 
 
 
D90 (µm) 
0.84 (0.04) 0.84 (0.04) 0.84 (0.04) 0.82 (0.03) 
AS 100 
 
D50 (µm) 
0.42 (0.02) 0.43 (0.02) 0.42 (0.3) 0.44 (0.02) 
 
D90 (µm) 
0.98 (0.06) 0.99 (0.05) 
AS 300 
 
D50 (µm) 
0.53 (0.02) 0.51 (0.04) 
not detectable 
due to 
coalescence/creaming 
 
Tab. 2-4: Droplet sizes of AS emulsions (300 bar, 8 cycles) containing DfNa 0.1 % (w/w) 
shortly after homogenization and after 24 h (pH adjusted to 6.5); mean (SD), (n = 9) 
 
 
 
 
 
after 
homogenization 
 
after 24 h 
 
D90 (µm) 
0.80 (0.02) 0.81 (0.03) 
AS 100 
 
D50 (µm) 
0.45 (0.02) 0.45 (0.02) 
 
D90 (µm) 
1.03 (0.05) 
AS 300 
 
D50 (µm) 
0.49 (0.04) 
not detectable 
due to 
coalescence/creaming 
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In the case of AS 100 stabilized systems, short term stability is not disturbed by pH 
adjustment (pH 6.5) or drug incorporation. By contrast, all tested AS 300 emulsions 
tend to destabilize within 24 h. As this can be observed for all AS 300 emulsions, it 
can be concluded that destabilization is not directly caused by drug incorporation or 
pH adjustment but by the weaker stabilizing character of AS 300 itself. Under the 
preparation conditions given, AS 100 is a more effective stabilizer.  
 
 
2.4 Conclusion  
 
In case of unknown molecular weights, molecular weight distribution and substitution 
degree the determination of viscosity and osmotic activity of AS dispersions may 
provide useful information about emulsifying properties. The AS type that exhibits a 
larger molecular weight distribution, i. e. AS 100, may contribute more effectively to 
the formation of fine and stable emulsions, which are less susceptible to drug 
incorporation or pH variations. Emulsions composed with AS 300 tend to destabilize 
more quickly. 
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3 Stability and compatibility/interaction studies on sodium diclofenac 
using microcalorimetry and differential scanning calorimetry 
 
3.1 Introduction 
 
Diclofenac (Df), a non-steroidal anti-inflammatory drug (NSAID), is a widely spread 
active substance in solid dosage forms [Al Gohary, 1998]. In eye drop formulations it is 
used as an alternative to topical steroids to avoid postoperative eye inflammation [Agata 
et al., 1984; González-Peñas et al., 1998]. Due to is low solubility it is commercially 
available as sodium diclofenac (DfNa) [Palomo et al, 1999].  
 
Recently it was shown that n-octenylsuccinate starch (AS), an emulsifying water 
soluble nutrition supplement, can improve the in vitro corneal permeation activity of 
DfNa [Baydoun and Müller-Goymann, 2003].  
 
Information about interaction potential are crucial in preformulation studies with new 
excipients since certain drug-excipient interactions can change stability and 
bioavailability of a product [Al Gohary, 1998]. In order to assess information on 
compatibility and stability of drugs in combination with excipients different methods, 
like differential scanning calorimetry (DSC) [Al Gohary, 1998; Palomo et al, 1999] and 
isothermal heat conduction calorimetry, using a thermal activity monitor (TAM), can 
be applied [Selzer et al., 1998]. Although thermal analyses do not replace chemical 
methods, valuable information about degree of interaction and change in 
characteristic features of a drug can be obtained.  
 
The literature describes different instabilities that can be observed during Df storage 
clearly depending on storage conditions. While the cyclization of Df to an indolinone 
derivative could only be detected in Df tablets that were stored under severe 
conditions (90 °C, 55% relative humidity (rH)) for 20 days but not in samples kept at 
40 °C, 50% rH for 28 days or in commercial tablets [Eyjolfsson, 2000]. The formation 
of two oxidative degradates found in solution and the solid state has also been 
described [Eyjolfsson, 2000]. On the other hand it could be shown that the formation 
of an inclusion complex with β-cyclodextrin improved thermal stability of DfNa in the 
solid state [Ćwiertnia et al., 1999]. 
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To measure the extent of interaction between DfNa and AS, microcalorimetry 
measurements were carried out. In order to avoid signals caused by chemical 
decomposition of DfNa, moderate temperatures (20 and 40 ºC) at high humidity 
(100% rH) were chosen for storage and measurements. For further characterisations 
of treated and untreated DfNa DSC and HPLC measurements were performed 
[Palomo et al, 1999].   
 
 
3.2 Experimental section 
 
3.2.1 Materials  
 
 
DfNa was purchased from Caesar & Loretz (Hilden, Germany), AS type 100, an 
emulsifying starch, was supplied by National Starch & Chemical (Manchester, United 
Kingdom); 
Acetonitrile and acetic acid (both HPLC grade) were obtained from J.T. Baker (Deventer, 
the Netherlands). Double-distilled water was used for all preparations. 
 
3.2.2 Experimental methods 
 
3.2.2.1 Isothermal heat conduction microcalorimetry (IHCC) 
 
The calorimeter used for these studies was the 2277 Thermal Activity Monitor (TAM, 
Thermometric AB, Jarfalla, Sweden). Two calorimeter units, which were kept in 25-l 
water bath to maintain a temperature constance of < ± 2 * 10 –4 K, were installed and run 
simultaneously. Each unit consists of a measuring and a reference channel. Difference 
in heat flow (P in µW) and heat output (Q in J) between sample and reference were 
recorded as a function of time. Powder samples were placed in a tightly sealed 3-ml 
glass ampoule with a teflon-coated butyl rubber disc and an aluminium cap. The 
amounts weighted were 200 mg and 400 mg for the mixtures in compatibility studies. 
Before lowering the ampoules to the measuring position they were equilibrated for at 
least 20 min to achieve the corresponding temperature. After that the sample vessel and 
a blank reference vessel were slowly lowered into the measurement position. Heat flow 
signals were monitored by the Digitam 4.0 software (Thermometric AB, Jarfalla, 
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Sweden). The apparatus was calibrated using the electrical calibration system between 
30 and 300 µW, depending on the heat flow expected. Calibration was carried out when 
the measuring range was changed or the apparatus was switched off. Measurements 
were performed at 20 and 40 °C. Relative humidity of 100% was adjusted by inserting a 
glass vial filled with double-distilled water. 
 
Compatibility studies were analysed using the Digitam 4.0 software program. 
 
 
3.2.2.2 HPLC conditions 
 
The HPLC system from Waters (USA-Milford MA) consisted of a 486 tuneable 
absorbance detector, a 712 plus autosampler and two 515 HPLC pumps. Separation 
was achieved with an analytical Hypersil® ODS (particle size 5 µm) column (125 mm 
x 4 mm) from Grom (Herrenberg, Germany). The analytical Software Millenium 32 
from Waters (Milford, MA, USA) was used to determine the peak sizes of the 
amounts of DfNa. 
 
The mobile phase consisted of double-distilled water/acetonitrile/acetic acid (50/50/2 
and 60/40/0.1). The components’ amounts were varied to achieve different polarities 
and thus retention times (Rt) for DfNa in order to detect side peaks (50/50/2, Rt≈3 
min, 60/40/0.1, Rt≈10 min). The flow rate was 1.6 ml/min and DfNa was monitored 
spectrophotometrically at 276 nm. The experiments were run for at least one hour. 
Linear correlation between peak area and DfNa concentrations was obtained within 
the concentration range of 0.05–25 µg/ml. The correlation coefficient was 0.999. 
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3.2.2.3 Differential scanning calorimetry (DSC) 
 
DSC thermograms were recorded with a Thermal Analysis System SSC 5200, 
Software: MAS 5700 MA-Station Version 3.2, SSC 5200H Disk-Station Version 3.2, 
Version/Typ: DSC 220C, Seiko Instruments, Tokyo, Japan). The apparatus was 
calibrated with indium and tin which were provided by the manufacturer. Samples 
weighing between 4 – 8 mg were placed in vented aluminium samples pans. 
Scanning runs were performed under atmospheric conditions within the range of 50–
320 °C at a heating rate of 6 K min-1.  
 
Moisture contents were determined by thermogravimetry (TG). Samples of 3–6 mg 
were weighed directly into open aluminium samples pans. Thermal analyses were 
conducted at atmospheric conditions. Scans were carried out from 20–120 °C (kept 
at 120 °C for 10 min under dynamic air flow) at a heating rate of at 5 K min-1. The 
equipment was calibrated with indium and tin. The loss of mass was recorded and 
analysed using software mentioned above. 
 
 
3.3 Results and discussion 
 
3.3.1 HPLC 
 
Within the storage period of 8 d none of the HPLC chromatograms (storage 
conditions: 20/40 °C at a relative humidity of 100%) showed additional peaks, 
indicating decomposition of DfNa. DfNa contents did not change within 8 d storage 
time. This means that signals, which occur in calorimetry studies within 8 d, where 
DfNa is kept under the same conditions, are not due to decomposition.  
 
 
3.3.2 DSC and TG 
 
The water amounts taken up by DfNa at 20 °C, determined by TG (Fig. 3-1), in 
dependence on time first show a linear increase approaching a limit value of 
18.84 %. This is in accordance with the literature [Fini et al., 2001] which presented a 
value of 18.38 % corresponding to four water molecules per molecule DfNa. Plotting 
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the heat flow volume, taken from the heat flow calorimetry profile, versus storage 
time results in a similar curve shape (Fig. 3-2).  
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Fig. 3-1: Water amounts taken up by DfNa at 20 °C, determined by TG (squares), and heat 
quantity measured by DSC (circles) versus storage time  
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Fig. 3-2: Heat flow conduction calorimetry profile of DfNa at 20 °C/ 100 % rH versus storage 
time and corresponding heat flow volume curve (circles)  
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As already described in the literature [Palomo et al, 1999; Fini et al., 2001] DSC 
curves of untreated DfNa (Fig. 3-3) show an exothermic decomposition signal (278 
°C ) followed by an endothermic melting signal (281 °C) [Palomo et al, 1999]. As 
soon as water is taken up by DfNa an additional water evaporation peak occurs 
starting at room temperature. The longer DfNa has been exposed to moisture the 
broader gets the signal (Fig. 3-3). Both DSC and TG data point out the formation of a 
tetrahydrate as already reported [Fini et al., 2001]. 
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Fig. 3-3: DSC curves of untreated DfNa and DfNa after storage (interrupted line) at 20 ºC/ 
100% rH, 7 d 
 
 
3.3.3 IHCC 
 
Measuring DfNa without defined rH provides a profile close to baseline (Fig. 3-4). 
Profiles achieved at an rH of 100% reveal first a slight decrease in heatflow and later 
a distinct peak. Heatflow subsequently approaches baseline. As compared to 40 °C, 
the profile obtained at 20 °C starts at lower values (86 μW) and drops off more 
slowly. The peak, which is less pronounced, is notably delayed and occurs after 
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121 h (Fig. 3-4). Water condensation, water adsorption, formation of hydrates as well 
as dissolving processes and hydration may cause occurrence of heat flow.  
Fig. 3-4: Heat flow profiles of DfNa at 20 ˚C at no defined rH (interrupted line) and at an rH of 
100% (grey line) and at 40 ˚C at an rH of 100% (black line) 
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Fig. 3-5 shows the heatflow measured curves obtained with DfNa, AS 100 and two 
DfNa-AS 100 1:1-mixtures (mASDfa and –b) using heat flow conduction calorimetry 
at 20 °C at an rH of 100%. The curve illustrating the difference in heatflow between a 
calculated/theoretical (thASDf) and the measured curves is rather low indicating 
weak interaction between AS 100 and DfNa, which indicates an acceptable 
compatibility/a low level of interaction. 
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Fig. 3-5: Heat flow conduction calorimetry profile of DfNa and AS 100 at 20 °C/ 100 % rH 
compared to a mixture DfNa and AS 100 (1:1), mASDf = measured curve (mixture), thASDf = 
theoretical/calculated curve  
 
 
3.4 Conclusion 
 
Microcalorimetric profiles indicated low interaction between drug and excipient, while 
heat signals achieved with DfNa alone are based on a mere physical uptake of water to 
form a DfNa tetrahydrate and not on chemical decomposition. 
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4 Development of n-octenylsuccinate starch stabilized emulsions for the 
non-enteral application route: short and long-term stability studies 
 
4.1 Introduction 
 
Lipophilic drugs are poorly soluble in water and therefore show low dissolution rates 
which often affects oral bioavailability. Micronization improves the drugs’ dissolution 
rates due to a specific larger surface area [Reverchon et al., 2004]. The incorporation 
of the lipophilic drug into solid lipid nanoparticles [Hu et al., 2004] or into an oil-in-
water (o/w) emulsion [Hansen et al., 2005] may show an increased oral 
bioavailability.  
 
Accordingly, highly lipophilic drugs can be incorporated in o/w emulsions intended for 
ophthalmic application to increase the drug’s bioavailability. Incorporated emulsifiers 
must reveal a low irritation potential. Emulsions stabilized with n-octenylsuccinate 
starch (AS) reveal a good eye tolerance [Baydoun et al., 2004].  
Since emulsions undergo a number of instability processes, including creaming, 
flocculation and coalescence, characterization and control of these processes are 
key aspects of the formulation of commercial products. Spray drying of o/w emulsions 
is an interesting method to achieve physical, chemical and microbial stabilization of 
both food and medical emulsions [Christensen et al., 2001; Dollo et al., 2003; 
Hansen et al., 2005].  
 
Likewise, in the case of ophthalmic and parenteral emulsions it is advantageous to 
achieve emulsions, which remain stable during autoclaving. In order to increase the 
resistance to the thermic shock induced by the autoclaving sterilization co-emulsifiers 
can be added [Jumaa et al., 1998; Buszello et al., 2000]. A method to obtain useful 
information on drug/excipient stability, excipient compatibility and the degree of 
interaction between different chemicals, such as emulsifiers, is the isothermal heat 
conduction calorimetry (IHCC), using a thermal activity monitor (TAM) [Selzer et al., 
1998; Phipps and Mackin, 2000]. Isothermal microcalorimetry is a technique by which 
the heat flow produced by a chemical, physical or biological process is continuously 
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monitored while the sample is kept at isothermal conditions [Phipps and Mackin, 
2000].  
 
The effort of this investigation was to develop an AS stabilized emulsion formulation 
intended primarily for ocular application. The amounts of the emulsifying agent AS (5, 
10, 15, 25 % (w/w)) and the oil phase (medium chain triglycerides (MCT), MCT-
castor oil 1:1, 5, 10, 15 % (w/w)) have been varied. Different co-emulsifiers, which 
have approved for parenteral and/or ocular application, i. e. an ABA block-copolymer 
(F68), polyoxyethylene castor oil (POC) and phospholipon 90 G (P90G) [Jumaa and 
Müller, 1998], have been combined with AS adjusting different concentration 
combinations in binary mixtures. Additionally the influence of the pH value (pH 4, 6, 
6.5, 7 and 7.5) on the emulsifying qualities of AS has been tested. A redispersable 
dry powder emulsion, stabilized with AS, was prepared by spray drying. 
Release/liberation experiments were performed with spray dried emulsions and 
compared with untreated systems.  
 
Short and long-term stability of AS emulsions as well as stability during the 
autoclaving process have been investigated visually and by laser diffraction. 
Interactions between emulsifiers were examined visually and were confirmed by 
IHCC. 
 
 
4.2 Experimental section 
 
4.2.1 Materials 
 
DfNa was purchased from Synopharm (Barsbüttel, Germany) and Caesar & Loretz 
(Hilden, Germany), medium chain triglycerides (MCT 812) from Hüls (Witten/Ruhr, 
Germany), purified castor oil from Henry Lamotte (Bremen, Germany), 
hydroxypropylmethylcellulose (HPMC) type Metolose 90 SH 400, substitution type 
2208, USP from Shin Etsu (Tokyo, Japan), sorbitol from Caesar & Loretz (Hilden, 
Germany), thimerosal from Synopharm (Barsbüttel, Germany), sodium hydroxide 
from Merck (Darmstadt, Germany); Pluronic® F68 (F68) and Cremophor® EL (POC) 
(both BASF, Ludwigshafen, Germany), Phospholipon® 90 G (P90G) (Nattermann, 
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Köln, Germany); acetonitrile and acetic acid (both HPLC grade) were obtained from 
J.T. Baker (Deventer, the Netherlands); sodium chloride, potassium dihydrogen 
phosphate and disodium hydrogen phosphate (all pro analysi), purchased from 
Merck (Darmstadt, Germany), were used to prepare isotonic phosphate buffer pH 7.4 
(PBS 7.4) according to the German Pharmacopoeia (DAB 2001); all substances used 
were of analytical or pharmacopoeial grade. Thimerosal 0.004 % (w/w) was added to 
all preparations for preservation.  
 
 
AS type 100, an emulsifying starch which is further referred to as AS, was supplied 
by National Starch & Chemical (Manchester, United Kingdom). Double-distilled water 
was used for all preparations.  
 
 
4.2.2 Experimental methods 
 
4.2.2.1 Emulsion preparation 
 
Besides the variation of the homogenization time, figure 4-1 illustrates the modifications 
tested to investigate emulsion formation and stability. AS 100 stabilized oil-in-water (o/w) 
emulsions with different oil phases (MCT 812 and MCT 812/castor oil (1:1)) and different 
AS-oil ratios (5/10/15 and 5/10/15/25 % (w/w)) were prepared. AS was mixed with cold 
water by stirring it gently on a magnetic stirrer until fully dissolved. AS moisture contents 
were previously determined by thermogravimetry (Thermal Analysis System SSC 5200, 
Software: MAS 5700 MA-Station Version 3.2, SSC 5200H Disk-Station Version 3.2, 
Version/Typ: DSC 220C, Seiko Instruments, Tokyo, Japan).  
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Spray 
drying 
Outer phase  
 
AS 100   5, 10, 15, 25% (w/w) 
pH value 
 
4/ 6/ 6.5/ 7/ 7.5 
Co-emulsifier 
 
POC  1/ 2/ 4% (w/w) 
F68 1/ 2/ 4% (w/w) 
PG90 0.25/ 0.5 (w/w)
Inner phase 
 
MCT 5/10/15% (w/w) 
MCT/castor oil 1:1  5/10/15% (w/w) 
 
Fig. 4-1: Different variations tested to investigate AS emulsion formation and stability.   
 
The aqueous dispersion was added in a stepwise manner to the oil phase and a pre-
emulsion was prepared (1 min, 8000 rpm) using an Ultra-Turrax (Janke & Kunkel, 
Staufen, Germany). The coarse pre-emulsion was passed at room temperature 
through a high pressure homogenizer (Niro Soavi, type: Panda, Parma, Italy) to 
obtain a submicron emulsion. In order to optimize the homogenization process of the 
specific emulsion, the system was passed repeatedly through the homogenizer 
monitoring achieved droplet diameters versus the number of homogenization cycles. 
The required pH was adjusted with a 0.1 N NaOH solution prior to and after emulsion 
preparation.  
 
Furthermore, to increase and investigate emulsion stability during autoclaving 
(121 °C, 2 bar, 20 min) three different co-emulsifiers, an ABA block-copolymer, 
Pluronic F68 (F68), polyoxyethylene castor oil (POC) and phospholipon 90 G (P90G) 
were combined with AS adjusting different concentration combinations in binary 
mixtures. 
 
DfNa loaded emulsions were prepared as described in chapter 2, paragraph 2.2.2.4. 
 
To test the influence of the pH value emulsions (AS 10 % (w/w), MCT 10 % (w/w)) 
were adjusted to 6, 6.5, 7 and 7.5 using a 0.1 N NaOH solution. Osmolality was 
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adjusted with sorbitol, if necessary, using a calibrated vapour pressure osmometer 
(Wescor 5500, Baumann-Medical, Wetzikon, Switzerland). 
 
Dry powder emulsions were achieved by spray-drying a stock emulsion (AS 100 
25 % (w/w), MCT 15 % (w/w)), pH was adjusted to 6.5 (1 N NaOH), on a Büchi spray 
dryer (Büchi Labortechnik, Flawil, Switzerland) at 180 ºC inlet temperature and 95 ºC 
outlet temperature as recommended for AS 100 by the manufacturer (National starch 
& Chemical). Furthermore an emulsion containing AS 10 % (w/w), and MCT/castor oil 
(1:1) 10 % (w/w) was spray dried (inlet 180 °C, outlet 95 °C). The moisture content of 
the dry emulsion was determined by thermogravimetry (see above).  
 
The dry emulsion was reconstituted in double distilled water using a magnetic stirrer. 
 
 
4.2.2.2 Liberation studies 
 
Liberation profiles for an AS 100 emulsion (7.5 % (w/w) and AS 100 (7.5 % (w/w)) 
reconstituted spray dried emulsion were compared. The stock emulsion contained 
22.5 % (w/w) AS 100, MCT 15 % (w/w) and DfNa 0.3 %, pH was adjusted to 6.5.    
The stock emulsion was diluted in double-distilled water adjusting 7.5 % AS and 5 % 
MCT (DfNa 0.1 %). The spray dried (inlet 180 °C, outlet 95 °C) stock emulsion was 
reconstituted in double-distilled water just the same after determination of water 
content by thermogravimetry (see above).  
 
An HPMC emulsion 0.75 % (w/w), containing 5 % (w/w) MCT and DfNa 0.1 % (w/v) 
prepared by high pressure homogenization (400 bar, 10 cycles) was also measured. pH 
of all systems was adjusted to pH 6.5 with a 0.1 N NaOH solution. 
  
Studies were performed throughout 6 h with a modified Franz diffusion cell [Franz, 1975] 
as described elsewhere [Refai and Müller-Goymann, 1999]. The donor compartment 
was filled with the polymer drug solutions whereas isotonic phosphate buffer pH 7.4 
(PBS) was used as acceptor medium. Analysis was performed by UV detection at 
276 nm.  
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4.2.2.2 Emulsion characterization 
 
Particle size distribution was analysed by laser diffraction (Mastersizer MS 20, 
Malvern, Worcs, United Kingdom) and calculated by Malvern SB 09 software using 
the Mie approximation. The emulsions were further characterized by transmission 
electron microscopy (TEM) [Friedrich and Müller-Goymann, 2003] and scanning 
electron microscopy (SEM) [Reichl, 2003] as described in the literature. Emulsions 
were stored at room temperature and observed for more than 12 months. 
 
 
4.2.2.3 Emulsifier interaction studies using isothermal heat conduction 
calorimetry (IHCC) 
 
The calorimeter used for these studies was the 2277 Thermal Activity Monitor (TAM, 
Thermometric AB, Jarfälla, Sweden). Two calorimeter units, which were kept in the 
25-l water bath of the microcalorimeter to maintain a temperature constancy of < ± 2 
* 10 –4 K, were installed and run simultaneously. Each unit consists of a measuring 
and a reference channel. Difference in heat flow (P in µW) and heat output (Q in J) 
between sample and reference were recorded as a function of time. Powder samples 
were placed in a tightly sealed 3-ml glass ampoule with a teflon-coated butyl rubber 
disc and an aluminium cap. The amounts weighted were 200 mg and 400 mg for the 
mixtures in compatibility studies and 100 mg in stability studies of DfNa. Before 
lowering the ampoules to the measuring position they were equilibrated for at least 
20 min to achieve the corresponding temperature. After that the sample vessel and a 
blank reference vessel were slowly lowered into the measurement position. Heat flow 
signals were monitored by the Digitam 4.0 software (Thermometric AB, Jarfälla, 
Sweden). The apparatus was calibrated using the electrical calibration system 
between 30 and 300 µW, depending on the heat flow expected. Calibration was 
carried out when the measuring range was changed or the apparatus was switched 
off. Measurements were performed at 20 and 40 °C. Relative humidity of 100 % was 
adjusted by inserting a glass vial filled with double-distilled water. 
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4.3 Results and discussion  
 
 
4.3.1 Emulsion properties and particle size distribution depending on process 
parameters, pH value and emulsion composition  
 
4.3.1.1 Influence of the homogenization time 
 
AS stabilized emulsions (Fig. 4-2), containing MCT as inner lipophilic phase (AS and 
MCT 10 % (w/w) each) prepared by high-pressure homogenization reveal 
monomodal particle size distributions with droplet sizes around 0.5 µm and a D 90 
value below 1 µm already at moderate homogenization conditions (300 bar, 4 cycles, 
20 °C).  
 
An AS stabilized emulsion containing AS 100 and MCT, 10 % (w/w) each, was 
prepared by high pressure homogenization (300 bar, 20 °C). Figure 4-2 shows the 
particle diameters (D90, D50 and D10) of the emulsion as a function of cycle 
numbers. In the beginning D90, D50 and D10 values are continuously decreased, i.e. 
1.06 µm (D90), 0.50 µm (D50) and 0.24 µm (D10) for cycle 3 and 0.90 (D90), 0.45 
µm (D50) and 0.20 µm (D10) for cycle 5. After remaining constant between cycle 5 
and 9, there is a clear particle diameter increase, especially of the D90 value, which 
is an indication of too much energy given to the emulsion. Stabilization with AS 100 
yields emulsions with a monomodal particle size distribution (300 bar, 5 cycles, 
20 °C) (results not shown).  
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Fig. 4-2: Particle size distribution of an AS-MCT emulsion (10 %/10 % (w/w)) depending on 
the number of homogenization cycles (300 bar, 20 °C). Mean ± SD (n = 3), D90 (black 
columns), D50 (grey columns), D10 (white columns) (µm).   
 
 
4.3.1.2 Influence of the AS/MCT concentration ratio 
 
While AS/MCT ratios of 5:5 and 10:10 yield similar particle sizes, the 15:15 ratio 
provides emulsions with smaller droplets (Fig. 4-3). Results achieved with AS 5 % 
(w/w) do not significantly differ when the amount of MCT incorporated is raised from 
5 to 15 % (w/w). Raising the AS concentration to 15 % (w/w) generally leads to 
smaller droplets and even results in a smaller particle size distribution upon 
homogenization with an equal MCT amount. At this specific AS concentration equal 
MCT concentrations seem to induce a more effective and more consistent 
homogenization process possibly in consequence of a higher shear effect. 
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Fig. 4-3: AS-MCT concentration combinations tested D90 and D50 (bold) mean values (µm) 
(n=3). Emulsions were prepared by high pressure homogenization (300 bar, 20 °C, 4 cycles).  
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Fig. 4-4: Particle size distribution of an AS-MCT emulsion (25 %/15 % (w/w)) depending on 
the number of homogenization cycles (450/50 bar, 20 °C). Mean ± SD (n = 3), D90 (black 
columns), D50 (grey columns), D10 (white columns) (µm) 
 
Furthermore, an emulsion containing AS 100 25 % (w/w) and MCT 15 % was 
prepared by high-pressure homogenization applying a pressure of 450 bar at the first 
stage and 50 bar at the second stage (Fig. 4-4). While most of the oil globule 
reduction takes place in the first stage, there is a tendency for clumping or clustering 
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of the reduced oil globules. The second stage valve permits the separation of those 
clusters into individual oil globules. To avoid heating, the emulsion was prepared 
under cooling with water (18 °C). D50 values of 0.45 µm are reached after the 4th 
cycle and are decreased to 0.38 µm after the 6th cycle. The D90 values get smaller, 
from 0.91 µm after cycle 4 and 0.68 after cycle 7. Particle sizes remain constant 
between cycle 7 and cycle 10.  
 
Figure 4-5 presents a TEM image of an AS stock emulsion (AS 25 % (w/w) and MCT 
15 % (w/w)), where the oil droplets (sizes far below 1 µm) seem to be tighly packed. 
As can be drawn from figure 4-6, these highly concentrated emulsions remain stable 
over longer than 14 months (20 °C storage temperature). It is well known that 
concentrated emulsions like mayonnaise do not need stabilizing, since the crowding 
effect of the droplets is sufficient to prevent creaming. Therefore, it can be beneficial 
to increase the apparent viscosity of the product (without exceeding a critical 
concentration) to form a stable continuous network. Stock emulsions can be spray 
dried or diluted prior to usage.  
 
 
 
 
 
 
 
 
 
  
Fig. 4-5: TEM image of an AS stock emulsion containing AS 25 % (w/w) and MCT 15% 
(w/w). 
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Fig. 4-6: Stability of an AS emulsion (AS 25 %, MCT 15 % (w/w)) at 20 °C; Mean ± SD (n = 
3); symbols include standard deviations  
 
As comparing the results obtained in Fig. 4-6 with the droplet sizes in Fig. 4-5 the limits 
of laser diffraction measurements become obvious since the extremely high presence of 
particles below 200 nm (Fig. 4-5) could only be detected by TEM.   
 
 
4.3.1.3 Stability to pH variations 
 
The pH value of an AS 100 dispersion 15% (w/w) is about 4. Emulsifying properties 
were tested at this pH value and at pH 6, 6.5, 7 and 7.5. To investigate whether the 
pH has an influence not only on emulsion stability but also on the emusification 
procedure, adjustment was once set before preparation of the pre-emulsion and once 
right after high-pressure homogenization.  
 
It was found that at pH-values above 7 AS completely loses its emulsifying 
properties. Emulsification with AS dispersions adjusted to pH 7 and higher is 
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impossible and emulsions adjusted after high-pressure homogenization visibly break 
within minutes.  
 
As long as the pH value is kept at values lower than 7, droplet sizes and stability are 
comparable for two corresponding emulsions (i. e. same composition, preparation 
and storage), no matter if the pH is set before or after homogenization (data not 
shown). At higher pH values deprotonation of the carboxylic acid functional group 
may lead to a negatively charged octenylsuccinate side chain. This weakens its 
lipophilic properties, which in turn may result in a weaker amphiphilic character of the 
AS molecule as a whole.  
 
If the lipophilic phase is able to additionally lower the pH due to the presence of free 
fatty acids, as in the case of castor oil, it is advantageous to first adjust the pH after 
high-pressure homogenization.  
 
Taking factors, such as drug stability, solubility and permeation, into consideration, 
the pH should be adjusted within a physiologically tolerated pH range, which lies 
between 5.8 and 11.4 for the ocular site of application [Dolder, 1990]. At pH 6.5, 
which was finally chosen for the preparation of most AS formulations investigated, AS 
emulsion, stability and ocular tolerance are well combined.  
 
 
4.3.1.4 Influence of the oil phase composition 
 
Besides pure MCT, a mixture of MCT/castor oil with a 1:1 ratio as the inner lipophilic 
phase, was investigated for emulsion formation and stability. MCT 812 has a density 
of 0.94–0.95 g/cm3 20°C which is close to that of water. In accordance with the law 
of Stokes a low difference between the densities of the dispersed and continuous 
phase increases emulsion stability. The incorporation of the relatively polar castor oil 
allows to prepare emulsions with a capacity for a higher drug uptake [Jumaa and 
Müller, 1998]. The D50 and D10 values achieved with the corresponding systems (i. 
e. same AS/lipophiic phase concentration ratio, pH value, homogenization and 
storage conditions), which only differ in the oil phase composition, are comparable. 
For an AS emulsion containing AS 10 % (w/w) and MCT/castor oil 1:1 10 % (w/w) the 
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diameters 0.49 µm (D50) and 0.24 µm (D10) were obtained at 300 bar after 8 cycles. 
In case of the D90 value it takes more than 8 cycles to decrease this value to data 
around 1 µm (1.01 µm).   
 
MCT leads to smaller D90 values particle sizes within shorter homogenization times 
(D90 0.8 µm after 4 cycles) in comparison to an MCT/castor oil mixture, which takes 8 
cycles until D90 becomes smaller than 1 µm. This may be due to the higher viscosity of 
castor oil, which leads to broad particle size distributions. Oil phases with higher 
viscosities need higher homogenizatioin pressures to obtain small particle size 
distributions. This was according to expectations as MCT shows a lower viscosity than 
castor oil.  
 
As presented in figure 4-7 emulsions consisting of AS 10 % (w/w) and MCT/castor oil 1:1 
10 % (w/w) destabilize within 3 months. While D50 and D10 values remain stable over 
14 months D90 values become larger after 3 months which can also be recognized 
macroscopically by obvious creaming.  
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Fig. 4-7: Stability of an AS emulsion (AS 10 %, MCT/castor oil 1:1 10 % (w/w)) at 20 °C; 
mean ± SD (n = 3); symbols include standard deviations 
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This problem can be overcome by increasing the emulsifier concentration. 
Emulsions, which consist of AS 15 % (w/w) and MCT/castor oil (1:1) 10 % (Fig. 4-8) 
yield emulsions (300 bar, 8 cycles, 20 °C) with (monomodal) particle size 
distributions comparable to the 10:10 ratio emulsions without castor oil (see results 
presented in chapter 2, 2.3.4). Stored at room temperature they are stable for at least 
6 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4-8: TEM image of an AS emulsion containing AS 15 % (w/w) and MCT/castor oil 1:1 
10 % (w/w). 
 
 
4.3.2  Drug stability/compatibility and emulsifier interaction studies 
using isothermal heat conduction calorimetry 
 
As AS emulsions of any concentration investigated break throughout autoclaving, 
different amounts of various co-emulsifiers were added (Fig. 4-1) in order to increase the 
emulsion stability. Binary mixtures of AS with F68 and POC, respectively, showed 
complete phase separation already during the pre-emulsification process indicating 
strong emulsifier interactions. This could also be drawn from the high difference in heat 
flow achieved in IHCC studies with 1:1 mixtures as compared to a calculated curve from 
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the heat flows of the pure substances (Figs. 4-9 and -10). The combination with P90G 
revealed a much weaker interaction level (Fig. 4-11).  
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Fig. 4-9: Heat flow profiles at defined rH (100 %) at 20 ˚C of F68 (grey line) and AS 100 
(black line) in comparison to calculated (calc) and measured (meas) mixture curves 
(interrupted lines) 
 
0 1000 2000 3000 4000
-10
0
10
20
30
40
50
60
70
80
90  POC
 AS 100
 AS/POC (1:1) calc
 AS/POC (1:1) meas
P
 (u
W
)/g
time (min)
 
 
 
 
 
 
 
 
 
 
Fig. 4-10: Heat flow profiles at defined rH (100 %) at 20 ˚C of POC (grey line) and AS 100 
(black line) in comparison to calculated (calc) and measured (meas) mixture curves 
(interrupted lines) 
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Fig. 4-11: Heat flow profiles at defined rH (100 %) at 20 ˚C of PL90G (grey line) and AS 100 
(black line) in comparison to calculated (calc) and measured (meas) mixture curves 
(interrupted lines) 
 
However, emulsions prepared with AS/P90G break within one week after autoclaving. 
Therefore AS emulsions should be prepared under aseptic conditions.  
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4.3.3 Dry powder emulsions 
 
When an emulsion composed of AS 100 10.0 % (w/w) and MCT 10.0 % (w/w) (Fig. 4-
12) adjusted to pH 6.5 is spray-dried (inlet 180 °C, outlet 95 °C) particle sizes get 
larger after spray drying and reconstituting the spray dried product (D90/ D50 
1.19 µm/0.51 (before) and 3.44 µm/1.60 µm (after)).  
  
 
Fig. 4-12: SEM image of a spray dried AS emulsion (AS 100 10.0 % (w/w) and MCT 10.0 % 
(w/w) 
 
Spray drying at the same conditions emulsions that consist of AS 25 % (w/w) and MCT 
15 % (w/w), altogether a non-evaporable content of about 40 % (w/w) results in 
emulsions with D90/D50 about 0.82/0.45 µm (water content below 5 %) before the 
drying process and after reconstitution. These spray dried emulsions, reconstituted ones 
and dry powders stored in a tightly sealed ampoule (20 °C), are stable for at least 6 
months. They can be easily redispersed prior to usage.   
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4.3.4 Liberation studies 
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Fig. 4-13: Liberation profiles of DfNa from different emulsion systems: (circles) AS 100/MCT 
7.5/5  (w/w); (squares) HPMC/ MCT 0.75/5  (w/w); (triangles) AS 100/MCT 812 7.5/5  (w/w) 
spray dried  
 
AS emulsions seem to release DfNa more slowly than an HPMC emulsion. Release can 
be additionally decreased when the emulsion has been spray dried which may be due to 
a solidification of the emulsifier at the interface. This effect may benefit a sustained or 
controlled release of the drug at the site of application.  
 
 
4.4 Conclusion 
 
AS are polymers, which are capable of stabilizing emulsions without using classic 
emulsifying agents like surfactants. Since AS loses emulsifying properties at pH values 
above 7, emulsions should be adjusted to 6.5 to achieve an acceptable compromise 
between stability and ocular tolerance. However, AS formulations cannot be sterilized by 
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autoclaving and have to be prepared aseptically. Stability during autoclaving could not 
be improved by adding PL90G or co-emuslifiers, like POC or F68. Especially in the case 
of the latter two this was due to significant interactions, which was confirmed by IHCC 
measurements. Combination with DfNa revealed a low level of interaction suggesting a 
good compatablity.    
 
AS emulsions can easily be spray dried and reconstituted prior to usage, whereas an 
emulsion with a non-evaporable content of 40 % (w/w) (AS 25 % and 15 %) proved to 
yield stable emulsions with comparable droplet sizes as obtained prior to spray drying. 
Spray dried emulsions reveal slower release profiles for DfNa as compared to non-spray 
dried emulsions. Therefore, considering AS, spray drying is an interesting method to 
formulate dry emulsions with a long storage stability and for controlled release 
formulations.  
 
Thus, when administered as an emulsion, AS may be useful for both the formulation of 
ophthalmic and other non enteral applications.  
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5 The eye and ocular tolerance studies 
 
 
5.1 Anatomy and physicochemistry of the eye  
 
5.1.1 The human eye 
 
Figure 5-1 presents a schematic view of the main anatomic elements of the human 
eye [Wheater et al., 1987].  
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Fig. 5-1: Sagittal view of the human eye with its main anatomic elements [adapted from 
Wheater et al., 1987]. 
 
 
5.1.2 Cornea 
 
The cornea is an important mechanical and chemical barrier, which limits the access 
of exogenous substances into the eye in order to protect intraocular tissues. The 
human cornea is a transparent, avascular tissue with a mean thickness of 500 µm in 
the central region becoming about 50 % thicker towards the periphery. It consists of 
five layers: corneal epithelium, Bowman's membrane, stroma, Descemet's membrane 
and endothelium (Fig. 5-2) [Hornof et al., 2004].  
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The corneal epithelium is composed of 5–6 layers of cells and makes up about 5 % 
(50-100 µm) of the total corneal thickness. It consists of a single layer of basal 
columnar cells, an intermediate zone (2–3 layers) of polygonal wing-shaped cells and 
superficial squamous cells (2–3 layers).  
 
Tight junctions between superficial epithelial cells prevent permeation of hydrophilic 
drugs and water and solutes from the tear fluid into the stroma [Greaves and Wilson, 
1993; Hornof et al., 2004]. 
 
Fig. 5-2: Microphotograph of human normal cornea (haematoxylin and eosin staining, 
magnification x 80); (1) epithelium, (2) Bowman’s membrane, (3) corneal stroma (substantia 
propria), (4) Descemet’s membrane (5) endothelium [Wheater et al., 1987].   
 
 
The corneal stroma makes up about 90 % of the corneal tissue which is bounded 
internally by the Descemet’s membrane and the endothelium, and externally by the 
Bowman’s membrane and the epithelium. It is composed of an extracellular matrix 
formed of hydrated collagens and proteoglycans. Due to its hydrophilic nature the 
stroma exerts a diffusional barrier only to highly lipophilic drugs [Greaves and Wilson, 
1993; Hornof et al., 2004].  
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The corneal endothelial monolayer maintains an effective barrier between the stroma 
and aqueous humour. Active ion and fluid transport mechanisms in the endothelium 
are responsible for maintaining corneal transparency [Hornof et al., 2004].  
 
 
5.1.3 Precorneal tear film 
 
The precorneal tearfilm is a highly specialized fluid layer continuously bathing the 
corneal epithelium, conjunctiva and walls of the conjunctival cul-de-sac. The ocular 
tear fluid maintains a non-keratinized surface essential for corneal transparency and 
lubrication required for the movement of the lids over the globe. Abnormalities of the 
tear film can lead to dysfunction of the conjunctiva and eyelids as well as to loss of 
corneal transparency [Greaves et al., 1992]. 
 
According to the “three layers theory”, the precorneal tear film consists of a 
superficial lipid layer, a central aqueous layer and an inner mucus layer (Fig. 5-3).  
 
Superficial  
lipid layer 
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mucin layer 
Corneal epithelium 
 
 
 
 
 
 
 
Fig. 5-3: Structure of the precorneal tear film. 
 
 
The superficial lipid layer is secreted primarily by the Meibomian glands, as well as 
the glands of Zeiss and Moll. It consists mainly of sterol esters, triacylglycerols and 
phospholipids, free sterols and free fatty acids. The function of this outmost layer of 
the tear film is to prevent tear evaporation from the ocular surface in order to maintain 
physiological tear osmolality of the aqueous layer underneath.  
 
The aqueous layer constitutes the middle layer of the tear film and is produced by the 
lacrimal gland and its accessory glands. The aqueous layer supplies the ocular 
surface with essential components including inorganic salts, glucose and urea, trace 
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elements, as well as vitamins (retinol, ascorbic acid), proteins and glycoproteins, 
including antibacterial proteins like lysozyme [Baeyens and Gurny, 1997; Qu and 
Lehrer, 1998]. The osmolality of the tear film is 310–334 mOsm/kg in normal eyes 
and is adjusted by the principal inorganic ions Na+, K+, Cl-, HCO3-, and proteins 
[Dolder, 1990]. The osmotic pressure of tears is slightly higher than that of blood due 
to constant evaporation of water from the tear film. The pH value of tear fluid lies 
between 7.1 and 7.6, the surface tension between 40 and 50 mN/m and the viscosity 
between 1.3 and 5.9 mPa.s [Dolder, 1990].  
 
The mucus layer, which is secreted onto the eye surface by the goblet cells, is 
intimately associated with the glycocalyx of the corneoconjunctival epithelial cells 
[Greaves and Wilson, 1993]. This layer promotes continuity of the tear film by 
reducing the surface tension. Mucus is the predominant component of the tear film 
forming the first barrier between the outside environment and the underlying corneal 
epithelial cells.  
 
More recent investigations regarding the structure and composition of the tear film 
indicate that the “three layers theory” needs to be revised. It was found that the in 
vivo structure of rat tear film is composed primarily of mucus, with a lipid layer 
covering its surface but without a free aqueous layer [Chen et al., 1997]. Estimates of 
the tear film thickness, found in the literature, varies from approximately 4 µm to 
40 µm and the real value remains controversial [Wang et al., 2003]. 
 
 
5.2 Ocular tolerance studies  
 
5.2.1 Ocular toxicity  
 
The eye possesses effective protective mechanisms like lacrimation, blinking, tear 
drainage and tear turnover, that prevent chemicals and other irritative objects/ 
environmental pollutants from remaining too long on the eye surface and maintain an 
adequate tear film. The cornea is densely innervated, which contributes to the 
immediate blinking reflex and retraction of the head upon irritation. 
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Nevertheless, highly potential drugs or toxic drugs/excipients that are applied on the 
eye may cause different toxic effects depending on the application site and whether 
the specific substance is absorbed or not. Local toxicity may result from a direct 
contact of a chemical with the eye and may be limited to superficial tissues like the 
cornea and conjunctiva (superficial local toxicity) or affect deeper tissues like the iris, 
crystalline lens or even the retina (deep local toxicity) [Furrer, 1999].  
 
Beside local toxicity also systemic toxic effects may occur if the applied substance is 
absorbed by the conjunctival vessels or by the alimentary tract after passing through 
the nasolacrimal system. On the other hand the eye may also be a target for toxicity if 
a drug or its metabolites reach the eye through the systemic circulation [Furrer, 
1999]. 
 
Ocular tolerance is the ability of ocular tissues to bear a given dose of a chemical 
without showing evidence of intoxication [Etter and Mayer, 1985]. While eye 
corrosion is an irreversible ocular tissue damage at the site of contact resulting in 
lesions of deep ocular tissues, eye irritation can be defined as a reversible 
morphological or physiological damage to the eye and its surrounding mucus 
membranes after direct exposure to a material on the surface of the anterior eye 
segment. The latter damage consists generally of non-immunological inflammatory 
reactions [Furrer, 1999].  
 
Ocular safety tests implicate pathological modifications affecting cornea, conjunctiva 
and iris. Any lesion causing a disruption of anatomical features (neovascularization, 
pigmentation, scarring) or a swelling of the cornea will alter corneal transparency 
resulting in visual impairment [Meek et al., 2003]. Corneal injuries comprise many 
various forms such as dryness (keratoconjunctivitis sicca), neovascularization and 
opacity [Kast 1991; Van Winkle, 1991]. The severity ranges from abrasion (local loss 
of epithelial cells), erosion (loss of several epithelial layers) and ulceration (loss of 
epithelial and stromal layers) to perforation (damage of the endothelium) [Furrer, 
1999]. Ocular irritation concerning the conjunctiva appears as an inflammatory 
reaction called conjunctivitis. The iris, being a vascular muscular structure, forms the 
pupil and regulates the amount of light that reaches the retina. Iridial irritation may be 
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associated with inflammation signs, like aqueous flare and aqueous cellular 
reactions, and lack of reaction to light [Furrer, 1999]. 
 
 
5.2.2 Methods to investigate ocular tolerance 
 
5.2.2.1 The Draize test for ocular irritation 
 
The evaluation of ocular toxicity is not only important to assess side effects of drugs 
and excipients in pharmaceuticals, but also crucial to assure a safe use of cosmetics, 
consumer products and industrial products.  
 
Since the 1940’s eye irritation traditionally has been evaluated using the Draize in 
vivo rabbit eye-irritation test [Draize et al., 1944]. This method is based on the 
macroscopic observation of the treated eyes of albino rabbits, after 0.1-ml (or weight 
equivalent) sample of test material is placed into their lower conjunctival cul-de-sac. 
The untreated eye is used as a control. Responses (e.g. injuries, redness, opacity, 
swelling, discharge) of the cornea, conjunctiva and iris, are graded at standard times, 
generally from 1 to 35 days after dosing. The tissue grades are combined into a 
weighted score following a scoring system that converts the qualitative observations 
of pathological evidence in quantitative data [Furrer 1999, Kulkarni et al., 2001]. 
The in vivo rabbit eye-irritation test is very simple, easy to conduct and requires no 
special instruments. Albino rabbits are easy to handle, available, have a relatively 
large ocular surface and the lack of pigmentation enables a good observation, 
especially of the iris. But despite of its widespread use it has frequently been 
criticized not only on behalf of animal welfare. Regarding the methodology the difficult 
interpretation of the results and the subjective scoring may lead to intra-
/interlaboratory variability which in turn leads to a limited reproducibility. A third 
important point of major criticism is the applicability to the human eye. A summary of 
the differences in ocular physiology between man and rabbit, mainly influencing 
preocular loss and absorption/permeation, is given in table 5-1. Selecting the rabbit 
as an animal model is only appropriate if the results obtained are predictive of the 
behaviour in humans [Reddy and Ganesan, 1996].  
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Tab. 5-1: Comparison of selected anatomical and physiological differences between the 
rabbit and human eye [adapted from Greaves et al., 1992; Reddy and Ganesan, 1996] 
Parameter Rabbit Human 
Tear volume 5–10 µl 5–10 µl 
Tear flow  0.5–0.7 µl/min 0.5–2.2 µl/min 
Tear turnover rate 8 %/min 16 %/min 
Tear film pH 8.2 7.4 
Drainage of instilled fluid Slow Fast 
Blink rate 4–5/h 15–20/min 
Corneal thickness 0.4 mm 0.5 mm 
Corneal diameter 15 mm 11 mm 
Corneal permeability  high low 
Bowman’s membrane Absent Present 
Nictitating membrane Present Absent 
 
For the reasons mentioned considerable work has been done to develop alternative 
methods to study ocular safety.  
 
5.2.2.2 Alternative in vitro tests 
 
In vitro methods allow a large number of measurements to be performed, easily 
controllable and reproducible, require less time, are painless and relatively 
inexpensive. The following paragraphs shortly outline some commonly used in vitro 
methods to evaluate the toxicity potential of chemicals. 
  
5.2.2.2.1 Isolated ocular tissues  
 
Corneal injury represents only one endpoint of in vivo eye irritancy, but it makes by 
far the greatest contribution to the maximum total Draize score. Therefore, isolated 
corneas of either bovine or porcine origin have been suggested as suitable models in 
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risk assessment. Irritation endpoints are opacification, coloration to fluorescein or 
enhanced permeability to a fluorescent dye [Herzinger et al., 1995] epithelial 
detachment or loss of corneal integrity [Ellingson et al., 1992; Baydoun et al., 2004]. 
Besides problems of availability and viability of the isolated organs, responses to 
toxic insults achieved with this method are difficult to quantify.  
 
 
5.2.2.2.2 Fertilized hen’s egg  
 
The chorioallantoic membrane (CAM), an extraembryonal circulatory system of the 
chicken embryo, is a highly vascularized, stratified tissue, which originally has been 
suggested to provide a model for the conjunctival tissue of the eye. The HET (Hen's 
Egg Test or Hühner-Embryonen-Test)-CAM test is a rapid, sensitive and inexpensive 
toxicity test and can give information on embryotoxicity, teratogenicity, systemic and 
immunopathological effects and on mucous-membrane irritation potencies of 
chemical substances [Lüpke, 1985; Märtins et al., 1992]. Irritation endpoints are 
lesions, coagulation and hemorrhage. Toxic potential can be expressed in terms of 
the concentration of test material that elicits a positive response in 50 % of the eggs. 
A positive response is considered to be a membrane lesion with a maximal diameter 
of more than 2 mm [Herzinger et al., 1995].  
 
Limitations of this assay are the bad predictability of potential in vivo irritation and that 
it does not permit the evaluation of sensory irritation or discomfort since the model 
used is no innervated tissue [Märtins et al., 1992]. 
 
 
5.2.2.2.3 Cultured cells  
 
One major advantage of cell culture systems lies in the possibility that cells can be 
obtained from the particular target organ, like the cornea, and from human origin 
[Reichl et al., 2004]. The number of surviving cells, counted e.g. in a hemocytometer 
or in an electronic cell counter, after exposure to the test material is probably the 
most simple endpoint. Alternatively the uptake and accumulation or enzymatic 
reduction of a dye, like neutral red or MTT, respectively, by viable cells can be 
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determined [Sina et al., 1995; Imbert and Cullander, 1997]. Like tests on isolated 
tissues assays with cultured cells are still not fully comparable to the in vivo situation. 
Tearing and blinking, for instance, limit the contact time of the test material and the 
cells, which may account for false positives achieved in vitro [Sina et al., 1995]  
 
 
5.2.2.2.4 Red blood cell haemolysis  
 
The haemolytic potential of surfactants was suggested to be indicative of their in vivo 
ocular irritancy [Pape et al., 1987; Pape and Hoppe 1990]. Red blood cells are 
readily available, either from animal or human origin, and easy to handle. Tensides 
possess a high affinity to react with cell membranes, affect functional and structural 
units of proteins and change membrane permeability. Using red blood cells the 
amount of released haemoglobin, due to membrane damage, can easily be detected 
and quantified spectrophotometrically [Bock and Müller, 1994; Jumaa et al., 2002]. 
The assay is rapid, inexpensive and yields reproducible results. The haemolysis 
assay is not proposed as an extensive alternative to the Draize test, but may provide 
useful information on tissue compatibility of newly developed surfactants or tenside 
formulations. This may help reduce the number of animals needed to perform a 
Draize test.   
 
 
5.2.2.3 Alternative in vivo methods  
 
Despite the advantages in vitro methods offer they are unable to reproduce the 
complete irritation response observed in the vivo situation. Since the eye is a very 
complex and sensitive organ one in vitro method cannot possibly assess all effects of 
test materials and the reaction of the living eye when exposed to them [Furrer, 1999]. 
None of the currently available in vitro methods has proven to be a valid substitute for 
in vivo ocular safety tests and at the most help to pre-screen new drugs/excipients. 
Only in vivo testing provides the full spectrum of potential reactions and enables a 
more reliable prediction of human eye irritancy.   
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There is a number of in vivo methods like (a) pachymetry (measurement of corneal 
thickness due to edema or ulceration, (b) tonometry (measurement of intraocular 
pressure after exposure to an irritant, (c) wound healing studies (objective 
observation of the delayed recovery time after contact with an irritant) or (d) the 
increase of corneal permeability to a marker dye as a consequence of tissue lesions 
[Furrer, 1999].  
 
Conventional light microscopy cannot be used for the in vivo examination of the eye. 
Especially thick specimens with overlapping structures produce an out-of-focus blur 
which reduces the contrast and resolution of the image. By contrast, a confocal 
microscope is a type of microscope in which a thick object like the cornea is 
illuminated with a focused spot of light. It permits the investigation of optical sections 
of relatively thick specimens (> 10 µm). Since confocal microscopy suppresses the 
out-of-focus blur, sharp three-dimensional images can be obtained. As described 
already elsewhere [Furrer et al., 1997] this is accomplished by two features as 
follows: 
 
(a) The arrangement of the condenser (part of the illumination system) and the 
objective lens (part of the detection system): both have the same focal 
distance and are disposed symmetrically with respect to the focal plane 
(confocal arrangement). 
 
(b) There is a spatial filter (in the form of a pinhole, diaphragm or slit) placed in 
front of the detector to ensure that only light from coming from the focal plane 
is collected.  
 
Either a white light source with a second spatial filter placed in front of it or a laser 
beam, which is already tightly bundled, is used to restrict the illumination to a small 
spot. This arrangement improves resolution by about 40 % but since the field of view 
is restricted to a single point the full image needs to be generated by scanning the 
specimen. This is carried out by moving the focus, both vertically and horizontally in a 
raster pattern along the optical axis. The two-dimensional images of a series of focal 
planes are subsequently transferred into a stack; this addition provides a three-
dimensional image [Furrer et al. 1997].  
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The confocal laser scanning microscope (CLSM) uses a laser beam instead of white 
light (Fig. 5-4). With the CLSM, only a single spot of laser light scans periodically the 
stationary object field. The light reflected, transmitted or emitted by the specimen, is 
then oriented to the detector by a dichroic mirror. The detector, generally a 
photomultiplier, converts the light to an amplified signal which can be processed 
further. This technique allows the rapid reconstruction of clear three-dimensional 
images but no visualization in true colours [Furrer et al., 1997].  
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Fig. 5-4: Schematic representation of a confocal laser scanning microscope [adapted from 
Furrer et al., 1997]: A laser beam is moved by a scanning device and focused on the cornea 
by an adjustable tube lens. The reflected or induced light is directed into a detector by a 
beam splitter (dichroic mirror). In-focus light (A) from the stromal tissue passes through the 
pinhole whereas out-of-focus light (B) remains undetected.  
 
The combination of the ophthalmoscope, which has originally been developed for the 
examination of the retina, with confocal and laser technologies provides a non-
invasive tool with a high resolution as achieved with electron microscopy to 
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investigate the anterior part of the eye [Furrer, 1999]. The confocal laser scanning 
ophthalmoscope (CLSO) coupled with a labelling technique of corneal lesions using 
fluorescein, enables an objective, reproducible, sensitive and simple evaluation of in 
vivo ocular toxicity [Maurer et al., 1999; Furrer et al., 2000]. CLSO is applicable to 
animals and directly to humans [Furrer, 1999].  
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6        n-octenylsuccinate starch: Evaluation of ocular tolerance 
 
Parts published in: 
Baydoun L, Furrer P, Gurny R, Müller-Goymann CC. 2004. New surface-active polymers 
for ophthalmic formulations: evaluation of ocular tolerance. Eur J Pharm Biopharm 58: 169–
75   
 
 
6.1 Introduction 
 
Polymeric hydrogels have been widely used to increase viscosity and consequently 
retention time of eye drops on the ocular surface in order to increase intraocular drug 
levels. The most widely used polymers include cellulosic derivatives, poly(vinyl alcohol), 
sodium hyaluronate, and carbomer [Felt et al., 2002]. The use of n-octenylsuccinate 
starch has been described for the formulation of anti-inflammatory eye drops [Baydoun 
and Müller-Goymann, 2003].  
 
Amphiphilic starch of the n-octenylsuccinate starch type (AS) is a chemically modified 
waxy maize starch gained by substituting hydrophilic starch moieties by lipophilic n-
octenylsuccinic acid groups [Gers-Barlag and Müller, 2002; Järnström et al, 1995]. 
Consequently, the starch acquires emulsifying properties due to feasible formation of 
hydrophobic-hydrophobic interactions. AS is used in the food and cosmetic industry 
[Viswanathan, 1999; Wesslén and Wesslén, 2002] as an alternative to traditional 
stabilizers such as spray dried gum acacia, vegetable proteins, lecithin, or gelatin 
[Järnström et al, 1995; McGlinchey, 1997].  
 
Sodium diclofenac, solubilized in an AS dispersion, has shown improved corneal 
permeation behaviour as compared to tested marketed eye drop preparations, where 
the drug is solubilized by means of polyoxyethylene castor oil (POC)  [Baydoun and 
Müller-Goymann, 2003]. Due to AS’s emulsifying properties, it is mandatory, when its 
use is intended for the ocular route, to assess in vivo its ocular tolerance. Indeed, 
surfactants or preservatives with surfactant properties used in eye drops are known to 
cause varying ocular irritations by mechanisms such as association with biological 
membranes resulting in changes to surface charge, alteration of barrier functions, or 
denaturation and cell death [Furrer et al., 2000; Patlewicz et al., 2000].  
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Currently, the Draize rabbit eye test is used to assess ocular irritancy. However this 
methodology has been criticized for its lack of objectivity and sensitivity. More recently, 
alternatives have been proposed to replace the Draize test including: light microscopy 
and confocal microscopy. These approaches have been shown to objectively quantify 
surfactant-induced eye irritation in the rabbit [Jester et al., 2001].  
 
The aim of the present study was to compare, with respect to their ocular tolerance, 
different AS types of unknown molecular weights and diverse emulsifying properties.  
Both types, AS 100 and 300, provided by different manufacturers, are identical in 
chemical structure but may differ in degree of substitution (ds), which does not exceed 
3 %. They are won from waxy maize starch, which is chemically modified and 
hydrolysed, by controlling the viscosity, to reduce the molecular weight of the starch 
molecule. The investigated AS types mainly differ in molecular weight and molecular 
weight distribution. Since, it was found that increasing the ds does not necessarily 
improve the emulsifying properties of AS [Viswanathan, 1999] both AS types were 
characterized by performing viscosity, vapour pressure and surface tension 
measurements in order to gain information on molecular weight and molecular weight 
distribution, which greatly influence emulsion formation and stability [Baydoun and 
Müller-Goymann, 2001].  
 
To evaluate the preparations' irritation potential, in vitro tissue acceptability studies on 
human erythrocytes and excised porcine cornea and in vivo ocular tolerance tests were 
carried out in rabbit eyes. After applying AS dispersions and emulsions at different 
concentrations in vivo to the rabbits’ corneas, tissue damage was assessed using a 
confocal laser scanning microscope following fluorescein labelling. Additionally, the 
tested formulations were incubated with human erythrocytes and excised porcine 
corneas. The amount of released haemoglobin due to membrane damage was 
quantified by UV detection and histological cross sections of treated pig eye material 
were evaluated by light microscopy for pathological modifications caused by an irritant 
substance. 
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6.2 Materials and methods  
 
6.2.1 Materials  
 
Medium chain triglycerides (MCT 812) and thimerosal were purchased from Synopharm 
(Barsbüttel, Germany), sorbitol from Hänseler AG (Herisau, Switzerland) and sodium 
hydroxide from Amtech-Chimie SA (Lausanne, Switzerland). Sodium fluorescein was 
obtained from Reactolab (Servion, Switzerland). Sodium chloride, potassium dihydrogen 
phosphate and disodium hydrogen phosphate (all pro analysi), purchased from Merck 
(Darmstadt, Germany), were used to prepare isotonic phosphate buffer pH 7.4 (PBS) 
according to the German Pharmacopoeia (DAB 2001); all substances used were of 
analytical or pharmacopoeia grade. 
 
AS type 100 and type 300, both emulsifying starches, were supplied by National Starch 
& Chemical (Manchester, United Kingdom) and Roquette frères (Lestrem, France), 
respectively. Double-distilled water was used for all preparations.  
 
 
6.2.2 Experimental methods 
 
6.2.2.1 Flow measurements 
 
Flow measurements were performed to asses the systems’ viscosities. The method 
applied is described in paragraph 2.2.2.1. 
 
6.2.2.2 Osmolality 
 
Osmotic activities of investigated preparations were analysed by vapour pressure 
measurements at 37 °C according to chapter 2, paragraph 2.2.2.2.  
 
6.2.2.3 Surface tension 
 
Surface tension measurements were carried out as described in paragraph 2.2.2.3. 
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6.2.2.4 Preparation of AS formulations for in vitro and in vivo tolerance 
tests  
 
The AS dispersions (AS D) investigated contained 2 % and 15 % (w/w) AS of both 
types. AS moisture contents were previously determined by thermogravimetry 
(Thermal Analysis System SSC 5200, Software: MAS 5700 MA-Station Version 3.2, 
SSC 5200H Disk-Station Version 3.2, Version/Typ: DSC 220C, Seiko Instruments, 
Tokyo, Japan). AS emulsions (AS E) were stabilized with 15 % (w/w) AS 100/300. 
The lipophilic phase consisted of MCT 812. Oil-in-water (o/w) emulsions (10 % (w/w) 
oil phase) were prepared by dissolving AS in cold water and adding it to the oil phase 
using an Ultra-Turrax (Janke & Kunkel, Staufen, Germany). The pre-emulsions were 
passed through a high pressure homogenizer (Niro Soavi, type: Panda, Parma, Italy) 
six times at room temperature applying a pressure of 400 bar (AS 100) and 300 bar 
(AS 300) to achieve submicron emulsions (D90 around 1 µm). Particle size 
distribution was analysed by laser diffraction (Mastersizer MS 20, Malvern, Worcs, 
United Kingdom) and calculated by Malvern SB 09 software using the Mie 
approximation. 
 
pH values of all formulations tested were adjusted to 6.5 using a 0.1 N sodium hydroxide 
solution as AS loses its emulsifying properties at pH values higher than seven, where 
emulsions tend to break quickly [Baydoun and Müller-Goymann, 2001]. Osmolality was 
adjusted with sorbitol using a calibrated vapour pressure osmometer (Wescor 5500, 
Baumann-Medical, Wetzikon, Switzerland) and ranged between 280 and 330 mOsm/kg. 
 
 
6.2.2.5 In vitro investigation: Red blood cell haemolysis and influence on 
porcine cornea integrity 
 
Red blood cells were obtained from human blood (27-year-old female with common 
blood chemistry) by centrifugation (5 min, 1000 × g). After the supernatant plasma 
was removed the erythrocytes were washed three times with PBS 7.4 in order to 
remove serum proteins. Using PBS 7.4 an erythrocyte stock dispersion with a fixed 
haemoglobin concentration was prepared. The stock dispersion was refrigerated and 
kept no longer than 24 hours.  
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One hundred microlitres of the stock dispersion were added to 1000 µl sample, well 
shaken and incubated at 37 °C for different time periods (15 min, 30 min, 1 h). The 
samples were shaken every 5 min. After centrifugation (3 min, 750 × g), to remove 
intact erythrocytes and debris, 100 µl of the supernatant were added to 2000 µl of an 
ethanol/HCl mixture (40 parts of ethanol 99 % (v/v) and 1 part of hydrochloric acid 
37 % (w/v)) and centrifuged again (3 min, 1000 × g). The ethanol/HCl mixture avoids 
haemoglobin precipitation [Jumaa and Müller, 2000]. 
 
The absorption of the subsequently achieved supernatant was measured by 
spectrophotometry at 398 nm against blank samples (ethanol/HCl mixtures containing 
the same amounts of AS and drug as the samples).  
 
Results were set in relation to control samples of 0 % lysis in PBS 7.4 and 100 % lysis in 
double-distilled water. Total haemolysis must show an absorption of about 2.0 ± 0.2 in 
order to obtain linearity in absorption concentration dependence.  
 
To examine the influence on corneal structure and integrity, cornea was removed 
from fresh pig eyes [Baydoun and Müller-Goymann, 2003] and incubated at 37 °C for 
2 h in the AS formulations. PBS and a sodium dodecylsulfate (SDS) solution in PBS 
0.1 % (w/w) were taken as references. Corneas were incubated for 0.5 h in SDS 
0.1 % (w/w). 
 
After incubation, the corneas were washed with PBS, and immediately fixed with a 
formalin solution 8 % (w/w). The material was dehydrated with an alcohol gradient, put in 
melted paraffin and solidified in block form. Cross sections (< 1 μm) were cut, stained 
with haematoxyline and eosine (H & E), blinded and microscopically observed for 
pathological modifications (n = 3) in co-operation with a pathologist.  
 
 
6.2.2.6 In vivo evaluation using confocal laser scanning ophthalmoscopy  
 
New Zealand albino rabbits of either sex, weighing between 4 and 5 kg were 
separately kept in an air-conditioned, illumination-controlled room at 19 ºC ± 1 ºC and 
76  Ocular Tolerance 
a relative humidity of 50 ± 5 %. They were fed a standard pellet diet and water ad 
libitum. All animals were healthy and free of clinically observable abnormalities. 
  
The experiments of the present investigation were run in accordance with the 
Association for Research in Vision and Ophthalmology (ARVO) resolution on the 
humane handling of animals in ophthalmic and vision research and were approved 
by the local ethics committees for animal experimentation. 
 
25 μl of each tested formulation were repeatedly applied onto the rabbit’s right 
cornea throughout three days, every 2.5 h four times per day and once on the fourth 
day right before the microscopy experiment.  
 
The fluorescent images of the treated rabbit corneas were visualized by CLSO using 
a previously described optical device [Furrer et al. 2000]. The total areas of corneal 
lesions were quantified by an image processing system [Furrer et al. 2000] and 
expressed in percent of the total corneal surface. Data were statistically compared 
applying the Student’s t-test (unpaired samples). A probability level of 0.05 was 
chosen for all comparisons. Calculations were made with a Microsoft Excel 7.0 
program. 
 
 
6.3 Results and discussion  
 
6.3.1  Characterization of AS types 
 
Investigations were performed with two AS types, AS 100 and AS 300, which are  
characterised in chapter 2. 
 
The specific characteristics of the different AS formulations evaluated in vivo and in 
vitro for ocular tolerance are summarized in table 6-1. 
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Tab. 6-1: Characteristics of different AS formulations (D = dispersion, E = emulsion) 
assessed for ocular tolerance, a osmolality adjusted with sorbitol, b not measured, mean value 
(n = 3). 
   
Osmolality (mOsm/kg) Viscosity (mPa s) 
 
D 2 % a
D 15 % 
AS 100 
 
E 15 % 
D 2 % 
D 15 % 
AS 300 
 
 E 15 % 
299 n.m.b
326 15.9 
320 40.0 
a282 n.m.b
a299 7.4 
a308 21.2 
 
 
6.3.2 In vitro evaluation of tissue acceptability 
 
Haemolysis of the AS 100 and AS 300 systems tested do not exceed 1 % even after 
one hour of incubation. The results achieved with different AS types (Fig. 6-1) do not 
differ significantly. 
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Fig. 6-1: Haemolytic activities of different AS formulations (D = dispersion, E = emulsion) 
depending on incubation time (37 °C). Mean ± SD (n = 3). 
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Figs. 6-2 a – c present corneal cross sections after incubation of freshly excised pig 
corneas with various preparations to investigate their influence on corneal cell 
structure and tissue integrity. After incubation in a physiological phosphate buffer 
solution pH 7.4 (Fig. 6-2 a) epithelium (EP) and stroma (ST) structure is maintained. 
Typical stratified epithelial layer can be recognised by the basal columnar cells and 
the squamous surface cells appearing with a bulge at the nuclei (NU). When the 
corneal epithelium is exposed to an irritant, like SDS (Fig. 6-2 b), previously narrow 
intercellular spaces are clearly widened, cells and nuclei are deformed and superficial 
epithelial cells are detached from tissue assembly.  
 
Treating corneas with the tested AS formulations as exemplified in Fig 6-2 c, showing 
a cornea cross section after incubation in AS 100 D 15 %, leaves corneal structure 
and integrity visibly unaffected. Both haemolysis and histologic experiments reveal a 
good AS tissue acceptability. 
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NU
EP 
ST
EP 
ST 
EP 
ST 
(a) 
(b) 
(c) 
 
Fig. 6-2: Histologic cross sections of excised porcine cornea showing epithelium (EP) 
and stroma (ST), stained with hematoxylin-eosin (scale bar 20 µm) after incubation at 
37 °C with: (a) Isotonic phosphate buffer (PBS) pH 7.4 (2 h) NU = nuclei; (b) Sodium 
dodecylsulfate (SDS) solution 0.1% (0.5 h) (c) AS 100 dispersion 15% (w/w), pH 6.5 (2 
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6.3.3 In vivo evaluation of ocular tolerance 
 
The extent of corneal surface damage caused by repeated instillation of AS 
preparations is shown in Fig. 6-4. Two different AS types with characteristics 
mentioned above were tested in comparison to data achieved with a physiological 
sodium chloride solution [Furrer et al., 2002]. Dispersions (D) containing 2 and 15 % 
(w/w) AS and emulsions (E) stabilized with 15 % (w/w) AS were evaluated for ocular 
tolerance (Tab. 6-1).  
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Fig. 6-3: Extent of corneal surface damage (%) in rabbits caused after instillation of various 
AS formulations (D, dispersion; E, emulsion) compared to a sodium chloride solution 
(0.9%). Mean value ± SD (n = 3 – 4), Student’s t-test (unpaired samples), *P < 0.05 
(significant difference) 
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Due to a detectable surface activity, all tested AS systems showed significantly 
higher corneal surface damage, ranging from 6.6 to 15.1 %, as compared to a 
physiological saline solution (Fig. 6-3), which causes about 2 % of damaged corneal 
surface. These damaged areas in the case of a saline solution are a result of 
physiological desquamation observed even in the healthy eye [Furrer et al., 1999]. 
Nonetheless, the total of fluorescent areas with AS treatment, representing harmed 
corneal tissue, never exceeded 19 % (Fig. 6-3). This indicates, according to a 
previously established scale [Kälin, 1994], a good tolerance for all AS preparations 
respecting the tested concentrations. 
 
With regard to dispersions, Fig. 6-3 reveals that raising the AS concentrations from 2 
to 15 % does not necessarily lead to a greater damage of corneal area. Both polymer 
types, AS 100 and 300, showed no significant differences. When comparing D 2 % 
with D 15 %, no significant increase of irritation is observed. In contrast, results 
obtained with preservatives and absorption enhancers have demonstrated the 
influence of the agents’ quantity on corneal injury [Furrer et al., 1999; Furrer et al., 
2002].  
 
Although AS 100 has more pronounced surface properties than AS 300, drawn from 
data of surface tension measurements and emulsion formation and stability [Baydoun 
and Müller-Goymann, 2001], both types reveal no notable differences (Tab. 6-2) 
when instilled in equal concentrations independent of the sort of formulation. The 
degree of polymerization, or in terms of starch derivatives the dextrose equivalent 
(DE) value, seems to have an effect on emulsifying properties but not on the extent of 
ocular irritation. 
 
Emulsions as carrier systems for ocular administration offer the possibilities of 
incorporating lipophilic or difficult-to-solubilize and -stabilize drugs, such as sodium 
diclofenac [Bock et al., 1994]. Ophthalmic emulsions with higher viscosities may 
extend pre-ocular retention times while, on the contrary, often a temporary blurred 
vision appears. Reports on the haemolytic behaviour of surface active agents have 
shown that erythrocyte lysis could be significantly decreased when the lytic agent 
was incorporated into an emulsion system [Jumaa and Müller, 2000]. This membrane 
protective effect described [Jumaa and Müller, 2000] could not be confirmed in eye 
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tolerance evaluation by confocal laser scanning microscopy. While the effects caused 
by an AS type 300 dispersion and emulsion (D/E 15 %) are comparable, AS 100 
imparts visible differences between D and E 15 % (Fig. 6-3, Tab. 6-2). Figs. 6-4 a–c 
show fluorescent images of three different AS preparations, D 2 and 15 % and E 
15 %. Damaged cornea tissue occurs as bright regions resulting in a total of 7.45 % 
(Fig. 6-4 a), 8.5 % (Fig. 6-4 b) and 15.1 % (Fig. 6-4 c). 
 
Tab. 6-2: Statistical comparison of ocular irritation caused by AS formulations using the 
Student’s t-test (unpaired samples, P < 0.05). P < 0.05 = significant difference, n.s. = no 
significant difference,           = not compared.                    .  
 
 
AS 100 
 
 
 
AS 300 
 
Formulation/ 
concentration 
D 2 % D 15 % E 15 % D 2 % D 15 % E 15 % 
D 2 %  n.s.  n.s.    
D 15 % n.s.  P < 0.05  n.s.  AS 100 
E 15 %  P < 0.05    n.s. 
D 2 % n.s.    n.s.   
D 15 %  n.s.  n.s.  n.s. AS 300 
E 15 %   n.s.  n.s.  
 
 
AS emulsions show, like AS dispersions, Newtonian flow behaviour (see results 
2.3.1), while AS 100 E 15 % produces a comparably high viscosity of 40.0 mPa s 
(Tab. 6-1). On the other hand, emulsions may break on contact with the cornea and 
lacrimal fluid which leads to higher local emulsifier concentrations. Both effects may 
explain the increased but still acceptable irritancy.   
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(a) 
(b) 
(c) 
Fig. 6-5: Fluorescent images of rabbit corneas illustrating corneal lesions (bright spots) after 
repetitive instillation of 3 different AS 100 preparations (S, solution; E, emulsion). 
(a) AS 100 S 2 % (w/w) represents 7.45 %, (b) AS 100 S 15 % (w/w) represents 8.5 %, 
(c) AS 100 E 15 % (w/w) represents 15.1 % damaged surface area  
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6.4 Conclusion 
 
Low haemolytic data and histological cross sections of treated excised pig corneas. 
indicated a good tissue acceptability of both AS types tested, which has been 
confirmed in vivo with confocal laser scanning microscopy in rabbit eyes. When 
comparing different AS types, varying in degree of polymerization and molecular 
weight distribution, higher concentrations or superior emulsifying properties do not 
necessarily increase ocular irritation. Polymer stabilized emulsions can be an 
appropriate alternative carrier system for highly lipophilic and poorly soluble ocular 
therapeutics. Hence, AS is a promising new excipient for ophthalmic formulations due 
to satisfactory solubilizing and emulsifying properties coupled with a good eye 
tolerance. 
 
 
References 
 
 
Baeyens V, Gurny, R. 1997. Chemical and physical parameters of tears relevant for the design of 
ocular drug delivery formulations. Pharm Acta Helv 72: 191–202  
  
Baydoun L, Müller-Goymann CC. 2001. Amphiphilic starch: a stabilising agent for medicinal emulsions. 
Arch Pharm, Pharm Med Chem  334 (Suppl. 2): 92  
 
Baydoun L, Müller-Goymann CC. 2003. Influence of n-octenylsuccinate starch on in vitro permeation 
of sodium diclofenac across excised porcine cornea in comparison to Voltaren ophtha. Eur J Pharm 
Biopharm 56: 73–9  
 
Baydoun L, Furrer P, Gurny R, Müller-Goymann CC. 2004. New surface-active polymers for ophthalmic 
formulations: evaluation of ocular tolerance. Eur J Pharm Biopharm 58:169-75 
 
Bock TK, Reer O, Müller BW. 1994. Emulsions as carriers for diclofenac sodium. Eur J Pharm Biopharm 
40 (Suppl.): 26 S 
 
Bock TK, Müller BW. 1994. A novel assay to determine the hemolytic activity of drugs incorporated in 
colloidal carrier systems. Pharm Res 11: 589–91 
 
Chen HB, Yamabayashi S, Ou B, Tanaka Y, Ohno S, Tsukahara S. 1997. Structure and 
composition of rat precorneal tear film. A study by an in vivo cryofixation. Invest Ophthalmol Vis Sci 
38 : 381–7  
 
Dolder R. 1990. Die Tränenflüssigkeit. in: Ophthalmika. Pharmakologie, Biopharmazie und Galenik 
der Augenarzneimittel. Dolder R, Skinner FS (Eds.): 12–3  
 
Draize JH, Woodard G, Calvery HO. 1944. Methods for the study of irritation and toxicity of 
substances applied to the skin and mucous membranes. J Pharmacol Exp Ther 82: 377–90 
 
Ellingson CM, Schoenwald RD, Barfknecht CF, Rao CS, Laban SL. 1992. Rapid toxicological 
model for use in assessing ocular drugs. Biopharm Drug Dispos 13: 417–36  
Ocular Tolerance  85 
Etter JC, Mayer JM. 1985. Biopharmacie des préparations ophthalmiques. Klin Monatsbl Augenheilkd 
186: 417–20  
 
Felt O, Einmahl S, Furrer P, Baeyens V, Gurny R. 2002. Polymeric Systems for Ophthalmic Drug 
Delivery, in: S. Dumitriu (Ed.), Polymeric Biomaterials, Marcel Dekker, New York: 377–421 
 
Furrer P, Mayer JM, Gurny R. 1997. Confocal microscopy as a tool for the investigation of the 
anterior part of the eye. J Ocul Pharmacol Ther 13: 559–78    
 
Furrer P. 1999. Development and application of an ocular tolerance test by confocal microscopy. PhD 
Thesis Lausanne, Switzerland  
 
Furrer P, Mayer JM, Plazonnet B, Gurny R. 1999. Ocular tolerance of preservatives on the murine 
cornea. Eur J Pharm Biopharm 47 (2): 105–12  
 
Furrer P, Plazonnet B, Mayer JM, Gurny R. 2000. Application of in vivo confocal microscopy to the 
objective evaluation of ocular irritation induced by surfactants. Int J Pharm 207: 89–98   
 
Furrer P, Mayer JM, Gurny R. 2002. Ocular tolerance of preservatives and alternatives. Eur J Pharm 
Biopharm 53 (3): 263–80  
 
Gers-Barlag H, Müller A. 2002. Emulsifier-free finely disperse systems of the oil-in-water and water-
in-oil type. United States patent application, Pub. No: US 2002/002007 A1 
 
Greaves JL, Wilson CG. 1993. Treatment of diseases of the eye with mucoadhesive delivery 
systems. Adv Drug Del Rev 11: 349–83  
 
Herzinger T, Korting HC, Maibach H. 1995. Assessment of cutaneous and ocular irritancy: a decade 
of research on alternatives to animal experimentation. Fundam Appl Toxicol 24: 29–41  
 
Hornof M, Toropainen E, Urtti A. 2005. Cell culture models of the ocular barriers. Eur J Pharm 
Biopharm 60: 207–25 
 
Imbert D, Cullander C. 1997. Assessment of cornea viability by confocal laser scanning microscopy 
and MTT assay. Cornea 16:666–74  
 
Järnström L, Lason L, Rigdahl M, Erikson U. 1995. Flocculation in kaolin suspensions induced by 
modified starches II. Oxidized and hydrophobically modified oxidized starch – in comparison with 
poly(viny alcohol) and carboxymethylcellulose. Colloids and Surfaces 104: 207–16. 
 
Jester JV, Li L, Molai A, Maurer JK. 2001. Extent of initial corneal injury as a basis for alternative 
eye irritation tests. Toxicology in Vitro 15: 115–30  
 
Jumaa M, Furkert FH, Muller BW. 2002. A new lipid emulsion formulation with high antimicrobial 
efficacy using chitosan Eur J Pharm Biopharm. 53:115–23  
 
Jumaa M, Müller BW. 2000. Lipid emulsions as a novel system to reduce the hemolytic activity of lytic 
agents: mechanism of the protective effect. Eur J Pharm Sci 9 (3): 285–90  
 
Kälin P. 1994 .Contribution à la validation d’un test de tolérance oculaire sur la souris. PhD Thesis 
Lausanne, Switzerland  
 
Kast A. 1991. Keratoconjunctivitis sicca and sequelae, mouse and rat . In: Eye and ear. Jones TC, 
Mohr U, Hunt RD (Eds.), Axel Springer (Pub.), Berlin Heidelberg New York, pp. 29–37   
 
Kulkarni A, Hopfinger AJ, Osborne R, Bruner LH, Thompson ED. 2001. Prediction of eye irritation 
from organic chemicals using membrane-interaction QSAR analysis. Toxicol Sci 59: 335–45  
 
Lüpke NP. 1985. Hen's egg chorioallantoic membrane test for irritation potential. Food Chem Toxicol 
23:287–91  
Märtins T, Pauluhn J, Machemer L. 1992. Analysis of alternative methods for determining ocular 
irritation. Food Chem Toxicol 30: 1061–7  
86  Ocular Tolerance 
 
Maurer JK, Parker RD, Petroll WM, Carr GJ, Cavanagh HD, Jester JV. 1999. Quantitative 
measurement of acute corneal injury in rabbits with surfactants of different type and irritancy. Toxicol 
Appl Pharmacol 158: 61–70  
 
McGlinchey. 1997. Les amidons spéciaux de type OSA comme stabilisants de boissons. Bios 
boissons conditionnement 28e année 267 : 29–32 
 
Meek KM, Dennis S, Khan S. 2003. Changes in the refractive index of the stroma and its extrafibrillar 
matrix when the cornea swells. Biophys J 85 2205–12  
 
Pape WJW, Pfannenbecker U, Hoppe U. 1987. Validation of the red blood cell test system as in vitro 
assay fort the rapid screening of irritation potential of surfactants. Mol Toxicol 1:  525–36  
 
Pape WJW, Hoppe U. 1990. Standardization of an in vitro red blood cell test for evaluating the acute 
cytotoxic potential of tensides. Arzneimittelforschung 40: 498–502  
 
Patlewicz GY, Rodford RA, Ellis G, Barratt MD. 2000. A QSAR model for the eye irritation of 
cationic surfactants. Toxicology in Vitro 14 (1): 79–84  
 
Qu XD, Lehrer RI. 1998. Secretory phospholipase A2 is the principal bactericide for staphylococci and 
other gram-positive bacteria in human tears. Infect Immun 66 (6): 2791–7  
 
Reddy IK, Ganesan MG. 1996. Ocular therapeutics and drug delivery: an overview. In: Ocular 
therapeutics and drug delivery: a multi-disciplinary approach. Reddy IK (Ed.), Technomic Publishing 
AG/Basel. Pp. 3–29   
 
Reichl S, Bednarz J, Müller-Goymann CC. 2004. Human corneal equivalent as cell culture model for 
in vitro drug permeation studies. Br J Ophthalmol 88: 560–5  
 
Sina JF, Ward GJ, Laszek MA, Gautheron PD. 1992. Assessment of cytotoxicity assays as 
predictors of ocular irritation of pharmaceuticals. Fundam Appl Toxicol 18: 515–21  
 
Van Winkle TJ. 1991. Corneal opacities, spontaneous, mouse. In: Eye and ear. Jones TC, Mohr U, 
Hunt RD (Eds.), Axel Springer (Pub.), Berlin Heidelberg New York, pp. 21–5    
 
Viswananthan A. 1999. Effect of degree of substitution of octenyl succinate starch on the 
emulsification activity on different oil phases. J Environmental Polym Degrad 7 (4): 191–6 
 
Wang J, Fonn D, Simpson TL, Jones L. 2003. Precorneal and pre- and postlens tear film thickness 
measured indirectly with optical coherence tomography. Invest Ophthalmol Vis Sci 44 (6): 2524–8 
 
Wheater PR, Burkitt HG, Daniels VB. 1987. Funktionelle Histologie. (2nd edition), translated by 
Lippert H, Urban und Schwarzenberg (Eds.), München, Wien, Baltimore, p. 328  
 
Wesslén KB, Wesslén B. 2002. Synthesis of amphiphilic amylose and starch derivatives. 
Carbohydrate Polymers 47: 303–11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
Part III 
 
 
Biopharmaceutical aspects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90  Biopharmaceutical Aspects  
7 General biopharmaceutical aspects in ocular therapy  
 
7.1 The ocular application route and bioavailability of ophthalmic 
drugs 
 
Topical administration is the route of choice for treatment of ophthalmic diseases due  
to the blood-ocular barrier, which is the main obstacle in the systemic treatment. Poor 
penetration of many drugs into the eye limits the extent to which the few systemically 
available medications can be used without incurring serious systemic side effects. 
two main sites of the blood-ocular barrier exist, which are the blood-aqueous barrier, 
controlling mostly inward movement, and the blood retinal barrier, controlling 
movement from the retina to the blood [Velez and Whitcup, 1999]. Topically applied 
drugs can reach the intraocular tissues by either the corneal and/or the non-corneal 
(conjunctival–scleral) pathways [Hosoya et al., 2005]. Lipophilic drugs, like timolol, 
pilocarpine or hydrocortisone, are preferably absorbed through the corneal pathway. 
By contrast, comparably small and hydrophilic molecules, such as D-mannitol and 
inulin, favour the conjunctival-scleral route, bypassing the anterior chamber and 
directly accessing the posterior segments of the eye [Hosoya et al., 2005]. Therefore, 
the cornea even though covering only one sixth of the total (human) eyeball surface 
area [Greaves and Wilson, 1993], is considered to be the main pathway for drug 
permeation into the aqueous humour and intraocular tissues.  
 
The permeation route through the cornea varies with the physicochemical properties 
of the drug molecule [Robinson, 1989]. Small uncharged lipid soluble molecules 
preferably take the transcellular, while the less lipophilic ones prefer the paracellular 
pathway. The literature also reports on the existence of carrier-mediated transcorneal 
drug transport in rabbit eyes, e.g. for levofloxacin and L-valyl ester of acyclovir 
[Kawazu et al., 1999; Anand and Mitra, 2002], and on the possible endocytosis of 
nanoparticles [Zimmer et al. 1991]. Despite of that for most topically applied drugs, 
passive diffusion along the concentration gradient, either transcellularly or 
paracellularly, is considered to be the main mechanism for permeation across the 
cornea. Other physicochemical drug properties, such as solubility, partition 
coefficient, molecular size and shape, charge and degree of ionization, also affect the 
route and rate of permeation [Greaves and Wilson, 1993]. Ocular absorption of a 
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drug can be enhanced substantially by increasing its lipophilic character and 
therefore the possibility to permeate directly through the cells by using the 
transcellular pathway. A rapidly penetrating drug has to possess a log octanol/buffer 
pH 7.65 partition coefficient greater than 1 to attain optimal penetration. However, if 
the partition coefficient becomes higher than log 2–3, the corneal permeability is not 
further increased due to the limited permeability of highly lipophilic drugs across the 
predominantly aqueous stroma [Schoenwald, 1993].  
 
Figure 7-1 illustrates the different permeation and elimination routes of the eye 
[Hornof et al., 2005]. 
 
 
Fig. 7-1: Biological barriers, penetration ( ) and elimination ( ) routes of the 
eye (tight barriers are indicated in red, others in green). (1): The main pathway for 
drugs to enter the anterior chamber is via the cornea. (2): Some large and hydrophilic 
drugs prefer the conjunctival and scleral route, and then diffuse into the ciliary body. 
(3): After systemic administration small compounds can diffuse from the iris blood 
vessels into the anterior chamber. From the anterior chamber the drugs are removed 
either by aqueous humour outflow (4) or by venous blood flow after diffusing across 
the iris surface (5). After systemic administration drugs must pass across the retinal 
pigment epithelium or the retinal capillary endothelium to reach the retina and 
vitreous humour (6). Alternatively, drugs can be administered by intravitreal injection 
(7). Drugs are eliminated from the vitreous via the blood–retinal barrier (8) or via 
diffusion into the anterior chamber (9) [adapted from Hornof et al., 2005]. 
 
92  Biopharmaceutical Aspects  
The amount of drug reaching the anterior chamber of the eye depends on two 
competing processes: the rate of drug loss from the precorneal area and the rate of 
drug uptake by the cornea and conjunctiva. Topically applied drugs must encounter 
and compete with the essential physiological processes, like blinking, tear turnover 
and (basal or irritation-induced) lacrimation, protecting the eye but increasing the rate 
of drug loss. All three processes remove the drug and, depending on the drug 
delivery system, the dosage form as well. Additional mechanisms, decreasing ocular 
drug levels, are protein binding and/or drug metabolism [Robinson, 1989].  
 
On the other hand for most drugs uptake by the cornea is too low. The cornea is a 
rather hydrophobic tight junction tissue limiting the absorption of most useful ocular 
therapeutics. The permeability of the corneal epithelium is rather low unless the 
outermost layer is damaged, either physically or by tissue inflammation. The corneal 
endothelium, though hydrophobic as well, is about 200 times more permeable and 
represents a weaker barrier [Greaves and Wilson, 1993]. Once the drug has 
penetrated into the cornea it has to diffuse through the hydrophilic stroma. This 
means that well-absorbed drugs have a mixed hydrophilic/hydrophobic nature with 
an intermediate partition coefficient. For a number of highly lipophilic drugs stroma 
and epithelium pose more difficulties and they tend to accumulate in the corneal 
epithelium. 
 
In summary, ocular drug availability is typically less than 10 % [Davies, 2000] which 
necessitates frequent dosing to maintain therapeutic drug levels. 
 
 
7.2 Optimization of ocular drug bioavailability  
 
One of the main problems of ophthalmic therapy is the maintenance of a therapeutic 
drug level in eye tissues and fluids for a prolonged time period, either through a 
longer contact time of the ocular dosage form or medication at the eye surface or 
slower drug elimination. Conventional eye-drop solutions, which account for 90 % of 
the currently marketed formulations, consist of a specifically formulated aqueous 
solution, which acts as the drug vehicle. Corneal drug penetration can be enhanced 
by directly increasing the drug concentration. This can also be reached by increasing 
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the precorneal reservoir/tear film thickness with viscolysers (e.g. cellulose-ethers, 
polyvinylpyrrolidone and polyvinylalcohol), the application of an immiscible ocular 
ointment or in-situ activated gel-forming systems [Rozier et al., 1989; 
Balasubramaniam et al., 2003]. The two former measures are often unsatisfactory for 
the patient due to changes in visual acuity or blurring. Different alternative strategies, 
the addition of ocular penetration enhancers or mucoadhesive excipients and the 
application of ocular inserts, will be discussed in the following paragraphs.  
 
 
7.2.1 Ocular penetration enhancers  
 
Ocular penetration enhancers, also known as “absorption promoters”, are chemicals 
that modify corneal epithelium integrity and thus promote corneal drug penetration 
and bioavailability [Furrer et al. 2002]. At first they where used as percutaneous 
penetration enhancers but many reports in literature show a clear effect on the 
corneal tissue. The permeability of beta-blockers in rabbit eye [Sasaki et al. 1995] or 
the systemic delivery of insulin could be improved [Yamamoto et al., 1989; Sasaki et 
al. 1994].  
 
The substances applied are mostly amphiphilic/surface active agents, such as 
polyoxyethylene glycol lauryl (-stearyl, oleyl) ether (Brij® 35, 78, 98), sodium 
glycocholate, sodium deoxycholate [Yamamoto et al., 1989], saponin, EDTA and 
ophthalmic preservatives like benzalkonium chloride or paraben [Sasaki et al., 2000]. 
While dimethyl sulfoxide (DMSO) or bile salts show a relatively good ocular 
acceptability, unfortunately some agents, like saponin, cause transient irritation or 
irreversible damage to the eye tissues [Furrer et al., 2002]. 
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7.2.2 Mucoadhesive formulations  
 
7.2.2.1 Bioadhesion and mucoadhesion 
 
The term “bioadhesion” commonly refers to the adhesion between two materials 
where at least one of the materials is a biological substrate. In a bioadhesive drug 
delivery system the excipient(s) of the formulation attach to a biological tissue. In 
case the formulation interacts with the mucus layer that covers a mucosal tissue, the 
term “mucoadhesion” is employed [Robinson, 1989; Edsman and Hägerström, 2005]. 
 
In general, the use of mucoadhesive drug delivery systems offers the advantage of 
enhanced drug bioavailability, for both local and systemic effects, due to a prolonged 
formulation contact time at the site of absorption [Chowdary and Srinivasa Rao, 
2004; Edsman and Hägerström, 2005]. Combined with a controlled drug release, the 
application of such systems improves the patient’s compliance by reducing the 
application frequency [Chowdary and Srinivasa Rao, 2004; Edsman and Hägerström, 
2005]. 
 
 
7.2.2.2 Structural features of the mucous layer and mucin 
 
The mucosa or mucous membrane is a moist tissue that lines particular organs and 
body cavities, such as nose, gastrointesinal tract and airways. Potential 
mucoadhesive drug delivery systems can therefore be developed for the buccal, oral, 
rectal, vaginal, nasal or ocular routes of application. 
 
The mucosa consists of the epithelium itself and the supporting connective tissue, 
the lamina propria, directly underneath. Deeper connective tissue which supports the 
mucosa is called submucosa [Chowdary and Srinivasa Rao, 2004; Edsman and 
Hägerström, 2005]. In single-layered epithelia, as in the intestine and bronchi, there 
are non-specialized and specialized (goblet cells) epithelial cells that secrete mucus 
directly onto the epithelial surface. Multi-layered stratified epithelia, like in the mouth 
and cornea, contain or are adjacent to tissue with specialized glands secreting 
mucus gel. The mucus’ primary function is to mediate the interactions between 
epithelial cells and their environment, by means of lubrication, maintaining the water 
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balance, binding particles and micro-organisms or taking part in the immune 
response [Chowdary and Srinivasa Rao, 2004; Edsman and Hägerström, 2005].   
 
Mucus, which refers to the total secretion from the mucous membrane, is mainly 
composed of mucin glycoproteins and lipids (0.5–5 %), water (95 %) and mineral 
salts (0.5–1 %). Further components are free proteins, enzymes and 
mucopolysaccharides. Mucins, which are the primary component, are a family of 
glycoproteins with a molecular weight of 1–40 million Da. The molecule is composed 
of a protein core, usually with a high serine and threonine content, and numerous O-
glycosidic-linked oligosaccharide side chains bound to the core in a “bottle-brush” 
arrangement. There are two forms: soluble secretory and membrane bound mucin. 
Secretory mucins form viscoelastic gels due to their high molecular weights and 
ability to form complexes through intermolecular disulfide bridges, hydrophobic 
interactions and physical entanglement [Greaves and Wilson, 1993; 
Ceulemans2002a, Edsman and Hägerström, 2005]. Gel-forming mucins (MUC2, 
MUC5AC, MUC5B and MUC6) are responsible for the rheological properties of 
mucus and belong to the largest glycoproteins known. Due to the presence of sialic 
acid and sulphate residues the glycoprotein is negatively charged at physiological pH 
[Ceulemans, 2002a]. Therefore mucin can be viewed as a polyelectrolyte with a high 
charge density capable of holding 30–50 times its weight of water [Greaves and 
Wilson, 1993]. 
 
In the eye, mucus is the predominant component of the ocular tear film, maintaining a 
wet and healthy surface. It is primarily composed of secretory mucin, MUC5AC, 
secreted from conjunctival goblet cells, while membrane-associated mucins, MUC1, 
MUC4 and MUC 16, are present on corneal (squamous) and conjunctival epithelial 
cells [Ellingham et al., 1999, Aristoteli and Willcox, 2003, Gipson, 2004]. MUC7, a 
small soluble mucin, is expressed by the lacrimal gland acini [Gipson, 2004]. Ocular 
mucin is polydisperse, consisting of species with different size, charge, and 
glycosylation patterns that contribute to the structure and function of mucus [Berry et 
al., 1996; Aristoteli and Willcox, 2003].  
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7.2.2.3 Principles of mucoadhesion 
 
The theories (adsorption, diffusion, electronic and wetting theory) that have been 
presented in connection with bioadhesion are based on previously developed 
theories explaining the adhesive performance of adhesives, glues and paints. They 
can be easily extended to describe the bioadhesion and mucoadhesion of polymeric 
materials to biological surfaces, respectively. According to the adsorption theory, the 
formulation adheres to the mucosa as a result of secondary chemical bonds, such as 
van der Waals forces, hydrophobic interactions, electrostatic attractions and 
hydrogen bonds. In the diffusion theory the polymer chains of the formulation diffuse 
into the mucus network and vice versa to form a semi-permanent adhesive bond 
through chain entanglements in the penetration region. The electronic theory 
assumes that an electron transfer develops from the contact between the polymer of 
the formulation and the mucus due to differences in their electronic structure. 
Adhesion occurs because of attractive forces across the electrical double layer 
formed at the interface.  
 
The wetting theory was developed for liquid preparations using the interfacial tension 
to predict spreading and adhesion. The work done in an adhesive bond can be 
calculated from the measured surface and interfacial tension [Edsman and 
Hägerström, 2005]. Of course several of these theories must be combined to explain 
the process of mucoadhesion of particular pharmaceutical excipients and 
formulations [Edsman and Hägerström, 2005], which follows the same pattern: after 
establishment of an intimate contact between the mucoadhesive formulation and the 
mucus layer, the polymer chains and the mucin network interpenetrate to finally form 
bonds depending on their chemical nature. Main structural properties, which enable 
the interpenetration of a polymer and a biological substrate, are for the polymer 
having sufficient polymer chain mobility and flexibility as well as a good solubility 
within the mucus layer, and for both the polymer and the biological substrate having 
a similar chemical network structure which is sufficiently open. 
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7.2.2.4 Factors influencing mucoadhesion 
 
There are many factors that can affect or influence the mucoadhesive interaction 
process. First of all mucoadhesion depends on the mucin type [Rossi et al., 1995] 
and mucin turnover [Lee et al., 2000]. Polymer-related factors are concentration, 
viscosity, molecular weight, degree of cross-linking, swelling and hydration [Mikos 
and Peppas, 1986; Junginger, 1991]. Further important factors are the pH [Lee et al., 
2000], ionic strength and electrolyte concentration [Rossi et al., 1995] of the medium 
and contact/swelling time of the formulation [Lee et al., 2000].  
Thinking of the mechanisms stated to be involved in the bioadhesion process, there 
are many factors, related to the mucin, medium, dosage form and polymer, which 
affect the formation of an intimate contact and interaction between the polymer and 
mucin. It became obvious that results in mucoadhesion studies even depend on the 
experimental setup or if the formulation is for instance dry or hydrated. Attributes that 
affect the mucoadhesive capacity of a polymer have been highly investigated and 
reported in the literature [Edsman and Hägerström, 2005].  
 
There is an optimum molecular weight at which the chains are small enough to 
interpenetrate, but also large enough to entangle with the mucin molecules. This 
optimum depends on the flexibility and conformation of the polymer chain. High 
flexibility forwards interpenetration and in turn depends on the polymer type, 
concentration and density of cross-linking. Flexibility becomes smaller with increasing 
cross-linking density and concentrations. On the other hand at too low concentrations 
there will be not enough chains available for interaction [Smart et al., 1984; Edsman 
and Hägerström, 2005]. The chemical structure, the presence of ionisable groups 
and hydrophilicity of the polymer are important for the polymer-mucin interaction 
process. Especially the ability to form hydrogen bonds (hydroxyl, amine, sulfate and 
carboxyl groups) and/or electrostatic interactions, which is influenced by the (pH-
dependent) charge density of the polymer, are significant polymer features [Ch’ng et 
al. 1985, Edsman and Hägerström, 2005]. A general conclusion which can be clearly 
drawn is that charged molecules show a better mucoadhesive capacity in 
comparison with non-ionic molecules, while when considering toxicity polyanions are 
preferred before polycations and carboxyl containing polymers are better than 
sulfated ones [Edsman and Hägerström, 2005].  
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Polyacrylic acid, a highly investigated polyanionic mucoadhesive polymer [Edsman et 
al., 1996; Ceulemans and Ludwig, 2002b], is capable of electrostatic and 
hydrophobic interactions, hydrogen bonding, and interdiffusion. Both the polyanionic 
hyaluronic acid [Lim et al., 2000] and polycarbophil [Lehr et al., 1991] show a 
prolonged precorneal residence time due to mucoadhesion, while the latter also 
offers an in-situ viscosity increase. Chitosan (polycationic) interacts with the 
negatively charged mucosal surface [Lehr et al., 1991, He et al., 1998]. Further 
mucoadhesive polyanionic polymers are carboxymethylcellulose [Bogataj et al. 2003] 
and polygalacturonic acid [Saettone et al., 1994]. 
 
 
7.2.3 Ocular inserts 
 
Ophthalmic inserts are solid or semisolid, erodible or non-erodible, devices that are 
meant to be placed in the cul-de-sac to deliver an accurate drug dose over an 
extended time period at a comparatively slow and/or a controlled rate. This might 
offer the advantage of an increased patient compliance due to a reduced medication 
frequency and a lower incidence of visual and systemic side effects as a result of a 
decreased drainage into the nasal cavity. Additionally, internal ocular tissues, e.g. 
uveal tract or vitreous humour, can be targeted more easily by absorption via the 
non-corneal conjunctival-scleral penetration routes [Hosoya et al.,2005] and, with 
respect to traditional eye-drop formulations, the absence of water will increase the 
formulation’s shelf life [Greaves et al., 1992; Gurtler et al., 1996].  
 
One of the most successful ocular insert is the Ocusert® Pilo (Alza Corp., Palo Alto, 
USA, 1982). It is an insoluble insert used in the glaucoma treatment. The rate of 
pilocarpine release is controlled by two rate-limiting membranes on either side of the 
drug reservoir. However, the satisfactory kinetic behaviour is mainly owing to the 
unique solubility characteristics of pilocarpine free base and therefore other drugs 
have not been delivered in this system. Since experience has shown that twenty 
percent of all patients lose the insert without being aware of it, patients fitted with the 
device should be checked regularly [Habib and Attia, 1986; Greaves et al., 1992]. 
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Further ocular inserts, like medicated contact lenses [Cendelin et al., 1994], the 
minidisc® or ocular therapeutic system (OTS), ophthalmic rods (= OR/Lacrisert®) 
[Greaves et al., 1992] and collagen shields [Le Bourlais et al., 1998], have been 
introduced. The application of water-insoluble but bioerodible/biodegradable 
[Deshpande et al., 1998] or water-soluble [Gurtler et al., 1996] polymeric delivery 
systems eliminates the need for removing the delivery system after drug release.  
 
Soluble ophthalmic drug inserts (SODI), originally introduced in 1976 by Maichuk 
[Greaves et al., 1992] for the delivery of pilocarpine, have been used for delivery of a 
broad spectrum of ocular drugs. The original unit, a thin homogeneous polymer 
platelet, was made from ABE copolymer, which is a macromolecule consisting of 
acrylamide, vinylpirrolidine and ethylacrylate residues. The insert is placed in the 
inferior conjunctival sac, where wetted by the tear film it becomes plastic within a few 
seconds and can easily adapt to the curved shape of the eye globe. During the 
following minutes (10–15 min) the film turns into a viscous polymer mass, whereupon 
it becomes a polymer solution (30–60 min) [Greaves et al., 1992]. Ever since, water-
soluble “medicated eye films” have been effectively developed and often investigated 
[Habib and Attia, 1986; Fitzgerald and Wilson, 1994] under variation of the polymers, 
preparation procedures, shape and handling (e.g. the new ophthalmic delivery 
system –NODS), of the delivery system [Greaves et al., 1992].   
 
Alternative dry application forms have been described in the literature. Dry eye drops 
are freeze-dried single doses, composed of a hydrophilic preservative-free polymer 
solution containing active ingredients, attached to a tip of soft carrier strips 
[Diestelhorst et al., 1999]. Hydrophilic minitablets for ocular use, which were 
prepared by direct compression of powder mixtures containing mucoadhesive 
polyacrylic acid, demonstrated a prolonged ocular retention in vivo [Ceulemans et al., 
2001, Di Colo et al., 2001; Weyenberg et al., 2004]. 
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7.3 Experimental methods to investigate mucoadhesion and ocular residence 
time 
 
Up to the present, most of information on mucoadhesive polymers has been provided 
by in vitro and ex vivo experiments. In ex vivo or in situ methods, isolated organs or 
tissues are adopted to imitate conditions in living organisms as closely as possible. In 
vivo techniques serve as the ultimate test for polymers that appear promising from 
initial screening using in vitro or ex vivo techniques. In ex vivo and in vivo methods 
the degree of mucoadhesion is derived from the residence time of the formulation at 
the site of application. Many different methods have been developed to investigate 
and compare various polymers in order to decide which one provides the longest 
residence time at the mucosal surface. Others have been employed to study the 
polymer-mucin interaction mechanism itself.  
 
 
7.3.1 In vitro methods 
 
The detachment force method, which is the most commonly employed in vitro test to 
study mucoadhesion, is based on the measurement of peel, shear or tensile stress 
when detaching a formulation from a mucosal surface, i.e. excised tissue or a mucus 
preparation, to calculate adhesion work from force-detachment curves [Lehr et al., 
1992; Thermes et al., 1992; Tamburic and Craig, 1997]. Even though these 
measurements don’t exactly reproduce the specific in vivo situation of the 
polymer/formulation tested, they give useful information about the strength of the 
combined mucoadhesive complex. There are several methods that have been 
developed for different kinds of formulations, like dry tablets [Duchêne and Ponchel, 
1997], microspheres [Chowdary and Srinivasa Rao, 2004] or semisolid vehicles 
[Edsman et al. 1996]. 
 
A simple rheological method to assess the mucoadhesive properties of polymer 
solutions and gels [Hassan and Gallo, 1990] simulates the interpenetration layer by 
mixing the polymer dispersion with the mucin dispersion. A rheological response 
parameter, like viscosity or elasticity, is measured for the mixture and compared with 
the rheological parameters of the polymer and the mucin separately. If the value for 
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the mixture is larger than the sum of the values for the polymer and the mucin, it is 
supposed that an interaction, based on entanglements, conformational changes or 
chemical interactions has occurred to produce a change in the rheological behaviour. 
The method has first been described for viscosity measurements but in the meantime 
it has been adapted and broadly used for different kinds of formulations and 
rheological techniques, mainly oscillatory shear rheology, particularly assessing 
viscoelastic parameters [Tamburic and Craig, 1997; Ceulemans et al. 2001, Edsman 
and Hägerström, 2005].  
 
Oscillatory shear rheology measurements, during which the viscoelastic sample is 
deformed sinusoidally, can be applied to specify whether the polymer system 
investigated is an entanglement network solution or a physical or chemical gel. 
Polymer networks can be divided into two main categories: covalently cross-linked 
materials (gels) and “entanglement networks”. However, quite a number of systems 
exist which possess some properties of both categories. These “physical gels” 
consist of chains “physically” cross-linked into networks, the cross-links themselves 
being of small but finite energy and/or lifetime. In many cases, the nature of the 
physical cross-links is not clearly known, often involving various forces such as 
coulombic, dipole-dipole, van der Waals, charge transfer, and hydrophobic and 
hydrogen bonding interactions [Ross-Murphy, 1995]. 
 
Covalently cross-linked networks are true macromolecules and formed by a variety of 
routes including cross-linking high molecular weight linear chains or step-addition 
polymerization of oligomeric multifunctional precursors. Their molecular weight and 
lifetime are both infinite [Ross-Murphy, 1995].  
 
By contrast, entangled networks are formed by the topological interaction of polymer 
chains, either in melt or solution, when concentration and relative molecular mass 
become larger than a critical value. In this case, they behave as ‘pseudogels’ at 
frequencies higher (time scales shorter) than the lifetime of the topological 
entanglements [Ross-Murphy, 1995]. 
 
In the case of a “Dynamic Stress Sweep” (dss) the elastic (G’) and viscous (G”) 
modulus are measured against an increasing oscillatory stress (or strain) at a 
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constant radial frequency ω. A double logarithmic plot of G’ and G” versus the stress 
can be generated and the linear viscoelastic region (LVER) can be determined. In a 
“Dynamic Frequency Sweep” (dfs) the elastic and viscous modulus are measured 
versus an increasing oscillatory angular frequency ω at a constant stress (strain) 
derived from the LVER. The dfs allows to determine the mechanical spectrum, where 
log G’ and log G’’ values are plotted versus log ω values. 
 
Although the main purpose of the dss experiment is to determine the LVER, the 
results can provide useful information about the structural nature of the polymer 
network. In the case of a high molecular weight polymer dispersion, three different 
situations can be encountered in the dss: G’ >> G’’ values for a chemically cross-
linked system, G’ > G” values for a network consisting of secondary bonds and 
G’ ≤ G’’ values for a physically entangled polymer dispersion.  
 
In a dfs chemically or physically cross-linked systems (strong and weak gels) yield G’ 
values higher than G’’ values (Fig. 7-2) with both moduli being mostly independent of 
the frequency (slope ≈ 0) [Ross-Murphy, 1995]. Owing to secondary interactions, the 
bonds remain fixed irrespective of the angular frequency applied. Therefore the same 
behaviour can be observed even at very low frequencies. 
 
G‘
G“
log G‘ log G“
log ω
Fig. 7-2: Dynamic frequency sweep of a strong or weak gel. 
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Fig. 7-3: Dynamic frequency sweep of an entangled polymer dispersion. 
 
 
Entangled networks on the other hand (Fig. 7-3) result in limiting slopes at low 
frequency (for the elastic modulus G’: slope = 2 and for the viscous modulus G’’: 
slope = 1) in a log-log plot of moduli versus frequency while at intermediate 
frequencies a plateau develops [Ross-Murphy, 1995]. However, in practice due to 
different overlapping interaction mechanisms results may not be that straightforward 
and easy to interpret.  
 
This means that in the case of interactions between mucin and the polymer, as can 
be drawn from a synergistic increase of viscoelasticity in the dss, the dfs results can 
indicate whether secondary chemical bonds or physical entanglements are 
responsible for these interactions. As already mentioned before, dfs measurements 
reveal differences between the slope values of secondary bond networks and 
physically entangled networks, which are most obvious in the low frequency range. 
The following response parameters can be considered: the slope of logG’/logω varies 
between 0 and 2 for respectively a perfect network of secondary bonds and a 
solution without any secondary bonds; the slope of logG”/logω varies between 0 and 
1 under the same conditions. Therefore, the kind of interaction can be derived from 
the difference between the slope values of the mechanical spectra of the 
polymer/mucin mixture and those of the single components. If the slopes of the 
mechanical spectra of the polymer-mucin mixture are smaller (closer to zero) than 
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the corresponding slopes of the mechanical spectra of the polymer and the mucin 
dispersion, the formation of additional secondary bonds after mixing the polymer 
dispersion and mucin can be confirmed [Ceulemans et al., 2001].  
 
Results, leading to the evidence of existent/inexistend polymer-mucin interactions, 
are not always easy to interpret and depend on the concentration of both the polymer 
and mucin, on the mucin type used [Madsen et al., 1998] and on several factors (pH, 
formulation, hydration state of the polymer, etc.) as noted above.  
 
In ocular mucoadhesion experiments by means of oscillatory rheology, porcine 
gastric mucin is applied most commonly. Ocular mucins are not commercially 
available but it was found that typical properties of ocular epithelial mucins, being 
responsible for the mucoadhesive interaction process, are in common with those 
found in gastric mucin [Argüeso and Gipson, 2001]. Characteristics that support the 
use of gastric mucins are that ocular mucins show an extensive sialylation and 
sulfatation of the carbohydrate side chains. Firstly, both sialic acid and sulfate groups 
are generally considered as the structural characteristic being responsible for the 
mucoadhesive interaction observed with gastric mucin [Argüeso and Gipson, 2001; 
Ceulemans 2002b]. Secondly, the rheological behaviour of ocular mucin is primarily 
determined by the gel-forming MUC5AC mucin, which is also responsible for the 
rheological behaviour of gastric mucin [Argüeso and Gipson, 2001; Ceulemans 
2002b]. 
 
When polymer dispersions intended for ocular use are applied topically as low-
viscous preparations, the polymer molecules are fully hydrated. Since the water 
transfer from the mucus to the applied dosage form can be an important factor in the 
mucoadhesion process, as the adhesive and cohesive nature of the mucus gel 
increases when the water content decreases, the hydration state of the 
mucoadhesive polymer has to be considered in order to evaluate the effectiveness of 
the mucoadhesive mechanism [Edsman and Hägerström, 2005]. 
 
Another parameter influencing the mucoadhesive interaction is the concentration of 
the polymer incorporated in the preparation. The polymer concentration should be 
sufficiently high to allow a significant interaction with the glycoproteins in the mucus 
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layer. By contrast, increasing the polymer concentration results in an increase of the 
viscosity, which may cause discomfort to the patient. The bonds between the 
polymer and mucin must be strong enough to resist the exceptionally high shear 
rates present in the eye. 
 
Furthermore, the strategy of mucoadhesion of ocular dosage forms will only be 
efficient if drug molecules are effectively retained in the precorneal area and the time 
course of the release of the drug from the mucoadhesive formulation and permeation 
into the corneal and conjunctival tissue matches the formulation’s increased retention 
time on the ocular surface.  
 
 
7.3.2 In vivo methods 
 
In vivo experiments, precorneal clearance or residence time studies, constitute the 
ultimate testing of an in vitro approved mucoadhesive formulation, as the 
physiological conditions may always alter the adhesive characteristics of the material 
tested. 
 
The main ocular in vivo technique to evaluate a mucoadhesive formulation is gamma-
scintigraphy, e.g. in rabbits [Durrani et al., 1995; Felt et al., 1999; Chowdary and 
Srinivasa Rao, 2004]. This technique allows studying the distribution and intensity of 
radioactivity after application of a radio-labelled ophthalmic dosage form. Elimination 
profiles can be compared either by measuring the time necessary for eliminating 50 % of 
the radioactivity or by measuring the proportion of the radioactivity remaining after a 
given time. 
 
Ocular fluorophotometery is the established method in clinical and laboratory areas 
for evaluating the permeability of the corneal epithelium [McNamara et al., 1997], the 
blood-retinal barriers and the blood-aqueous barrier. By measuring the concentration 
profile of the tracer sodium fluorescein within the anterior eye segment, after 
instillation or injection of a sodium fluorescein solution, the dynamics of intraocular 
diffusion and elimination can be accurately observed. It is a non-invasive method 
causing minimal disturbance to normal physiological functions. The results provide 
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information about the physiological and pathological state of the eye, e.g. with 
diabetic retinopathy, and permit the detection of physiological changes and progress 
in medical treatment.    
 
Meanwhile, as reported in the literature, fluorophotometry has been successfully 
adopted to study the in vivo tearfilm/cornea and anterior eye segment kinetics after 
application of a liquid or a solid ocular dosage form containing sodium fluorescein 
[Ludwig and van Ooteghem, 1989; Ceulemans et al., 2001; Lux et al., 2003]. The 
fluorescence decay of sodium fluorescein in the precorneal tearfilm/cornea, anterior 
chamber and lens can be assessed to study the applied vehicles properties to 
improve ocular residence time or permeation. The increase of bioavailability and the 
prolongation of the precorneal retention time can be due to an increased viscosity of 
the vehicle [Ludwig and van Ooteghem, 1989] and/or the interaction between the 
formulation and the mucus layer present in the tear film. The apparent sodium 
fluorescein concentration in the anterior chamber is a principal measure of 
bioavailability. The concentration decay in the tearfilm/cornea, expressed as the 
percentage decrease per minute during basal lacrimation, may provide useful 
information about the ocular residence time of the fluorescent tracer as compared to 
a conventional eye drop solution.  
 
The way the slit lamp fluorophotometer works is to project a beam of blue light in the  
detector
halogen lamp
filter
scanning lens
eye
blue light
fluorescence light
TMFig. 7-4: Schematic representation of a scanning fluorophotometer (Fluorotron  
Master OcuMetrics, Mountain View, CA, USA). 
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form of a vertical slit into the eye (Fig. 7-4). The radiation is emitted by a tungsten 
halogen lamp and passes through a slit and two excitation filters (transmission 
borders at 415 and 491 nm). At the same time, the detector, a movable scanning 
lens, filtered (transmission borders 532 and 630 nm) to allow only fluoresced light, is 
focussed on the same point in the eye. Since fluorescence can originate from each 
excited molecule along the excitation beam and radiates in all directions the pick up 
optics are also equipped with a slit, designed to gather only a slit image of the 
radiation originating from the focal plane of the excitation radiation.  
fluorophotometer
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Fig. 7-5: Principle of ocular scans. Upper: a fluorescence scan of the anterior segment is 
obtained by moving the intersection diamond, the ‘measurement volume‘, between 
excitation beam and fluorescence viewing  beam along the optical axis of the eye. 
Lower: fluorescence profile; AC = anterior chamber [adapted from Müskens et al., 2001]. 
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Only fluorescence at the intersection of the source light path and the detector light 
path is recorded and the fluorescent compound of interest is measured at only that 
particular point in the eye.  
The apparatus moves this point of focus 149 times along the optical axis of the 
patient’s/volunteer’s eye, who has been asked to look at a fixation lamp in line with 
the lenses, in order to build up a profile of fluorescence (Fig. 7-5). The different 
positions are at a 0.25 mm distance of each other. 
 
The signal measured by the photodetector at each scan-position is the total 
fluorescence of the ‘measurement volume’ as viewed by the detector. This volume is 
defined by the width and height of the excitation radiation beam, the width and height 
of the emission beam and by the angle of the two beams at their intersection. The 
dimensions of this diamond shaped measurement volume limit the spatial resolution 
of the fluorophotometer; only objects more than 0.5 mm removed from each other 
can be distinguished separately. Therefore, the cornea and the tear film response 
cannot be separated and are visible as a single response (Fig. 7-5). A more recently 
described Fluorotron model [Lux et al., 2003] seems to be more precise and allows 
the distinction between cornea and tear film due to a smaller measurement volume.  
For a detailed scanning of the anterior segment of the eye the fluorophotometer can 
be equipped with an anterior chamber adapter. The magnification of this special lens 
is about two times larger compared to the standard lens. On a scan made with the 
anterior chamber adapter only the fluorescence from the first half of the eye (cornea 
and tear film, anterior chamber and lens) is registered. 
 
The tear turnover (TTO; %/min) is the percentage decrease of the fluorescein 
concentration in the tear film per minute due to the basal tear flow. The TTO at tx 
minutes after instillation of the preparation, expressed as percent per minute, is 
defined as [van Best et al., 1993]: 
 
 
 
  C C
(Eq. 1) /min)(%
tC
− t tx+1x
x
tx
TTO 100 ·  =
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where Ct = concentration of fluorescein in the cornea/tear film compartment (ng/ml) at 
time t (min) after instillation. Assuming a monophasic decay of the tear film 
fluorescein with a decay constant k  (min-1): t
 
(Eq. 2) – k t . t  C(t) = C  . e              (ng/ml)  (0)
 
 
one obtains: 
   
TTO = 100 · (1 - e – k t)  (%/min)   (Eq. 3) 
 
Further assuming that the fluorescence measured is proportional to the fluorescein 
concentration in the cornea/tear film compartment, kt is equal to the decay constant 
as obtained by exponential regression to the data points obtained (Fig. 7-6). In case 
of a solution, the fluorescence decay is due to normal lacrimal drainage. However, in 
case of a polymer dispersion or a solid dosage form, the decay of the tracer is 
influenced by the elimination of the preparation (hydration of the preparation, 
dissolution and diffusion of the tracer out of the polymer network). Therefore, an 
Apparent Fluorescein TurnOver (AFTO) is defined [Ceulemans et al., 2001]: 
   
 
AFTO = 100 · (1 - e – k e)   (%/min)         (Eq. 4) 
 
Where k  = apparent elimination coefficient (min-1e ) of the monophasic decay of the 
cornea/tear film fluorescein concentration after application of a preparation. The first 
three measuring points of the fluorescence decay curve, which are influenced by 
reflex blinking and tearing, are excluded to calculate k  and AFTO (Fig. 7-6). e
 
 
However, some factors could influence the response parameters used, which might 
result in both false positive (a polymer or formulation can increase the precorneal 
residence time of a liquid formulation without showing a significant interaction with 
the mucus layer) or false negative (the precorneal residence time of the polymer is 
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prolonged, but the tracer is still drained rapidly through the meshes of the polymer 
network) results [Ceulemans et al., 2001].  
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Fig. 7-6: Determination of the AFTO (apparent tear turnover). Only data points 
between the dashed vertical lines are used for tear turnover determination 
(monophasic decay) [Ceulemans 2002a].
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8 Influence of n-octenylsuccinate starch on in vitro permeation of sodium 
diclofenac across excised porcine cornea in comparison to Voltaren 
ophtha  
 
Published in: Baydoun L, Müller-Goymann CC. 2003. Influence of n-octenylsuccinate 
starch on in vitro permeation of sodium diclofenac across excised porcine cornea in 
comparison to Voltaren ophtha. Eur J Pharm Biopharm 56 (1): 73–9  
 
8.1 Introduction 
 
Non-steroidal, anti-inflammatory drugs (NSAIDs) have proven to be a good 
alternative to topical steroids in the treatment of ocular inflammation. Undesired 
effects of steroids to the eyes include the development of posterior subcapsular 
cataracts and secondary infections due to an immunosuppressive effect. Further a 
steroid induced elevation of intraocular pressure very often occurs which is reversible 
once the steroid application is ceased [Goodman and Gilman, 1996]. 
 
The activity of NSAIDs is mainly based on an inhibitory effect on the synthesis of 
prostaglandins. A number of NSAIDs are approved for ocular application. 
Flurbiprofen and suprofen are used against intraoperative miosis during cataract 
surgery; ketorolac is given for seasonal allergic conjunctivitis and diclofenac for post-
operative inflammation [Goodman and Gilman, 1996; Agata et al., 1984; González-
Peñas et al., 1998]. Ibuprofen and nepafenac have also been reported to be effective 
in the treatment of ocular inflammation [Pignatello et al. 2002; Ke et al, 2000]. 
 
Corneal permeation depends mainly on the drug’s molecular size [Grass et al., 1988; 
Ahmed et al. 1986], on its oil/water partition coefficient [Flynn et al., 1974; Grass et 
al. 1984, 1988; Yoshida and Topliss, 1996] and its degree of ionization [Edwards and 
Prausnitz, 2001; Huang et al., 1983]. Ionizable acidic or basic compounds penetrate 
corneal epithelium mainly in their un-ionized form, which is more lipid soluble 
[Benson, 1974; Mitra and Mikkelson, 1988]. The rate and extent of transcorneal 
transport is influenced by the fraction of ionized and un-ionized molecules, which in 
turn depends on the pKa of the drug and the pH of the formulation [Goskonda et al., 
1999]. Since most NSAIDs are weak acids ionization at lacrimal fluid pH reduces 
drug penetration and permeation rates, and thus drug potency. Lowering the pH of 
the preparation may on one hand positively influence permeation rates and drug 
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stability [Backensfeld et al., 1991] but on the other hand the solubility of these 
substances is affected. pH decrease is additionally limited and should be adjusted 
within a physiologically tolerated pH range, which lies between 5.8 and 11.4 [Dolder, 
1990], finding an acceptable agreement with the drug’s stability optimum.  
 
Aqueous sodium diclofenac (DfNa) solutions are chemically and physically unstable 
[Backensfeld et al., 1991]. Therefore the commercial product Voltaren ophtha 
contains polyoxyethylene-35-castor oil (POC) to solubilize 0.1 % (w/v) DfNa. 
According to the manufacturer the solubilizing effect is based on micellization of the 
drug.  
 
As reported in the literature, DfNa solutions may also be stabilized by the formation 
of inclusion complexes using cyclodextrins [Backensfeld et al., 1991; Reer et al., 
1994; Davies, 2000]. Owing to a weaker binding strength between DfNa and the 
specific cyclodextrin derivative in comparison to POC, DfNa permeation rates can be 
improved. Solutions with decreased pH values are even more effective due to a 
higher diclofenac partition coefficient [Reer et al., 1994]. In vivo experiments in 
rabbits have shown that ocular absorption is enhanced in presence of tramazoline, 
an alpha-receptor stimulant [González-Peñas et al., 1998]. 
 
Amphiphilic starch (AS) is a chemically modified waxy maize starch with both hydrophilic 
and lipophilic surface properties. It is gained by esterification of starch with n-
octenylsuccinic acid [Wolf et al., 2001]. AS is capable of producing polymer stabilized 
emulsions while on the other hand it may solubilize poorly soluble drugs [Baydoun and 
Müller-Goymann, 2000, 2001; Gers-Barlag and Müller, 2002]. Oil-in-water emulsions 
have proven to be appropriate carrier systems for DfNa [Bock et al., 1994]. 
 
Ophthalmic preparations require an acceptably low toxic behaviour. As described in the 
literature, the ocular tolerance of amphiphilic substances can be assessed by performing 
haemolysis studies [Reer et al., 1994; Bock et al. 1994; Pape and Hoppe, 1990; Bock 
and Müller 1994; Reinhart and Bauer, 1995; Kraus et al., 1990; Jumaa and Müller, 2000; 
Nürnberg and Frieß, 1994] which correlate highly with the Draize test and may allow to 
reduce the number of animals needed for in vivo studies [Pape and Hoppe, 1990]. 
Reports on red blood cell studies performed with Voltaren ophtha reveal high haemolytic 
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activities, which indicate a very low tolerance [Reer et al., 1994, Baydoun and Müller-
Goymann, 2000]. It was supposed that the haemolytic effect is caused by the surfactant 
POC [Reer et al., 1994].  
 
The primary objectives of the present study were to investigate the influence of AS 
on corneal in vitro permeation behaviour of DfNa. Permeation studies were 
performed through excised porcine cornea from different AS preparations, i.e. 
solutions and an emulsion system. Special focus was put on the variations 
considering AS concentrations, pH value and presence of preservative. Data were 
compared to those of a POC solution, a pure buffer solution, Voltaren ophtha and 
Voltaren ophtha sine (not preserved). All preparations contained DfNa 0.1 % (w/v) in 
accordance with Voltaren ophtha. 
 
In order to interpret previously obtained results of permeation studies [Baydoun et al., 
2002], saturation concentrations of DfNa depending on solubilizer type, solubilizer 
concentration and pH were also determined.  
 
Moreover an attempt was made to explain the high in vitro haemolysis data achieved 
with Voltaren ophtha. Besides DfNa and POC, Voltaren ophtha eye drops contain 
boric acid and tromethamine1 for osmolality and pH adjustment and the preservative 
thimerosal (manufacturer information). POC, which is also known as Cremophor EL, 
is often applied in parenteral emulsions as it is well tolerated by human erythrocytes 
[Jumaa and Müller, 2000]. Various solutions containing different substance 
concentrations and combinations were screened to find the component or 
components combination responsible for the high haemolytic effect. 
 
 
 
 
 
 
 
 
 
 
1 The name of the marketed product following this composition is currently “Diclo CV”, while 
the unpreserved formulation is still referred to as Voltaren ophtha sine. Both are still provided 
by the manufacturer mentioned. 
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8.2 Materials and methods 
 
 
8.2.1 Materials  
 
DfNa was purchased from Synopharm (Barsbüttel, Germany), medium chain 
triglycerides (MCT 812) and tromethamine from Hüls (Witten/Ruhr, Germany), 
purified castor oil from Henry Lamotte (Bremen, Germany), polyoxyethylene-35-
castor oil (POC, Cremophor® EL) from BASF (Ludwigshafen, Germany), sorbitol from 
Caesar & Loretz (Hilden, Germany), thimerosal from Synopharm (Barsbüttel, 
Germany), boric acid and sodium hydroxide from Merck (Darmstadt, Germany). 
Voltaren ophtha® and Voltaren ophtha® sine (not preserved) were provided by 
Novartis ophthalmics (Weßling, Germany). Sodium chloride, potassium dihydrogen 
phosphate and disodium hydrogen phosphate (all pro analysi), purchased from 
Merck (Darmstadt, Germany), were used to prepare isotonic phosphate buffer pH 7.4 
(PBS 7.4) and pH 6.4 according to the German Pharmacopoeia (DAB 2001); all 
substances used were of analytical or pharmacopoeial grade. 
 
Acetonitrile and acetic acid (both HPLC grade) were obtained from J.T. Baker (Deventer, 
the Netherlands); AS type 100, an emulsifying starch, was supplied by National Starch & 
Chemical (Manchester, UK); double-distilled water was used for all preparations. 
 
 
8.2.2 Experimental methods 
 
8.2.2.1 Preparation of AS formulations  
 
All preparations investigated contained 0.1 % (w/v) DfNa and were preserved with 
thimerosal 0.004 % (w/v) in accordance with Voltaren ophtha. pH values were adjusted 
to 6.5 and 7.4 using a 0.1 N sodium hydroxide solution. Preparations were isotonized 
with sorbitol if necessary. The investigated POC solution contained 5 % (w/w) solubilizer.  
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AS dispersions were prepared at concentrations of 15 and 20 % (w/w) in double-distilled 
water using a magnetic stirrer. Moisture contents were previously determined by 
thermogravimetry (Thermal Analysis System SSC 5200, Software: MAS 5700 MA-
Station Version 3.2, SSC 5200H Disk-Station Version 3.2, Version/Typ: DSC 220C, 
Seiko Instruments, Tokyo, Japan).  
 
An oil-in-water (o/w) emulsion (10 % (w/w) oil phase) stabilized with 15 % (w/w) AS 
100 was prepared. The oil phase consisted of MCT 812 and castor oil (1:1). AS was 
fully dissolved in cold water and added in a stepwise manner to the oil phase using 
an Ultra-Turrax (Janke & Kunkel, Staufen, Germany). The pre-emulsion was passed 
through a high pressure homogenizer (Niro Soavi, type: Panda, Parma, Italy) six 
times at room temperature applying a pressure of 400 bar. The stock emulsion (AS 
100 22.5 % (w/w), and lipophilic phase 15 % (w/w)) was mixed with a DfNa solution 
adjusting to a drug concentration of 0.1 % (w/v) and homogenized again to achieve a 
submicron emulsion (D90 below 1 µm). Particle size distribution was analysed by 
laser diffraction (Mastersizer MS 20, Malvern, Worcs, UK) and calculated by Malvern 
SB 09 software using the Mie approximation. pH was adjusted to 6.5 since a 
breaking of the emulsion was observed at pH values higher than 7 [Baydoun and 
Müller-Goymann, 2000]. 
 
Osmotic activities of investigated preparations were analysed by freeze point 
measurements (Halbmikroosmometer, Knauer KG, Berlin, Germany; the apparatus 
was calibrated with a sodium chloride solution (400 mOsm/kg) and bidistilled water (0 
mOsm/kg)) and vapour pressure measurements (Dampfdruckosmometer type: No 
11.00, Knauer KG; the apparatus was calibrated with sorbitol solutions within the 
concentration range of 3.0–8.0 % (w/w); the correlation coefficient obtained was > 
0.999). The osmolalities of all preparations tested in permeation experiments, 
excluding PBS pH 7.4, are listed in table IV.2.1. 
 
Viscosities were determined using a capillary viscosimeter (Ubbelohde viscosimeter) at 
a temperature of 20 °C. 
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8.2.2.2 Permeation experiments through excised porcine cornea 
 
Preparation of diffusion apparatus: Prior to the experiments the corneas were carefully 
removed from the freshly enucleated pig eyes by incising the sclera circularly at 
approximately 2 mm from the corneal rim and immediately stored in PBS 7.4. The bulbi 
were transported in a safely closed plastic bag to avoid dehydration at approximately 
4 °C and prepared within 1 h of death. Permeation experiments were carried out with 
modified Franz diffusion cells (Fig. 8-1) [Franz, 1975]. The excised cornea was 
positioned on the receptor half-cell facing it with the endothelial surface. A small amount 
of silicon paste was placed on the ground glass below the cornea to prevent leakage 
and a polycarbonate filter TMTP 5 μm (Millipore, Eschborn, Germany) was put 
underneath for higher stability. The donor medium consisted of the investigated 
formulation while PBS 7.4 was used as receptor medium. The cells used had a diffusion 
area ranging from 0.1963–0.2376 cm2 and a receptor volume varying between 5.8 and 
9.2 ml. The cells were kept at 37 ºC in a water bath and the receptor solutions were 
vigorously stirred with magnetic stirring bars.  
 
isotonic
phosphate  buffer
pH 7.4
excised
porcine cornea
donor
water bath
at 37 °C
magnetic stirring bar
250µl-Hamilton syringe
 
Fig. 8-1: Modified Franz diffusion cell 
Samples of 250 μl were taken from the receptor compartment over 20 h to obtain 
correlation coefficients of 0.99 for all permeation profiles. Permeation profiles which 
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showed a sudden increase in permeation behaviour or correlation coefficients < 0.99 
were disregarded due to a possible loss of corneal tissue integrity throughout the 
experiment.  
 
The sampled volumes were replaced by fresh PBS 7.4. Permeated DfNa was 
analysed by UV-HPLC at 276 nm. Permeation coefficients were calculated according 
to Refai and Müller-Goymann (1999). 
 
The HPLC system from Waters (Milford, MA, USA) consisted of a ‘486’ tuneable 
absorbance detector, a ‘712 plus’ autosampler and two 515 HPLC pumps. 
Separation was achieved with an analytical Hypersil ODS (particle size 5 µm) column 
(125 × 4 mm) from Grom (Herrenberg, Germany). The analytical Software Millenium 
32 from Waters was used to determine the peak sizes of the permeated amounts of 
DfNa. 
 
The mobile phase consisted of double-distilled water/acetonitrile/acetic acid 
(50/50/2). The flow rate was 1.6 ml/min and DfNa was monitored 
spectrophotometrically at 276 nm.  
 
Linear correlation between peak area and DfNa concentrations was obtained within 
the concentration range of 0.05–25 µg/ml. The correlation coefficient was 0.999. 
 
 
8.2.2.3 Red blood cell haemolysis studies 
 
Red blood cells were obtained from human blood (27-year-old female with common 
blood chemistry) by centrifugation (5 min, 1000 × g). After the supernatant plasma 
was removed the erythrocytes were washed three times with PBS 7.4 in order to 
remove serum proteins. Using PBS 7.4 an erythrocyte stock dispersion with a fixed 
haemoglobin concentration was prepared. The stock dispersion was refrigerated and 
kept no longer than 24 hours.  
 
One hundred microlitres of the stock dispersion were added to 1000 µl sample, well 
shaken and incubated at 37 °C for different time periods (15 min, 30 min and 1 h). 
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The samples were shaken every 5 min. After centrifugation (3 min, 750 × g), to 
remove intact erythrocytes and debris, 100 µl of the supernatant were added to 
2000 µl of an ethanol/HCl mixture (40 parts of ethanol 99 % (v/v) and 1 part of 
hydrochloric acid 37 % (w/v)) and centrifuged again (3 min, 1000 × g). The 
ethanol/HCl mixture avoids haemoglobin precipitation [Jumaa and Müller, 2000]. 
 
The absorption of the subsequently achieved supernatant was measured by 
spectrophotometry at 398 nm against blank samples (ethanol/HCl mixtures containing 
the same amounts of AS and drug as the samples).  
 
Results were set in relation to control samples of 0 % lysis in PBS 7.4 and 100 % lysis in 
double-distilled water. Total haemolysis must show an absorption of about 2.0 ± 0.2 in 
order to obtain linearity in absorption concentration dependence.  
 
AS 100 dispersions containing 2, 4, 6, 8 and 10 % (m/m) AS with and without 0.1 % 
DfNa (m/v) were tested and compared to a pure DfNa solution 0.1 % (m/v) in double 
distilled water (0 % AS, isotonized with sorbitol, pH adjusted to 6.5)  For comparison 
Voltaren ophtha® (0.1 % DfNa) and Voltaren ophtha sine (unpreserved, 0.1 % DfNa) 
were tested.  
 
8.2.2.4 Solubility studies 
 
To investigate saturation concentrations of DfNa, AS 100 and POC solutions with 
increasing solubilizer amounts were prepared (AS 100: 2, 4, 6, 8 and 10 % (w/w), POC: 
0.1, 0.5, 1, 5 % (w/w)). Surplus amounts of DfNa were added to the solutions and stirred 
for 48 h at a temperature of 20 °C on a magnetic stirrer. After centrifugation DfNa 
concentrations of the supernatant were measured by UV detection at 276 nm. The 
studies were performed at pH 6.5 (PBS 6.5, phosphate buffer 6.4 prepared according to 
the German Pharmacopoeia, adjusted to pH 6.5 with HCl) and 7.4 in phosphate buffer 
solutions. 
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8.3 Results and discussion 
 
8.3.1 In vitro permeation studies 
 
Fig. 8-2 shows that AS dispersions seem capable of promoting corneal DfNa 
permeation activity when compared to permeation profiles of Voltaren ophtha. 
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Fig. 8-2: Permeation profiles of preserved and unpreserved AS 100 15 % (w/w), pH  
7.4 and Voltaren ophtha 
 
 
In order to exclude a possible permeation enhancing effect caused by the 
preservative, dispersions with and without thimerosal were tested. As demonstrated 
in Fig. 8-2 and Table 8-1 showing permeation profiles and permeation coefficients, 
neither in the case of an AS dispersion 15 % (w/w) pH 7.4 nor in the case of Voltaren 
ophtha did thimerosal influence the permeation activity of DfNa. These findings are in 
agreement with results reported on the ocular tolerance of preservatives [Furrer et 
al., 1999, 2002]. In vivo experiments on murine cornea showed that a 0.01 % 
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thimerosal solution is not more damaging than a physiological saline solution [Furrer 
et al., 1999].        
 
The permeation profiles in Fig. 8-3 reveal that the highest permeability is visibly 
reached with solutions of DfNa in pure phosphate buffer pH 7.4. A 15 % (w/w) AS 
100 dispersion shows higher corneal permeability than Voltaren ophtha. However, 
permeation activity is greatly reduced with rising AS 100 concentrations, as the 
profile for a 20 % (w/w) AS 100 dispersion shows (Fig. 8-3). To a certain extent a 
higher viscosity is responsible for smaller diffusion speeds. 
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Fig. 8-3: Permeation profiles of sodium diclofenac solutions containing different amounts 
of solubilizer 
 
 
Nevertheless, AS 100 with a concentration of 20 % (m/v), which reveals a dynamic 
viscosity of 48.2 mPa s, shows permeation data comparable with Voltaren ophtha or 
a POC solution 5 % (w/w) (Fig. 8-3). Both reveal viscosity values around 1 mPa s. 
This indicates that drug permeation is also influenced by interactions between drug 
and solubilizer.  
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 Permeation coefficient a 
P (cm/s) * 10-6  
n Osmolality a 
(mOsm/kg)  
    
Voltaren ophtha 1.17 ± 0.25 9 310 ± 4.6 
    
Voltaren ophtha sine 1.33 ± 0.15 4 308 ± 3.6 
    
AS 100 dispersion 15 % 
(w/w)  
with thimerosal pH 7.4 
 
2.51 ± 0.28 
 
4 
 
310 ± 4.0 
    
AS 100 dispersion 15 % 
(w/w) 
without thimerosal pH 7.4 
 
2.75 ± 0.34 
 
4 
 
324 ± 5.3 
    
AS 100 dispersion 15 % 
(w/w)  
pH 6.5 
 
2.37 ± 0.10 
 
5 
 
326 ± 7.1 
    
AS 100 dispersion 20 % 
(w/w)  
pH 7.4 
 
1.11 ± 0.10 
6 
 
433 ± 9.8 
    
AS 100 emulsion 15 % 
(w/w)  
pH 6.5 
 
1.24 ± 0.11 
 
3 
 
320 ± 5.6 
    
POC solution 5 % (w/w) 
pH 7.4 
 
1.63 ± 0.09 
 
6 
 
299 ± 2.5 
    
PBS, pH 7.4 9.63 ± 0.83 3  
Tab. 8-1: Permeation coefficients and osmolalities (n = 3) of different preparations 
containing sodium diclofenac 0.1 % (w/v),  a each value represents mean ± SD 
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Solubility profiles (Fig. 8-4) point out the solubilization capacities of AS and POC at 
different pH values and concentrations. POC leads to comparably high saturation 
concentrations. AS only increases solubility at pH 6.5 while it seems to lose 
solubilizing qualities at pH 7.4. This agrees with the loss of emulsifying properties at 
pH values exceeding 7 [Baydoun and Müller-Goymann, 2000]. Another cause for 
reduced interactions may be a greater repulsive effect due to negatively charged 
octenylsuccinate side chains and also negatively charged DfNa at higher pH values.  
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Fig. 8-4: Saturation concentrations of sodium diclofenac versus solubilizer  
concentration (n = 3) 
 
Reports dealing with corneal DfNa permeation have shown that permeation data 
correlate with binding forces between drug and complexing or solubilizing agents 
[Reer et al., 1994]. Data obtained with AS also point out that permeation is generally 
decreased in presence of a solubilizing agent, in accordance with results achieved 
with complexing agents [Reer et al., 1994]. Higher absorption rates from micellar 
solutions can only be expected if the tenside monomers influence the structure of the 
epithelial cells or the tight junctions or if the drug molecules can easily leave the 
micelles to be absorbed. 
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A higher solubilizing ability, as in the case of POC, and higher solubilizer 
concentrations lead to diminished permeation activities. In the case of POC the 
solubilizing mechanism is based on a micellization of the drug while the mechanism 
of interaction between AS and DfNa is still unknown. AS may form inclusion 
compounds; however, the interactions seem to be weaker than those achieved with 
POC.  
 
The permeation coefficients (Table 8-1) further show that incorporation of DfNa into 
an emulsion system also reduces the drug’s permeation capacity. This can be 
explained by a higher viscosity of the system as compared to the pure starch 
dispersion. But since DfNa itself is an amphiphilic compound it may as well be 
integrated to the system’s interface which can lessen the ability of DfNa to permeate 
through the physiological membrane due to a reduced concentration gradient of the 
free drug. 
  
Although an improved permeability was expected for pH 6.5 due to a higher 
lipophilicity of acidic substances at lower pH values [Reer et al., 1994], the 
permeation coefficient does not significantly differ from that achieved at pH 7.4 
[Baydoun et al., 2002]. This can be due to a pH-dependent change in the AS 
configuration linked with the changes in solubilising capacities (Fig. 8-4). A lower pH 
should promote permeation but since AS seems to be a stronger solubilizer at pH 6.5 
a more rapid permeation of DfNa is hindered.  
 
 
8.3.2 Haemolysis studies  
 
Within 15 min none of the investigated AS 100 preparations including a pure 0.1 % 
(w/v) DfNa solution show haemolysis data higher than 1 % (Fig. 8-5). While Voltaren 
ophtha shows a very high haemolysis, as already reported in the literature [Reer et 
al., 1994, Baydoun and Müller-Goymann, 2000], which is about 33 % after 15 min 
(Fig. 8-5) and 87 % after 60 min (Fig. 8-6), the AS and DfNa systems’ haemolytic 
effect remains below 1 % after 1 h (data not shown).  
 
It was supposed that the haemolytic effect of the commercial product is caused by 
the surfactant contained [Reer et al., 1994] but, as indicated in Fig. 8-6, the haemolytic 
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 activity of Voltaren ophtha becomes smaller when sorbitol 4 % (w/w) is added. This is 
an indication of a mere osmotic haemolysis. Additionally, POC solutions of 1, 2.5 or 
5 % (w/w), isotonized with sorbitol and adjusted to pH 7.4 yield no markedly high 
haemolysis (Fig. 8-6). Replacing sorbitol by sodium chloride or adjusting pH with 
sodium hydroxide instead of tromethamine led to the same results already pointed 
out in Fig. 8-5 (data not shown). 
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Fig. 8-5: Haemolytic activities of different AS dispersions as compared to a pure DfNa 
solution  0.1 % (w/v) (0 % AS) and to Voltaren ophtha after 15 min incubation at 37 ºC (n = 3)  
 
In order to assess the component(s) in Voltaren ophtha which are responsible for the 
high haemolysis data, the preparations listed in Fig. 8-6 were tested. It can be seen 
that an isotonized POC solution (Fig. 8-6, columns 3–5) does not show significant 
haemolytic potential.  
 
The apparent high haemolytic activity of boric acid (Fig. 8-6, column 1) is also 
lowered immensely when the solution contains sorbitol. Column 6 and 7 in Fig. 8-5 
reveal the same: in the presence of sorbitol the haemolysis of a POC/boric acid 
mixture is diminished.  
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Red blood cells show high haemolytic data when mixed with isotonic amounts of 
boric acid. This is due to the uptake of boric acid by the erythrocyte. If there is no 
additional isotonizer (sorbitol) the osmotic activity drops to hypotonic values, water 
flows into the cells followed by their breakdown. The erythrocyte membrane is not 
impermeable to all substances such as urea or boric acid [Jumaa and Müller, 1999]. 
This effect has also been described in articles dealing with parenteral emulsions. 
Emulsions isotonized with glycerol (2.5 % (w/w)) show high haemolytic activities 
Fig. 8-6: Haemolytic activities of Voltaren ophtha, Voltaren ophtha sine and Voltaren 
ophtha containing sorbitol 4% (w/w) in comparison to different preparations after 60 min 
incubation at 37 ºC (n = 3) 
1: boric acid 1.857% (w/w), sorbitol 5% (w/w), pH 7.4, adjusted with tromethamine  
2: boric acid 1.857% (w/w), pH 7.4, adjusted with tromethamine 
3: POC 1% (w/w), sorbitol 5% (w/w), pH 7.4, adjusted with NaOH 0.1 N  
4: POC 2.5% (w/w), sorbitol 5% (w/w), pH 7.4, adjusted with NaOH 0.1 N 
5: POC 5% (w/w), sorbitol 5% (w/w), pH 7.4, adjusted with NaOH 0.1 N 
6: POC 5% (w/w), boric acid 1.857% (w/w),  sorbitol 5% (w/w), pH 7.4, pH 
adjusted with NaOH 0.1 N 
7: POC 5% (w/w), boric acid 1.857% (w/w), pH 7.4, adjusted with NaOH 0.1 N 
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when incubated with red blood cells, while glycerol did not have any lytic properties 
when added to an already isotonic system [Jumaa and Müller, 1999].  
 
 
8.4 Conclusion 
 
The high in vitro haemolysis found with Voltaren ophtha is primarily based on an osmotic 
effect due to the erythrocyte’s membrane uptake of boric acid which serves as an 
isotonizing substance. In this case the in vitro haemolysis test is no reliable method to 
evaluate the ocular irritation of Voltaren ophtha.  
 
Haemolysis investigations respecting the toxic behaviour of the investigated DfNa-AS 
systems reveal that these formulations do not significantly affect the human erythrocyte.  
 
As compared to Voltaren ophtha, AS indirectly supports the permeation activity of 
DfNa. It could be seen that the permeated amount depends on concentrations and 
solubilizing abilities of the solubilizer used. The highest permeation activity can be 
reached with solubilizer-free systems. Perfusion speed is greatly reduced when a 
solubilizer is added.  
 
Although AS does not solubilize DfNa as efficiently as POC, it leads to higher 
permeation values due to a quicker release of the drug from the drug-polymer 
complex. Since pH, within the tested range, does not greatly influence permeation 
behaviour an eye drop formulation containing AS adjusted to pH 6.5 is proposed due 
to higher saturation concentrations reached for DfNa at this pH value. 
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9 Rheological study of the n-octenylsuccinate starch-mucin interaction 
mechanism  
 
9.1 Introduction 
 
Divers bioadhesive drug delivery systems have been investigated to prolong the 
residence time of a dosage form at specific sites, which promotes drug absorption.  
 
Together with mucin-related and medium-related factors [Rossi et al., 1995; Lee et 
al., 2000] various conditions and properties related to the polymer, such as 
concentration, viscosity, molecular weight or swelling and hydration, have been 
described, which support the interaction process of a polymer with the mucin layer 
[Mikos and Peppas, 1986; Junginger, 1991]. Several structural features of a polymer 
in a dosage form are known to effect the formation of intimate contact and 
participation in the interaction polymer-mucin process. An important chemical 
characteristic is the presence of ionisable groups and strong hydrogen-bonding 
groups (-OH, -COOH), enabling the polymer to form hydrogen bonds and/or 
electrostatic interactions at the polymer mucin interface [Ch’ng et al. 1985, Edsman 
and Hägerström, 2005]. Polycationic polymers like chitosan interact with the 
negatively charged mucosal surface [Lehr et al., 1991, He et al., 1998] while 
polymers with high surface energy properties favour the spreading onto mucus [Lehr 
et al., 1992]. 
 
Recently a thiolated poly(methacrylic acid)-starch composition with improved 
mucoadhesive properties, based on the formation of disulfide bonds between the 
thiolated polymer and cysteine-rich subdomains of the mucous gel, was developed 
and investigated [Bernkop-Schnürch et al., 2004].  
 
Amphiphilic starch of the n-octenylsuccinate starch type (AS) is a chemically modified 
waxy maize starch gained by substituting hydrophilic starch moieties by lipophilic n-
octenylsuccinic acid groups [Gers-Barlag and Müller, 2002; Järnström et al, 1995]. 
Consequently, the starch acquires emulsifying properties due to feasible formation of 
hydrophobic-hydrophobic interactions. Despite the surface active properties AS 
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displays, in vivo investigations in rabbit eyes have attested a good ocular tolerance of 
both AS dispersions and emulsions [Baydoun et al., 2004].  
 
The aim of the present study was to investigate possible interaction properties of AS 
with mucin using oscillatory shear rheology. Dynamic stress sweeps of different AS-
mucin concentration combinations have been recorded. In order to clarify if 
rheological synergism is based on the formation of secondary bonds dynamic 
frequency sweeps have been performed. 
 
 
9.2 Materials and methods 
 
9.2.1 Materials  
 
Sorbitol was purchased from Caesar & Loretz (Hilden, Germany), mucin Type II: 
crude from porcine stomach from Sigma Chemicals (St. Louis, MO, USA). Sodium 
chloride (Federa, Brussels, Belgium) and calcium chloride, magnesium chloride and 
potassium chloride, sodium hydrogen carbonate, sodium dihydrogen phosphate 
dihydrate and disodium hydrogen phosphate dihydrate, all purchased from Merck 
(Darmstadt, Germany), were used to prepare Simulated Lacrimal Fluid (SLF) and 
isotonic phosphate buffer pH 7.4 (PBS). PBS consists of NaH2PO4.2H2O (4.03 g/l) 
and Na2HPO4·2H2O (16.25 g/l). SLF consists of KCl (1.79 g/l), NaCl (6.31 g/l), 
NaHCO3 (2.18 g/l), CaCl2 (44.4 mg/l) and MgCl2 (47.6 mg/l) and pH was adjusted to 
pH 7.4 using 1 N HCl. Purified or double-distilled water was used for all preparations. 
All used substances were of pharmacopoeial or reagent grade. N-octenylsuccinate 
starch (AS), AS type 100, was supplied by National Starch & Chemical (Manchester, 
United Kingdom). 
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9.2.2 Experimental methods 
 
9.2.2.1 Preparation of tested AS and mucin dispersions for rheological 
measurements  
 
An AS 100 stock dispersion containing AS 40 % (w/w) in double-distilled water, 
adjusted to a pH value of 6.5 using a 0.1 N NaOH solution, was prepared in advance. 
This polymer dispersion was stirred for about 1 h at room temperature using a 
magnetic stirrer and was kept in the refrigerator (6 ± 2 °C) for at least 24 h in order to 
achieve complete polymer hydration.  
 
The examined AS 100 dispersions were prepared by diluting the required amount of 
the polymer stock dispersion with PBS adjusting AS 100 concentrations of 25, 27.5 
and 30 % (w/w). Moisture contents of the starch powder were previously determined 
by thermogravimetry (Thermal Analysis System SSC 5200, Software: MAS 5700 MA-
Station version 3.2, SSC 5200H Disk-Station Version 3.2, version/type: DSC 220C, 
Seiko Instruments, Tokyo, Japan). 
 
To prepare the mucin dispersions (12, 16 and 20 % (w/w)) the required amount of 
mucin powder was dispersed in SLF using a magnetic stirrer. To ensure complete 
hydration of the mucin the dispersions were stirred for 24 h at room temperature.  
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Fig. 9-1: Mucin-polymer concentration combinations tested, open circles: dss 
measurements (n=3); filled circles dss and dfs measurements (n=3); centre 
point (asterisk): dss and dfs measurements (n=9). 
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To analyse the degree and mechanism of interaction between AS 100 and mucin, 
equal amounts (w/w) of polymer dispersion and mucin dispersion were mixed 
reducing the concentration of both the polymer and mucin in half. This dilution 
procedure should as much as possible simulate in vivo conditions as obtained after 
instillation of an eye drop. Since, under normal circumstances, the maximum volume 
of the precorneal tear film is about 10 µl and the maximum volume which can be held 
by the eye without spilling to the cheek is 20 µl, the instillation of a 10 µl eye drop 
leads to a 1:1 dilution with lacrimal fluid [Robinson, 1989; Ceulemans, 2002].  
 
In order to compare the rheological response of the polymer/mucin mixture with the 
rheological behaviour of the single components, equal amounts of the AS dispersion and 
the mucin dispersion were mixed with SLF, respectively. The polymer dispersion’s 
rheological features are due to polymer/polymer, polymer/PBS and polymer/ SLF 
interactions while on the other hand mucin/mucin and mucin/SLF interactions are 
measured. Dynamic stress sweeps (dss) and dynamic frequency sweeps (dfs) have 
been performed with seven different concentration combinations, AS/mucin 25/12,  
25/20, 27.5/12, 27.5/16 (centre point), 27.5/20, 30/12 and 30/20 % (w/w), as illustrated in 
figure 9-1. 
 
 
9.2.2.2 Oscillatory shear rheology 
 
Oscillatory shear rheology was applied to study the samples’ visco-elastic properties, 
which were assessed by the calculation of storage moduli (G’), which represent the 
elastic part, and loss moduli (G’’), which represent the viscous part of the studied 
sample. Polymer-mucin interactions, either through secondary bond formation, 
physical entanglement or a combination of both, can be drawn from a synergistic 
increase of visco-elasticity as compared to the visco-elastic properties of the single 
components [Ross-Murphy, 1995; Ceulemans et al., 2001]. 
 
The influence of AS on the mucin network was analysed using a Carri-Med CSL² 100 
rheometer (TA Instruments, Brussels, Belgium) fitted with a double-concentric 
cylinder geometry. A pre-shear period (20 s, 20 1/s) was applied to disperse the 
preparation homogeneously in the geometry. After that the sample was left for 5 min 
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to rebuild and equilibrate to a measuring temperature of 32° ± 0.1 °C in accordance 
with the temperature at the eye surface [Morgan et al., 1995]. All rheological 
measurements in this study were performed at 32° ± 0.1 °C.  
 
During a dynamic stress sweep (dss), at a constant radial frequency ω of 1 rad/s, 
oscillation stress was increased logarithmically. A double logarithmic plot of G’ and 
G’’ versus stress is produced to detect the linear visco-elastic region (LVER), which 
is characterized by a directly proportional relationship between the stress applied and 
the strain of the sample. From the LVER a stress value was selected to perform a 
dynamic frequency sweep (dfs). The performance of a dynamic frequency sweep, 
during which the oscillatory angular frequency ω was increased logarithmically from 
0.1 to 10 rad/s, enables to clear up the exact interaction mechanism between the 
polymer and mucin.  
 
 
9.3 Results and discussion 
 
Dss profiles of the different AS concentrations and their influence on mucin reveal 
that the higher the polymer and mucin concentrations, the higher the dynamic moduli 
G’ (Figs. 9-2, -3 and -4) and G” (Fig. 9-4) become. The greater elastic response 
obtained through combination with mucin 16 % (w/w) (~ 0.3 Pa) and mucin 20 % 
(w/w) (~ 0.2 – 0.3 Pa) as compared to mucin 12 % (w/w) is probably mainly due to 
the increased mucin concentration. When compared to the literature mucin 
concentrations tested were chosen exceptionally high for the in vitro studies in order 
to facilitate a rheological response, although such high concentrations can be 
expected directly on the corneal and conjunctival surface in vivo. However, 
differences in elasticity between the three AS concentrations tested and their 
influence on the elasticity of mucin could not be clearly exposed (Figs. 9-2, -3). 
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Fig. 9-2: Dynamic stress sweep illustrating the influence of AS on the viscoelasticity 
of mucin 12% (w/w); mean values of G‘ (n = 3); AS 25% (w/w) (squares); AS 27.5% 
(w/w) (triangles); AS 30% (circles); AS/SLF (grey symbols), AS/mucin (black 
symbols), calculated AS/mucin curves (open symbols), mucin (asterisks).   
 
 
0,01 0,1 1
1E-7
1E-6
1E-5
1E-4
1E-3
0,01
0,1
lo
g 
G
' (
Pa
)
log stress (Pa)
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9-3: Dynamic stress sweep illustrating the influence of AS on the viscoelasticity of 
mucin 20% (w/w); mean values of G‘ (n = 3); AS 25% (w/w) (squares); AS 27.5% (w/w) 
(triangles); AS 30% (circles); AS/SLF (grey symbols), AS/mucin (black symbols), calculated 
AS/mucin curves (open symbols), mucin (asterisks).  
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Fig. 9-4: Dynamic stress sweep illustrating the influence of AS 27.5% (w/w) on the 
viscoelasticity of mucin 16% (w/w); mean values (n = 9) of G‘ (open symbols) and G“ (filled 
symbols); mucin/SLF (triangles); AS/SLF (diamonds), AS/mucin  (circles), calculated 
AS/mucin curve (open squares). 
 
Curves resulting from a dss of the specific mucin/polymer mixtures reveal higher G’ 
values than a calculated curve resulting from the sum of the single components’ 
curves (Figs. 9-2, -3 and -4). This synergistic increase of elasticity is either caused by 
the formation of secondary bonds, physical entanglement of both components or a 
combination of both. The ratio G’/G” roughly indicates whether a sol (G’ < G”) to gel 
(G’> G”) transition occurs when mixing polymer and mucin dispersions. The polymer-
mucin mixture being a gel while both the mucin-SLF and polymer-SLF dispersions 
being a sol could not be observed when AS 27.5 % (w/w) and mucin 16 % (w/w) 
were combined (Fig. 9-4), which also applies to the other concentration combinations 
tested (data not shown). All analysed samples behave, within the stress range 
applied, mainly viscous (Fig. 9-4). Therefore the formation of an elastic interaction 
between AS and mucin cannot be clearly documented which means that the polymer 
mucin mixture is not characterized by secondary bonds (G’ values smaller than G” 
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values). The presence of the considerable elastic response as compared to the 
single components points to a transient network stabilized by physical entanglement.  
This conclusion can be confirmed by dfs data (Tab. 9-1), which enable to clarify the 
characteristics of the networks analyzed.  
 
If the slopes obtained with the different polymers and mucin-polymer mixtures are 
considered, it can be concluded that all dispersions tested contain molecular 
networks consisting of a combination of physically entangled and cross-linked chains 
since the slopes are larger than zero but smaller than 2 (log G‘/log ω) (tab. 9-1). The 
frequency dependence quantified by the slope values (tab. 9-1) points to the 
presence of a considerable amount of transient physical bonds between AS and 
mucin.   
 
Tab. 9-1: Frequency dependence of the dispersions tested, mean values ± SD (n=3), a(n=9). 
 
 log G’/log ω ± SD 
AS 25 % / SLF (1:1) 0.765 ± 0.15 
AS 27.5 % / SLF (1:1) 0.350 ± 0.06 
AS 30 % / SLF (1:1) 0.365 ± 0.08 
AS 25 % / mucin 12 % (1:1) 0.770 ± 0.06 
AS 25 % / mucin 20 % (1:1) 0.865 ± 0.18 
AS 27.5 % / mucin 16 % (1:1) 0.588 ± 0.15a
AS 30 % / mucin 12 % (1:1) 0.340 ± 0.03 
AS 30 % / mucin 20 % (1:1) 0.210 ± 0.08 
 
An elastic mucoadhesive bond formation is indicated by the slope log G’/log ω for the 
polymer-mucin mixture being lower (less frequency dependent) than the slope values 
of both polymer/SLF and mucin/SLF dispersions [Ross-Murphy, 1995].  
 
This particular behaviour is not observed for any AS concentration tested. Since the 
slopes, that is the frequency dependence, of the AS/mucin mixtures and the 
corresponding AS/SLF mixtures do not differ significantly (Student’s t-test, P < 0.05), 
no additional secondary bond formation is obtained and the increase of elasticity as 
indicated by the dss data is probably caused by an increase of physical 
entanglement between AS and mucin only. A possible explanation for the complete 
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absence of secondary bonds could be the negative charge of the AS molecule. 
Electrostatic repulsion could occur between AS and mucin, also charged negatively. 
On the other hand the degree of substitution (ds) with respect to ionic functions, in 
commercially available AS (usually 0.015) [Viswanathan, 1999], may be too low to 
induce electrostatic interactions with mucin.  
 
 
9.4 Conclusion 
 
Dynamic stress sweep measurements clearly indicate a rheological synergism when 
AS and mucin are combined. However, dynamic frequency sweeps reveal that in the 
case of the presented AS/mucin mixtures interactions are limited and not based on 
the formation of secondary bonds but on physical entanglement. Further 
investigations at different pH values or with respect to dry or solid AS formulations, 
such as powders, tablets or films, are necessary.  
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10 Evaluation of different n-octenylsuccinate starch formulations for 
ophthalmic application: investigation of ocular kinetics by means of 
fluorophotometry 
 
 
10.1 Introduction 
 
Low ocular drug bioavailability, which results from a number of ocular anatomical and 
physiological constraints, which include the comparably poor permeability of the 
corneal epithelial membrane, the nasolacrimal drainage, blinking and tear dynamics, 
necessitates frequent dosing to maintain therapeutic drug levels.  
 
The efficacy of topically administered ocular therapeutics is influenced, e.g., by the 
metabolism and permeation features of the drug incorporated as well as on the 
ophthalmic vehicle. Numerous attempts have been made to increase ocular 
bioavailability either by the development of prodrugs [Lee and Robinson, 1986] with 
an enhanced corneal penetration or by optimising the drug delivery systems with 
respect to a prolonged preocular residence time. Most commonly hydrogels based on 
natural, synthetic or semi-synthetic polymers [Ludwig et al., 1992] are applied to 
increase the contact time with the eye surface and reduce drug elimination. High 
molecular weight polymers like hyaluronic acid [Greaves and Wilson, 1993], have 
been shown to slow the turnover of the preocular tearfilm.  
   
For a number of highly lipophilic therapeutics, to which the cornea is relatively 
permeable, the formulation of a suitable dosage form poses high difficulties. Aqueous 
eye drop solutions are broadly accepted by patients but do not meet the specific 
drug’s demand for sufficient dissolution/solubilization. Surface active solubilising 
agents may also act as penetration enhancers, which in turn may elevate tear flow 
due to ocular irritation [Furrer et al.; 2002].  
 
Oil-in-water emulsions are particularly valuable in the delivery of water-insoluble 
drugs. The drug, dissolved in the internal oil phase, can be kept in the preferred 
solution state [Ding, 1998]. In vivo data obtained from o/w-emulsions demonstrate 
that emulsions can be effective delivery systems [Lallemand et al., 2003] with a 
potential of sustained drug release [Tamilvanan and Benita, 2004]. Cationic lipid 
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emulsions, prepared with cationic lipids, such as stearylamine/oleylamine, or 
chitosan have a good spreading coefficient on the negatively charged cornea and 
conjunctiva due to electrostatic attraction which supports the lipophilic drug ocular 
disposition [Tamilvanan and Benita, 2004].  
 
The administration of ocular inserts, developed to maintain and control drug release 
for a long period of time, still shows a low acceptance by both patients and 
physicians. To some extent this attitude can be changed by the application of soluble 
[Gurtler et al., 1996] or bioerodible inserts [Deshpande et al., 1998], which spare the 
patient the final removal of the dosage form. Soluble inserts consist of a hydrophilic 
and water soluble polymer. In the case of a soluble drug, soluble inserts are more 
suitable than a solution to control the diffusion process, while in the case of a less 
soluble drug, they are more capable than a suspension to control the dissolution 
process [Ding, 1998]. Films based on the mucoadhesive gelatin, developed for 
ophthalmic surgery (Gelfilm®) or drug delivery [Bonferoni et al., 2003], have been 
described in the literature. Employing an anionic polymer to interact with an alkaline 
drug, incorporated in a mucoadhesive film matrix, proved to be useful in modulating 
in vitro drug release profiles [Bonferoni et al., 2003]. 
 
n-octenylsuccinate starch (AS), which is also being discussed as a gelatin substitute 
(manufacturer information), shows excellent emulsifying [Viswanathan, 1999] and, in 
combination with polymers like poly(vinylchloride) or polyethylene, film forming 
attributes [Jane et al. 1991, Evangelista et al., 1991]. In vitro studies, on human 
erythrocytes [Baydoun and Müller-Goymann, 2003] and on porcine cornea, and vivo 
studies in rabbits have indicated a good ocular tolerance to AS [Baydoun et al., 2004, 
see Part II, chapter 5].  
 
Results obtained from oscillatory rheology measurements do not allow to assign a 
strong polymer-mucin interaction capacity to the AS dispersions investigated in the 
previous paragraph (Part III, chapter 8). However, the addition of mucoadhesive 
polymers to ocular dosage forms may increase the residence time but not the 
bioavailability, if the drug is not successfully retained in the vehicle [Ceulemans et al., 
2001]. Therefore, the aim of the present study was to investigate whether the 
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emulsifying and film forming features of AS could be deployed to develop an ocular 
drug delivery system with a prolonged contact time.  
 
Ocular fluorophotometry has been utilized to assess the precorneal retention of 
different AS formulations, containing a fluorescent marker, in healthy male and 
female volunteers. The systems evaluated were an AS dispersion, an AS stabilized 
o/w-emulsion and a cast AS film. The systems were kept as simple as possible to put 
special focus on the AS and to exclude other factors that might increase ocular 
retention.  
 
 
10.2 Materials and methods 
 
10.2.1 Materials  
 
Sodium fluorescein (Na-fluorescein) was purchased from Sigma (St Louis, MO, 
USA), medium chain triglycerides (MCT 812) from Hüls (Witten/Ruhr, Germany), 
sorbitol from Caesar & Loretz (Hilden, Germany), thimerosal from Synopharm 
(Barsbüttel, Germany), purified castor oil from Henry Lamotte (Bremen, Germany), 
sodium dihydrogen phosphate dihydrate and disodium hydrogen phosphate 
dihydrate from Merck (Darmstadt, Germany). Sodium dihydrogen phosphate 
dihydrate and disodium hydrogen phosphate dihydrate were used to prepare isotonic 
phosphate buffer pH 7.4 (PBS). PBS consists of NaH2PO4·2H2O (4.03 g/l) and 
Na2HPO4·2H2O (16.25 g/l). N-octenylsuccinate starch (AS), AS type 100, was 
obtained from National Starch & Chemical (Manchester, United Kingdom). 
 
Purified or double-distilled water was used for all preparations. All used substances 
were of pharmacopoeial or reagent grade.  
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10.2.2 Experimental methods 
 
10.2.2.1 Preparation of AS formulations for in vivo measurements 
 
An AS 100 dispersion was prepared at a concentration of 15 % (w/w) in double-distilled 
water using a magnetic stirrer.  
 
An oil-in-water (o/w) emulsion (10 % (w/w) oil phase) stabilized with 15 % (w/w) AS 
100 was prepared. The oil phase consisted of MCT 812 and castor oil (1:1). AS was 
fully dissolved in cold water and added in a stepwise manner to the oil phase using 
an Ultra-Turrax (Janke & Kunkel, Staufen, Germany). The pre-emulsion was passed 
through a high pressure homogenizer (Niro Soavi, type: Panda, Parma, Italy) six 
times at room temperature applying a pressure of 400 bar. Particle size distribution 
was analysed by laser diffraction (Mastersizer MS 20, Malvern, Worcs, UK) and 
calculated by Malvern SB 09 software using the Mie approximation. pH was adjusted 
to 6.5 since a breaking of the emulsion was observed at pH values higher than 7 
[Baydoun and Müller-Goymann, 2003]. 
 
The osmotic activities of the AS dispersion and emulsion were analysed by vapour 
pressure measurements at 37 °C (vapour pressure osmometer type: No 11.00, Knauer 
KG, Berlin, Germany; the apparatus was calibrated with a sodium chloride solution (400 
mOsm/kg) and bidistilled water (0 mOsm/kg)). Sorbitol was added if necessary to 
achieve iso-osmotic systems. 
 
Viscosities were determined using a capillary viscosimeter (Ubbelohde viscosimeter) at 
a temperature of 20 °C. 
 
Both the dispersion and the emulsion contained 0.1 % (w/v) Na-fluorescein as a 
fluorescent marker and were preserved with thimerosal 0.004 % (w/v). pH values of both 
preparations were adjusted to 6.5 using a 0.1 N sodium hydroxide solution.  
 
AS films were prepared by casting a polymer dispersion 40 % (w/w) in double-
distilled water, adjusted to pH 7 with a 0.1 N sodium hydroxide solution, into Teflon 
moulds (0.5 g/cm²). The polymer dispersion was stirred for 24 h on a magnetic stirrer 
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to ensure complete hydration. Glycerol was added, to achieve the required 
concentration of 1 % (w/w) in the dry product, and blended with the suspension for 2 
h before casting the films. Na-fluorescein was incorporated adjusting a concentration 
of 2 % (w/w) in the dried material. The thickness of the films was maintained as 
uniform as possible by the use of dispersions containing a constant total amount of 
solids. Bubble-free, transparent films were obtained by drying under vacuum for 
approximately 48 h at room temperature to constant weight. The films were cut into 
small, accurately weighed (about 5 mg) pieces, wrapped in aluminium foil and kept 
refrigerated (6 ± 2 °C) for no longer than 7 d prior to the fluorophotometric study. The 
moisture content was determined using a Karl Fischer titrator (Mettler DL35, Mettler-
Toledo, Switzerland) (n=3).  
 
The Na-fluorescein concentrations of the systems were chosen according to the 
sensitivity of the fluorophotometer applied. Fluorescence values higher than 2000 ng/ml 
result in fluorescein self-absorption and counting-saturation of the fluorophotometer 
electronics. Fluorescence values lower than four times the corneal autoabsorption may 
yield irreproducible results [Van Best et al., 1993; Ceulemans et al., 2001].  
 
AS moisture contents were previously determined by thermogravimetry (Thermal 
Analysis System SSC 5200, Software: MAS 5700 MA-Station Version 3.2, SSC 5200H 
Disk-Station Version 3.2, Version/Typ: DSC 220C, Seiko Instruments, Tokyo, Japan).  
 
Since AS preparations cannot be sterilized by autoclaving, the starch gets 
decomposed and AS emulsions break, they must be prepared and kept under 
aseptic conditions. 
 
 
10.2.2.2 Investigation of anterior eye kinetics in human volunteers 
 
Fluorophotometry of the anterior segment of the human eye was performed in the 
present study to investigate the anterior eye kinetics after application of a liquid or a 
solid ocular dosage form containing AS and the fluorescent tracer Na-fluorescein. 
The apparent Na-fluorescein concentrations (ng/ml) in the anterior eye segment, i.e. 
the cornea/tearfilm compartment and the anterior chamber compartment, were 
determined at regular times after application using a FluorotronTM Master 
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(OcuMetrics, Mountain View, CA, USA). The apparatus was equipped with a special 
lens, the anterior segment adapter, for detailed scanning of corneal and tear 
fluorescence and is calibrated according to the literature [Ceulemans, 2002a]. 
 
The measuring protocols were those approved within the framework of a concerted 
action of the European Community biomedical program on ocular fluorophotometry 
[Van Best et al., 1993]. Four healthy volunteers (two men/two women), who were 
thoroughly explained the aim of the study, agreed to participate. Each preparation 
was applied at least three times to one volunteer, after which mean values and 
standard deviations were calculated.  
 
The cornea like the lens fluoresces naturally. Corneal autofluorescence (λex 415 nm–
491nm, λem 515 nm–630 nm) is the intrinsic fluorescence that arises from 
endogenous fluorophores that are physiologically present in the cornea, and is 
considered an indicator of disease induced changes, e.g. due to open angle 
glaucoma or diabetes mellitus [Müskens et al., 2001]. Therefore prior to the 
application of each respective formulation, the autofluorescence level of the 
cornea/tearfilm and anterior chamber compartment was measured to adjust the 
values obtained for autofluorescence after application of the preparation. To exclude 
increased autofluorescence values by the presence of the specific AS formulations 
Na-fluorescein-free systems were applied to the eye of the volunteers after which the 
autofluorescence was determined as a function of time. Since the blank systems did 
not change the anterior segment autofluorescence level of any volunteer it can be 
assumed that changes in the fluorescence after application of the systems tested are 
only due to the extrinsic fluorescence of Na-fluorescein.  
 
After recording the autofluorescence pattern, 10 µl of the liquid preparation 
(dispersion/emulsion) were instilled using a sterile Eppendorf pipette or one AS film 
(moisture content about 20 %) was applied into the lower conjunctival sac of the 
volunteer’s right eye. At well-defined time periods, the concentration of the fluorescence 
tracer in the cornea/tear film and the anterior chamber was measured. In case of a liquid 
preparation, the tracer concentration in both compartments was determined every 2 
minutes during ½ hour and once after 45 min. In the case of the films concentrations 
were determined every 2 minutes during ½ hour, up to 1 h every 10 min, up to 3 h every 
30 min and up to 8 h each hour after application.  
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The Tear TurnOver (TTO; %/min), which is the percentage decrease of the 
fluorescein concentration in the tear film per minute due to the basal tear flow, can be 
calculated at a defined time after instillation of the preparation [Van Best et al., 1993] 
(see also . 
 
Assuming a monophasic decay of the tear film fluorescein with a decay constant kt (min-
1) and that the fluorescence measured is proportional to the fluorescein concentration in 
the cornea/tear film compartment, kt is equal to the decay constant as obtained by 
exponential regression to the data points obtained (Figs. 10-1, -2 and -3). In case of a 
dispersion, the fluorescence decay is due to normal lacrimal drainage. However, in case 
of a polymer dispersion, polymer emulsion or an AS film, the decay of the tracer is 
influenced by the elimination of the preparation. Therefore, an Apparent Fluorescein 
TurnOver (AFTO) is defined as [Ceulemans et al., 2001]: 
 
AFTO = 100 · (1 - e – ke)   (%/min)         (Eq. 1) 
 
Where ke = apparent elimination coefficient (min-1) of the monophasic decay of the 
cornea/tear film fluorescein concentration after application of a preparation. The first 
three measuring points of the fluorescence decay curve, which are influenced by 
reflex blinking and tearing, are excluded to calculate k e and AFTO. 
 
Besides the measurement of the tracer concentration in the tear film, the apparent 
fluorescein concentration in the anterior chamber as a function of time was measured 
to evaluate the specific formulation’s influence on the corneal permeation and on the 
bioavailability. The parameters used to characterize the kinetics of the preparations 
are Cmax (maximum apparent fluorescein concentration achieved; ng/ml) and tmax 
(time at which Cmax is reached; min). Area under the curve (AUC) from time 0 to the 
time at the last measurable concentration (AUClast: dispersion and emulsion) and to 6 
h (AUC6h: film) was calculated according to the linear trapezoidal rule using an Origin 
6.1 program. 
 
Data were statistically compared applying the Student’s t-test (unpaired samples). A 
probability level of 0.05 was chosen for all comparisons. Calculations were made with 
a Microsoft Excel 7.0 program. 
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10.3 Results and discussion 
 
10.3.1 Sodium fluorescein elimination in the cornea/tear film compartment 
 
The results of the AFTO (Eq. 1) calculations for all tested preparations (dispersion, 
emulsion and film) are presented in table 10-1.  
 
The mean AFTO value for the AS dispersion is 12.79, for the AS emulsion 8.30 and 
for the AS film is 3.03 %/min. The AFTO data were statistically compared applying 
the Student’s t-test (unpaired samples). A probability level of 0.05 was chosen for all 
comparisons. Calculations were made with an Origin 6.1 program. The comparison 
of the three preparations reveals significant differences (P < 0.05) of AFTO data 
between all of the three formulations investigated. On the other hand, considering 
each single preparation, the differences between the volunteers is not significant (P < 
0.05).  
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Fig. 10-1: Determination of the tear turnover (TTO) after application of an AS solution 
(volunteer A, TTO=14.66 %/min). Only data points between the dashed vertical lines are 
used for tear turnover calculation (monophasic decay).  
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Tab. 10-1: Mean apparent fluorescein turnover (%/min) (n = 3) ± SD after application of 
the reference solution (0.1 % (w/v) Na-fluorescein in PBS), the AS dispersion (15 % (w/w) 
AS, 0.1 % (w/v) Na-fluorescein and 0.004 % (w/v) thimerosal in double-distilled water, pH 
6.5), the AS emulsion (15 % (w/w) AS, 10 % (w/w) MCT 812 and castor oil (1:1) and 0.004 % 
(w/v) thimerosal in double-distilled water, pH 6.5) and the AS film (2 % (w/w) Na-fluorescein, 
1 % (w/w) glycerin, AS 80 % (w/w), water ad 100 %), the AFTO differences between the 
three preparations are significant, while, considering each single preparation, the differences 
between the volunteers is not significant (Student’s t-test, unpaired samples, P < 0.05), 
n.m. = not measured. 
Volunteer AS dispersion AS emulsion AS film  
A 13.46 ± 0.91 9.20 ± 0.75 2.98 ± 1.51 
B 12.11 ± 1.31 7.82 ± 2.46 3.56 ± 0.25 
C n.m. 8.59 ± 0.90 n.m 
D n.m 7.60 ± 1.63 n.m 
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Fig. 10-2: Determination of the tear turnover (TTO) after application of an AS emulsion 
(volunteer A, TTO=9.25 %/min). Only data points between the dashed vertical lines are 
used for tear turnover calculation (monophasic decay).   
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Fig. 10-3: Determination of the tear turnover (TTO) after application of an AS film 
(volunteer A, TTO=1.59 %/min). Only data points between the dashed vertical lines are 
used for tear turnover calculation (monophasic decay).  
 
When comparing the AFTO values of the different preparations tested the most rapid 
elimination of Na-fluorescein from the cornea/tearfilm compartment is visible after the 
application of an AS dispersion (Fig. 10-1 and tab. 10-1), which is followed by the AS 
emulsion (Fig. 10-2 and Tab. 10-1). A significantly slower drainage from the 
cornea/tearfilm compartment is reached after the application of an AS film (Fig. 10-3 
and Tab. 10-1).  
 
This order was expected since, besides the lack of evidence indicating a sufficient 
AS-mucin interaction [Baydoun et al., 2002], the dispersion reveals a lower viscosity 
(15.9 mPa s) as compared to the emulsion (40.0 mPa s). Moreover, the dispersion 
may be less able to retain the tracer at the eye surface because Na-fluorescein can 
diffuse quickly out of the predominantly hydrophilic system. In contrast, the emulsion 
slows down the elimination. Na-fluorescein, a paracellular marker, has shown in 
permeation experiments across mucosal membranes that it prefers to take the 
paracellular path, which is the route rather hydrophilic molecules take [Clausen and 
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Bernkop-Schnürch, 2000]. The presence of lipophilic components (MCT and castor 
oil) complicates the diffusion of the, at the pH present (6.5), hydrophilic molecule.      
 
After the application of a film the Na-fluorescein elimination rate is decreased 
probably on account of the film dissolving process. Firstly, the film has to take up 
water before it will be transformed into a high viscous solution. Diffusion rate is 
significantly reduced by the much higher viscosity and the closer polymer network 
meshes [Camber and Edman, 1989] owing to the elevated polymer concentration 
inside the hydrated film.   
 
 
10.3.2  Sodium fluorescein elimination in the anterior chamber compartment 
 
The mean values of the kinetic parameters, Cmax, tmax and AUC, characterising the 
kinetic course of the apparent Na-fluorescein concentration in the anterior chamber 
of each volunteer are listed in the tables 10-2 and -3. 
 
The apparent Na-fluorescein concentration in the anterior chamber is significantly 
increased after the application of each tested formulation (Tabs. 10-2 and 10-3). After 
the application of a dispersion and, respectively, an emulsion Cmax is reached 
immediately after the instillation, whereas (Tab. 10-2) in the case of the films tmax is 
slightly delayed (about 1.6 min) due to the dissolving process the film has to undergo 
before the entire Na-fluorescein amount is released. 
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Tab. 10-2: Mean value ± SD of the kinetic parameters (n = 3) characterising the profile of the 
apparent Na-fluorescein concentration in the anterior chamber as a function of time after 
application of an AS dispersion and an AS emulsion; Cmax is reached at tmax = 0 min, i.e. right 
after application; AUClast = Area under the curve from time 0 to the time at the last 
measurable concentration, n.m. = not measured.  
  
AS dispersion 
 
AS emulsion 
 
V
ol
un
te
er
 Cmax 
 
(ng/ml) 
tmax  
 
(min) 
AUClast
 
(ng h/ml) 
Cmax  
 
(ng/ml) 
tmax 
 
(min) 
AUClast
 
(ng h/ml) 
       
A 42,67 ± 3,10 0 1.71 ± 0.48 12.15 ± 1,96 0 0.88 ± 0.32 
B 23,15 ±13,41 0 1.35 ± 1.16 20.04 ± 9.07 0 0.92 ± 0.40 
C n.m   15.13 ± 14.81 0 0.80 ± 0.21 
D n.m   56.45 ± 32.16 0 2.82 ± 0.72 
 
 
Although volunteer A displays a significant decrease in Cmax when an emulsion is 
applied instead of a dispersion, altogether Cmax data of all preparations investigated 
do not differ significantly (Student’s t-test, unpaired samples, P < 0.05).  
 
Tab. 10-3: Mean value ± SD of the kinetic parameters (n = 3) characterising the profile of the 
apparent Na-fluorescein concentration in the anterior chamber as a function of time after 
application of an AS film, AUC6h = Area under the curve from time 0 to 6 h,  a n = 2. 
Volunteer Cmax 
 
 (ng/ml) 
tmax  
 
(min) 
AUC6h
 
(ng h/ml) 
    
A 51.36 ± 22.47 1.4 ± 0,35 49.67 ± 7.69 
B a 39.01 ± 15.50 1.73 ± 1,61 19.53 ± 1.82 
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However, profiles of the apparent fluorescein concentration of the anterior chamber 
as a function of time, considered over an extended time period, (Fig. 10-4) point out 
the differences between the three systems on hand. 
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Fig. 10-4: Apparent fluorescein concentration (mean values (n=3)) of the anterior chamber 
compartment as a function of time after application of an AS dispersion (squares), an AS 
emulsion (circles) and an AS film (triangles) in volunteer A. 
 
 
Relating to anterior chamber kinetics of Na-fluorescein the differences between the 
dispersion and the emulsion are not significant. Although the AFTO for the emulsion 
was improved as compared to the dispersion there is an indication on a comparable 
or even increased diffusion rate from the dispersion. However, in case of an 
amphiphilic or lipophilic drug, which greatly influences the drug’s diffusion dynamics 
within the formulation, the results may be different. As already reported on diclofenac 
permeation [Baydoun and Müller-Goymann, 2003] the drug incorporation within an 
emulsion reduces permeation rates which, associated with the increased ocular 
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contact time obtained upon emulsion administration, can be useful for the 
development of sustained release formulations.  
 
Although the amount of NaFLU applied with a film (100 µg after the application of a 
5 mg film containing 2 % Na-fluorescein) was 10 fold larger than the amount applied 
with a dispersion or an emulsion (10 µg after a 10 µl-instillation of a 0.1 % Na-
fluorescein solution and emulsion), comparable Cmax values for all volunteers are 
obtained. 
 
The film curve, like the dispersion and emulsion curves, drops comparably fast but 
while Na-fluorescein disappears within one hour after the instillation of an emulsion 
or dispersion, even 8 h after having applied a film Na-fluorescein was still detectable 
(5,62 ± 0,22 ng/ml, volunteer A) in the anterior chamber. Though not directly 
comparable, at similar Cmax data, the AUC can be significantly increased after the 
application of a film as compared to the dispersion/emulsion (Tabs. 10-2 and -3).  
 
Pulse entry is a common and yet highly undesirable, pharmacokinetic characteristic 
associated with eye drops. The initial high drug concentration found in tears followed 
by a rapid decline may lead to a potential risk of toxicity [Ding, 1998]. By application 
of an AS film drug release and corneal permeation seems to be controlled more 
effectively.  
 
 
10.4 Conclusion 
 
Preocular retention time of NaFLU incorporated in an AS formulation could be 
effectively increased following the order dispersion<emulsion<film. Nevertheless, 
dispersion and emulsion exhibit comparable Cmax / AUC data in the anterior chamber, 
where NaFLU disappears within 1 h. AS films facilitate the application of higher 
NaFLU doses at a comparable Cmax but an inevitably larger AUC due to a more 
controlled release and permeation. AS films may be useful in both the treatment of 
precorneal and intraocular diseases. In the case of poorly water-soluble drugs the AS 
emulsion offers a good alternative to conventional aqueous eye drops/suspensions. 
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Summary and general conclusions 
 
 
AS are polymers, that are capable of stabilizing emulsions without using classic 
emulsifying agents like surfactants. AS types that exhibit a larger molecular weight 
distribution may contribute more effectively to the formation of fine and stable 
emulsions. Emulsions with particle sizes (D90) below 1 µm and a notable long-term 
stability can easily be achieved.  
 
However, AS emulsions of either tested concentration and pH break throughout 
autoclaving. This remained unchanged after the addition of co-emulsifiers commonly 
used to prepare parenteral emulsions. Some partly even prevented emulsion formation 
from the first due to strong interactions. Therefore AS formulations generally need to be 
prepared under aseptic conditions. 
 
Since AS loses emulsifying properties at pH values above 7, emulsions should be 
adjusted to 6.5 to achieve an acceptable compromise between stability and ocular 
tolerance.  
 
AS emulsions can easily be spray dried and reconstituted prior to usage, whereas an 
emulsion with a non-evaporable content of 40 % (w/w) (AS 25 % and 15 %) proved to 
yield stable emulsions with comparable droplet sizes as obtained prior to spray drying.  
 
Toxicology data achieved with in vitro and in vivo measurements indicated a good 
tissue acceptability and eye tolerance of the AS types tested, which makes it an 
appropriate surface active polymer and stabilizing agent for ocular preparations. 
 
As compared to Voltaren ophtha, AS indirectly supports the permeation activity of 
DfNa. Although AS does not solubilize DfNa as efficiently as POC, it leads to higher 
permeation values due to a quicker drug release from the drug-polymer complex. 
Since pH, within the tested range, does not greatly influence permeation behaviour 
an eye drop formulation containing AS adjusted to pH 6.5 is proposed due to higher 
saturation concentrations reached for DfNa at this pH value. 
 
160  Summary and general conclusions  
Although interactions with (ocular) mucin seem to be limited fluorophotometric 
investigations in human volunteers revealed that the preocular retention time of Na-
fluorescein could be effectively increased with the application of an AS emulsion as 
compared to an AS dispersion, and an AS film as compared to an AS emulsion. The 
ocular application of soluble AS films even resulted in detectable fluorescein 
concentrations over an extended time period of several hours in the anterior chamber 
suggesting that AS films may be useful in both the treatment of precorneal 
(inflammation, infection) and intraocular (glaucoma, cataract, infection) diseases. 
 
Considering conventional aqueous eye drops, AS offers good alternatives, such as 
emulsions and dry redispersable emulsions for poorly water-soluble drugs, AS 
dispersions with increased corneal DfNa permeation and AS films for controlled 
delivery and an enhanced ocular bioavailability. Hence, due to satisfactory 
solubilizing and emulsifying properties coupled with a good tissue and eye tolerance, 
AS is a promising new excipient for ophthalmic and other non-enteral formulations.    
 
  
 
 
 
